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ABSTRACT

The studies presented within this dissertation provide the first description of
PRDM1 (also known as Blimp-1 or PRDI-BF1) function in natural killer cells. NK cells
are major effectors of the innate immune response via antigen-independent cytotoxicity
and link to the adaptive immune response through cytokine release. Molecular
mechanisms mediating NK activation are relatively well-studied; however, much less is
known about the mechanisms that restrain activation.
In the first study, the transcriptional repressor PRDM1 is shown to be a critical
negative regulator of NK function. Microarray analysis was used to characterize
transcriptional changes associated with cytokine-mediated activation.

PRDM1 is

expressed at low levels in resting NK cells and three distinct PRDM1 isoforms are
selectively induced in the CD56dim NK population in response to activation. PRDM1
coordinately suppresses the production of IFNγ, TNFα and TNFβ through direct binding
to multiple conserved regulatory regions. Ablation of PRDM1 expression leads to
enhanced production of IFNγ and TNFα but does not alter cytotoxicity, whereas overexpression blocks cytokine production. PRDM1 response elements are defined at the
IFNG and TNF loci.
To further delineate the targets of PRDM1-mediated regulation in NK cells,
global approaches were utilized. Experiments utilizing chromatin immunoprecipitation
coupled to promoter tiling arrays identified 292 novel direct targets of PRDM1 binding.
x

These studies revealed widespread binding of PRDM1 to the genome, which was not
limited to proximal promoter regions. Furthermore, microarray analysis of stimulated
NK cells combined with PRDM1 knockdown has enabled the identification of genes
responsive to PRDM1 knockdown using primary cells. Collectively, these experiments
identify both direct and indirect targets of PRDM1 regulation and help define a PRDM1centered gene regulatory network in NK cells.
Data presented in the final chapter pertains to an independent project aimed at
identifying small molecule inhibitors of the methyltransferase G9a, which is recruited by
PRDM1 and is required for silencing of target genes. A mass spectrometry-based assay
was developed and used to screen a small molecule library. Several hits were identified
and combinatorial chemistry yielded several compounds with < 20µM IC50 values. In
cell-based assays, however, treatment with the small molecules had limited efficacy,
indicating additional chemical modifications are necessary to yield bioactive compounds.
The data presented here demonstrate a key role for PRDM1 in the negative
regulation of NK activation and position PRDM1 as a common regulator of the adaptive
and innate immune response.

xi

CHAPTER I
INTRODUCTION

Part I: PRDM1 Structure and Function
Initial Characterization
The transcriptional repressor Positive Regulatory Domain containing protein 1,
with Zinc Finger Domain (PRDM1) is the founding member of a 17-member protein
family characterized by the presence of an amino-terminal PR domain. It was first
identified in 1991 by Tom Maniatis and colleagues as Positive Regulatory Domain I
Binding Factor 1 (PRDI-BF1) by screening a cDNA expression library with a probe
containing multiple PRDI sites (1).

This protein was shown to be virus-inducible,

capable of binding to the PRDI DNA element of the IFNB promoter in footprinting
experiments and sufficient for repression of a reporter gene under the control of the PRDI
element. Thus, PRDM1 was established as a negative regulator of interferon-β in virallyinfected cells.
Several years later the murine homolog was isolated in Mark Davis’s laboratory
by using a subtractive cloning approach to identify genes associated with the acquisition
of plasma cell phenotypic properties (2). The authors named the isolated gene Blimp1
(B-lymphocyte induction of maturation protein 1) and provided initial evidence that it
may play a crucial role in the differentiation of antibody-producing plasma cells.
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Interestingly, these groups reporting independently did not realize they were analyzing
the same gene product, albeit in two different experimental systems (3).

Thus,

pleiotropic functions of PRDM1 were established early after its initial description.

Genomic Organization, Protein Structure and Functional Domains
Human PRDM1 is a large, multi-domain protein containing 789 amino acids;
murine Blimp1/Prdm1 contains 859 amino acids. Not including the murine 70 amino
acid extension on the amino terminus, the two orthologs are 90% identical. Human
PRDM1 is located on chromosome 6q21 and spans approximately 23,600bp. Seven
exons are spliced to form the full-length protein (Figure 1). Exon usage is identical
between mouse and human with the exception of an extra amino-terminal exon present
only in the mouse (4). A truncated isoform was identified in human myeloma cells and is
transcribed from an independent promoter, resulting in the deletion of 100 amino acids

Figure 1: PRDM1 exon organization, functional domains and isoforms. Three
isoforms of PRDM1 are encoded by seven exons. Acidic regions are present in both the
amino- and carboxy-terminal portions of the molecule. Five zinc fingers are present
between residues 575-707. Proline-reach regions are clustered near the center of the
molecule. The PR domain is located near the amino terminus and is disrupted in the β
isoform.
2

and a disrupted PR domain (5).

This amino-terminal truncation has been termed

PRDM1β, while the full-leng th p rotein is referred to as PRDM1 α. In both human and
mouse a deletion of the penultimate exon (PRDM1Δ6 or Prdm1Δ7, respectively) has also
been observed (4, 6).
The PR domain is located near the amino-terminal of the PRDM1 protein. This
domain has been suggested to mediate protein-protein interactions in vitro (7), however,
its in vivo functions have not been experimentally demonstrated. The region has high
homology to the Su(var)3-9, Enhancer-of-Zeste, Trithorax (SET) domain, originally
defined as an epigenetic modifier in Drosophila (8). This domain is commonly found in
lysine-specific histone methyltransferases and its presence defines the PR-family of
proteins. Despite the high degree of homology to SET, the PR-domain lacks intrinsic
methyltransferase activity. An NMR structure of the closely-related PRDM2 has been
determined and reveals that the highly-conserved PR domain diverges significantly from
that of other lysine methyltransferases. It has a disordered post-SET domain and lacks
the

characteristic

Zn-Cys

ion

coordinating

motif

present

in

other

lysine

methyltransferases (9). The truncated PRDM1β isoform is transcribed from an alternate
promoter present within the third intron and produces an alternate exon 155bp upstream
of exon four (5). This exon contains a novel translational start site resulting in a protein
with three novel amino acids (methionine-glutamate-lysine) and a disrupted PR domain.
The N-terminal acidic region may be important for stability. Mutations in proline
48 have recently been shown to impart increased susceptibility to degradation (10).
Furthermore, the interacting co-repressor Reptin52 fails to interact with PRDM1β,
suggesting that it may be required for protein-protein interactions (Desai, unpublished
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observation). The central proline-rich domain (PRD) may also be important for proteinprotein interactions as specific structural motifs generated by proline residues can provide
docking sites for PRD-binding proteins (11). Indeed, this region facilitates the interaction
with several partners such as Groucho, LSD1 and HDAC2 (12)

Mechanisms of Action
PRDM1 is a classic zinc finger DNA-binding transcription factor. The five zinc
fingers recognize the consensus sequence (A/C)AG(T/C)GAAAG(T/C)(G/T), found in
the proximal region of target genes (13).

This sequence is closely related to the

recognition sequences of the interferon regulatory factors (IRFs).

IRF transcription

factors function as both activators and repressors and regulate numerous aspect of
immune function. Thus, one mechanism of PRDM1-mediated repression is the direct
competition for regulatory sites, resulting in displacement of IRFs and a decrease in
transcription. Some degree of functional redundancy exists within the zinc finger domain
because only two of the five fingers are required to maintain DNA-binding activity (14).
Furthermore, these residues are required for nuclear localization because deletion results
in cytosolic accumulation of the mutant PRDM1 protein (Győry, unpublished
observation).
In addition to passive repression via competition with activating factors, PRDM1
also exhibits active repression mediated through specific recruitment of co-repressors and
histone-modifying enzymes. Interactions with HDAC2 are required for the repression of
c-myc and HDAC inhibitors decrease the repressive ability of PRDM1 in reporter gene
assays (15, 16).

HDAC recruitment does not require a functional PR domain as
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PRDM1α and PRDM1β both co-purify HDAC activity and mediate TSA-sensitive
repression (5).
PRDM1 also functionally interacts with several molecules involved in the
regulation of histone methylation. Recruitment of G9a requires a region encompassing
the first two zinc fingers and results in increased di-methylation of histone 3 lysine 9
(H3K9) at the IFNB promoter to mediate silencing (15). PRDM1 recruitment of the
arginine methyltransferase PRMT5 results in symmetrical di-methylation of argine 3 in
both H2A and H4, silencing Dhx38 in primordial germ cells (17). Additionally, an
interaction with PRMT7 has been shown to occur in T-cam2 cells, a cell line derived
from a germ cell tumor (18). The H3K4-specific lysine specific demethylase 1 (LSD1)
has also been shown to interact with PRDM1 in murine B-cells and occurs through the
proline-rich domain of PRDM1 (19).

LSD1 demethylates H3K4, a histone mark

associated with gene activation. Thus, the removal of this histone modification likely
enhances repressive ability. PRDM1-mediated repression is further reinforced via the
recruitment of a variety of co-repressors such as members of the Groucho family (20) and
Reptin52 (Desai, unpublished observation).

PR Family Members
The PR domain defines a protein family which currently includes 17 members.
PRDM1, RIZ1 (PRDM2) and MDS1-EVI1 (PRDM3) represent the founding members of
the family and are the best characterized. RIZ1 was identified as a retinoblastomainteracting protein and was shown to be a transcriptional repressor that binds to Sp1
elements (21, 22). RIZ1 functions as a tumor suppressor and is inactivated in gastric
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tumors (23).

MDS1-EVI1 is a fusion protein resulting from a MDS1 and EVII

translocation and is frequently found in patients suffering from myelodysplastic
syndrome. Interestingly PRDM1, RIZ1 and MDS1-EVI1 are all characterized by the
presence of alternate isoforms with disrupted PR domains. These alternate isoforms have
frequently been observed in malignant tissues and have been suggested to be oncogenic,
lacking the tumor suppressive functions of the full-length proteins (24).
PR family members have been named PFM1-PFM14 starting from PRDM4,
however, members are officially named PRDM_ and this convention is most common in
the literature. All family members contain the characteristic PR domain and Krüppel-like
zinc fingers and appear to act as DNA-binding transcription factors, with the exception of
PRDM11 (PFM8) which lacks zinc fingers. Due to extensive rearrangements, PR family
members vary widely in amino acid length and number of zinc fingers. For example,
PRDM8 (PFM5) and PRDM12 (PFM9) have only three zinc fingers, while PRDM15
(PFM12) has 17 zinc fingers.

Orthologs have been found in all metazoans and a

generally positive correlation exists between number of PR family members within a
species and organism complexity (25).
Expansion of the PR family occurred primarily due to gene duplication events and
has resulted in a large number of functionally diverse transcription factors with tissueand temporally-restricted expression patterns. For example, PRDM16 (PFM13, MEL1)
controls brown fat adipogenesis through a PPARγ-dependent mechanism (26, 27).
PRDM14 (PFM11), on the other hand, is required for primordial germ cell specification
(28). PRDM9 (PFM6) is associated with “hotspots” of meiotic recombination and its
function may have contributed to speciation events, driving genetic divergence (29-33).
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Currently, many of the remaining PR family members remain poorly characterized, but
likely mediate unique functions.

Roles in Embryonic Development and Non-Immune Lineages
Roles for PRDM1 in early embryonic development have been established in
model organisms. Germline knockout of Prdm1 in mice results in early embryonic
lethality, confirming a requirement for its activity in early development (34). PRDM1 is
expressed as early as embryonic day seven in a variety of mesoderm-derived tissue
precursors in a spatially and temporally restricted manner indicating important roles in
early cell-fate decisions (35). In zebrafish, the PRDM1 homolog Ubo specifies the
location of the neural crest in response to BMP signaling and is required for sensory
neuron formation (36).

Early formation and delineation of bone patterning is also

regulated by Ubo as mutations induce severe defects in pectoral fin structure (37).
PRDM1 dose-dependently regulates the formation of caudal pharyngeal arches,
secondary heart field and sensory vibrissae in mice (38).
Recently, PRDM1 has been shown to be involved in terminal differentiation of
several diverse tissues. PRDM1 is required for osteoclast differentiation in a calciumdependent mechanism that is mediated by NFATc1 (39). PRDM1 favors osteoclast
differentiation, while BCL6 suppresses the process (40). PRDM1 is also involved in the
differentiation of epidermal cells. Its function is required for keratinocytes to transition
from the granular to cornified layer via the regulation of approximately 250 genes (41).
This diverse repertoire of PRDM1 functions is consistent with its conservation across
many metazoan species.
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Roles in B lymphocytes
The initial subtractive cloning approach of the Davis Laboratory suggested that
Blimp1 was a key regulator of plasma cell terminal differentiation (2). [Note: the use of
Blimp1 or PRDM1 reflects naming conventions in the literature, Blimp1 typically refers
to murine work, while PRDM1 denotes human. For clarity, PRDM1 is used exclusively
here]. Indeed, Prdm1 was identified as a unique cDNA clone induced in BCL1 cells
upon stimulation with IL-2 and IL-5, which initiates a plasmacytic differentiation
program. In both stable transformants and transient transfection assays, the Prdm1 gene
product increased surface expression of syndecan 1 (CD138), induced immunoglobin
secretion, and increased cell size and granularity (2). Thus, introduction of Prdm1 was
sufficient to induce phenoptypic changes associated with plasma cells (Figure 2).

Figure 2: PRDM1 functions in plasma cell differentiation. Upon antigen encounter,
naïve mature B cells undergo a differentiation process in order to functionally mature into
antibody-secreting plasma cells. PRDM1 and several other transcription factors, such as
IRF4 and XBP-1, are required for this phenotypic transition.
8

Exit from cell cycle is a hallmark of plasma cell differentiation and is
accompanied by a reduction in the cell cycle regulator c-myc. PRDM1 represses c-myc
upon induction of plasma cell differentiation and leads to either differentiation or
apoptosis, depending on the cell lines used (42).

Induction of apoptosis occurs

preferentially in immature B-cells with ectopic PRDM1 expression, suggesting a
“gatekeeper” role, with apoptosis resulting when cells are not “primed” to differentiate
(43).

This observation has clinical correlatives in terms of B cell lymphomas and

predicts that induction of PRDM1 in lymphomas may provide therapeutic benefit.
Subsequent studies identified target genes of PRDM1 in the context of plasma cell
differentiation. PRDM1 was shown to regulate the Class II transactivator (CIITA), which
is the master regulator of MHC class II expression, providing a mechanism for the downregulation of antigen presentation function that accompanies plasma cell differentiation
(44). PRDM1 also directly represses Pax5, which is required for B cell maturation, but is
silenced in plasma cells (45). Microarray analyses cataloged transcriptional changes
associated with PRDM1 demonstrating the existence of an extensive gene regulatory
network. PRDM1 directly regulates a number of transcription factors such as Spi-B and
Id3 (46). In a second study, functional domains of PRDM1 were also shown to mediate
differential gene expression patterns.

Of 376 genes differentially expressed with

enforced PRDM1 expression, disruption of the PR domain abrogated the regulation of 31,
while disruption of the carboxy-terminus abrogated the regulation of 12 (47). Together,
these microarray analyses identified nearly 600 unique PRDM1-dependent transcripts
and demonstrate modular nature of PRDM1-mediated repression.
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Through the regulation of key transcription factors, PRDM1 is the master
regulator of plasma cell differentiation. Induction of XBP1 and IRF4 expression and loss
of PAX5 expression are all required for the generation of plasma cells (48-50). Loss of
PAX5 expression initiates the commitment to plasma cell generation and PRDM1 acts
downstream of PAX5 to regulate the transition (51). PRDM1 is also required for the
maintenance of long-lived plasma cells populations within the bone marrow. Conditional
ablation of Prdm1 in pre-formed plasma cells results in decreased numbers of plasma
cells and reduced Ig secretion upon secondary challenge (52). Consistent with this,
Prdm1 knockdown in plasma cells initiates apoptosis (53). Thus, PRDM1 expression
must be maintained subsequent to differentiation.

Role as a Tumor Suppressor
Given the importance of PRDM1 in the terminal differentiation of B lymphocytes
it is not surprising that it has been investigated as a tumor suppressor. Deletions of the
genomic region surrounding PRDM1 (6q21-22) are relatively common in lymphomas,
which suggests a tumor suppressive role. Indeed, portions of the 6q arm are lost in ~25%
of lymphoid malignancies and 6q21-23 deletions are one of the most frequently
encountered genetic lesions (54). In fact, one study found 6q21 deletions in 85% of
samples analyzed (55).

Furthermore, inactivating mutations have been identified in

diffuse large B cell lymphomas (DLBCL) by several groups (56-58).

DLBCL are

derived from the late stages of B cell development. Consequently, PRDM1 mutations
have not been found in germinal center-derived lymphomas which arise from early stage
B cells that are not dependent upon PRDM1.
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Recent data has shown that in vivo

inactivation of PRDM1 causes increased incidence of various lymphocyte-derived
malignancies and this incidence is significantly enhanced when NFκB is constitutively
active (10, 59).

Thus, PRDM1 is a bona fide tumor suppressor gene in B cell

lymphomas.
NK-derived malignancies represent a relatively rare fraction of lymphoid-derived
malignancies in the United States and Europe, but exhibit increased incidence in Asia and
South America.

NK malignancies are classified as either extranodal NK/T-cell

lymphoma (nasal type) or aggressive NK-cell leukemia, are uniformly CD3-CD56+ and
are typically EBV-infected (60). Deletion of 6q21-23 is the most common genetic lesion
found in NK lymphomas (61).

Various studies have reported 6q21 deletions with

frequencies between 20 and 100% of samples analyzed (62). A recent study used high
resolution array comparative genomic hybridization (aCGH) analysis to map
chromosomal abnormalities in NK-derived tumor cell lines and patient samples. The
authors identified a 2Mbp minimal region of 6q21 (containing PRDM1 and two other
known genes, ATG5 and AIM1) that was deleted in 60% of the samples analyzed
(Figure 3) (62). Thus, PRDM1 may also function as a tumor suppressor in NK-derived
lymphomas.

11

Figure 3: Minimal 6q21 deletion found in B and NK-derived Lymphomas. A
minimal, commonly deleted region found in NK lymphomas has been described in a
significant fraction of NK lymphomas. Deletion of this region is also frequently
associated with B cell lymphomas.

Interestingly, the tumor suppressive nature of PRDM1 may not be universal.
Studies in breast cancer cells demonstrate that PRDM1 is expressed at high levels in
estrogen receptor α (ERα) negative tumors (63).

PRDM1 is activated by RelB,

suppresses ERα promoter activity and is associated with increased migratory capacity
(63).

Thus, PRDM1 functions as an oncogene in breast cancer cells because its

expression is mechanistically linked with both treatment resistance and metastasis. Thus,
PRDM1 exhibits pluripotent effects on tumor growth, which are very likely context and
cell-type specific.
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Roles in T-lymphocytes
Recent studies have demonstrated that PRDM1 mediates unique, non-overlapping
functions within the T cell compartment, positioning PRDM1 as a crucial regulator of
lymphocyte biology.

Germline deletion of Prdm1 results in embryonic lethality,

however, conditional strategies have allowed the dissection of PRDM1 function. Crosses
of mice bearing a floxed Prdm1 allele to Lck-Cre mice yield progeny with a severe
inflammatory phenotype that die at an early age from colitis (64). Conditional knock out
T cells from these mice are hyper-responsive. They produce higher levels of IL-2 and
IFNγ and are increased in number in peripheral circulation. An alternate genetic ablation
strategy whereby Prdm1-deficient fetal liver cells are used to reconstitute Rag1-/- mice
also demonstrates profound T cell-mediated inflammatory pathology (65).
PRDM1 is up-regulated in CD4+ T cells and regulates the differentiation of
effector subsets (Figure 4). It abrogates Th1 polarization via suppression of Ifng, tbx21,
and bcl6 (66). A negative feedback loop exists whereby PRDM1 is induced in response
to IL-2 and then silences both Il2 and its activator Fos resulting in decreased proliferative
capacity in vivo (67, 68). The inverse relationship between PRDM1 expression and
BCL6 observed in B cells is maintained in CD4+ T cells because PRDM1 prevents the
polarization into T follicular helper cells by suppressing BCL6 (69). Very recently,
PRDM1 has been shown to be required for IL-10 production and tissue homeostasis of
CD4+CD25+ T regulatory cells in an IRF4-dependent manner (70).
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Figure 4: PRDM1 functions in CD4+ T cells. PRDM1 contributes to the polarization
of CD4 subsets. PRDM1 negatively regulates Th1 and Tfh subsets, while promoting the
polarization of Th2 and Treg subsets.
In CD8+ T cells PRDM1 controls effector functions and is required for terminal
differentiation of CD8+ T cells (Figure 5).

Prdm1-deficient CD8+ T cells fail to

efficiently migrate to the lung in response to influenza infection, in part due to
diminished expression of the chemokine receptor Ccr7 (71). Prdm1-deficient CD8+ T
cells exhibited higher levels of TNFα and IFNγ in response to antigen stimulation, but
lower levels of transcripts associated with cytotoxic granules Prf1, Gzmb and Gzmk (71).
PRDM1 expression is highest in terminally-differentiated effector cells, limits the
proliferative capacity of CD8+ T cells and restricts the potential of effector cells to
differentiate into memory cells (72). During chronic infection, PRDM1 expression is
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highest in exhausted subsets and is correlated with up-regulation of inhibitory receptors
such as PD-1 and LAG-3 (73). Thus, PRDM1 regulates multiple facets of CD8+ T cell
effector function.

Figure 5: PRDM1 functions in CD8+ T cells. In CD8+ T cells PRDM1 expression
accumulates as naïve cells move toward exhaustion. Its expression is required for
efficient recall responses and restricts the potential of effector cells to develop into
memory cells.
Roles in Myeloid Lineage
PRDM1 functions not only within the lymphocyte lineage, but in myeloid-derived
cells as well. Expression is elevated in human granulocytes relative to monocytes and
over-expression drives terminal differentiation of the promonocytic U937 cell line (74).
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In dendritic cells, PRDM1 is associated with maturation and is highly induced in
response to maturation-inducing stimuli, such as LPS, TNFα and CD40L (75). PRDM1
competes with IRF8 for binding to EICE sites present in the myeloid-specific class II
transactivator promoter (CIITApI).

Down-regulation of CIITApI requires G9a and

HDAC2 and provides a mechanism for the attenuation of class II transcription that
accompanies DC maturation. Furthermore, in mice PRDM1 represses pro-inflammatory
cytokines (Ccl6, Il6) and knockdown diminishes DC maturation in vitro and in vivo (76).
Thus, PRDM1 mediates critical functions associated with myeloid differentiation.

Part II: Natural Killer Cells
Initial Characterization
Natural killer (NK) cells are a subset of lymphocytes representing 10-15% of
circulating peripheral blood mononuclear cells. As circulating lymphocytes these cells
localize to a variety of organs and can be found in the spleen, lymph nodes and liver. NK
cells were first identified in the late 1970’s by several independent groups via their ability
to lyse tumor cells via MHC-independent mechanisms (77, 78). Indeed, non MHCrestricted cytotoxicity is a defining hallmark of NK cells, but NK cells are also potent
producers of cytokines and mediate antibody-dependent cytotoxicity.

NK cells are

identified on the basis of cell surface phenotype: CD3-CD56+ in humans and CD3-DX5+
in mice. NK cells function in tumor surveillance, graft rejection and response to viral and
bacterial pathogens through direct killing and cytokine production. Thus, NK cells are
critical intermediates between the adaptive and innate immune systems.
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Development and Subset Diversity
A detailed understanding of NK development has only recently begun to emerge.
Early studies revealed that bone marrow ablation using either

89

Strontium or estradiol

treatment significantly reduced NK cell numbers, while not affecting B and T cell
numbers to the same extent, presumably because they develop external to the bone
marrow (79, 80). Transplantation studies also revealed that a functional bone marrow
niche was critical for NK development, suggesting that extrinsic signals from the bone
marrow provide key signaling events to drive NK development (81-83). Current models
postulate that NK progenitors originate and develop primarily within the bone marrow,
but may undergo subsequent functional maturation in secondary lymphoid organs such as
the spleen and lymph nodes (84).
In the earliest stage of NK development within the bone marrow, CD34+
hematopoietic stem cells (HSC) develop into early lymphoid progenitors (ELP)
expressing c-Kit and FLT3, both of which are abundant within the stromal niche. These
ELP have diminished propensity to develop into myeloid cells, but are not irreversibly
committed to the lymphoid lineage (85). Upon further differentiation, ELP become
common lymphoid progenitors (CLPs) expressing IL-7Rα with surface phenotype Lin(CD3-CD19-Ter119-Gr-)c-KitdimSca-1dim (86). Commitment to the NK lineage occurs
when CLP become NK progenitors (NKP) via acquisition of surface IL-2/15Rβ
expression (87, 88). This receptor along with the common γ chain imparts the ability to
respond to IL-15, which is critical for development of mature NK cells in vivo (89, 90).
This is supported by observations that IL-15 and/or IL-2 support in vitro NK
development from bone marrow progenitors in both mice and humans (87, 88).
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Furthermore, IL-2Rβ-deficient mice have significantly decreased numbers of circulating
NK cells, which also do not exhibit cytotoxicity in vitro (91).
In the mouse, these NKP do not exhibit cytotoxicity nor do they express mature
NK markers such as NK1.1 or DX5. NKP express several transcription factors such as
Ets1, PU.1 and Id2, which are all known regulators of early hematopoiesis (92). Defects
in these transcription factors cause severe reductions in bone marrow-derived NK cells
and NKP (93-96).

Functional maturation of NKP is characterized by extensive

remodeling of surface receptor expression. It is at this stage where surface expression of
mature NK markers such as NK1.1 and DX5 are acquired, however, intermediates
between NKP and mature NK cells have been identified that are DX5-NK1.1+ (92).
In humans, HSC present in the bone marrow with surface phenotype
CD34dimCD45RA(+)β7bright have been identified as bona fide NK precursors in humans
(97). This fraction is also highly enriched in human lymph nodes, which has been
suggested to be a site of functional maturation. Indeed, CD56brightCD16dim/- are highly
enriched in lymph nodes and are currently thought to be the first stage of NK maturity.
These cells have longer telomeres, increased proliferative capacity and can be
differentiated into CD56dim in vitro (98).

These cells represent only ten percent of

circulating NK cells and possess the ability to produce large amounts of cytokines, but a
diminished capacity for cytolysis.

Conversely, CD56dimCD16+ NK cells are the

predominant population in circulation, are highly cytotoxic and secrete decreased
quantities of cytokines (99).
Important differences exist between the CD56dim and CD56bright subsets. Gene
expression profiling has identified hundreds of differentially-expressed transcripts that

18

generate phenotypic diversity (100, 101). CD56bright NK cells express IL-2Rα, which
facilitates the formation of the trimeric, high affinity IL-2 receptor imparting the ability to
respond to picomolar concentrations of IL-2 (102).

They also express L-selectin

(CD62L), which may facilitate differential homing and distribution among secondary
lymphoid organs (103). CD56dim cells express higher levels of KIR transcripts, which
likely impart regulatory control over the enhanced cytotoxic capacity of these cells.
Furthermore, expression of CD16 (the low-affinity FcγIII receptor) is responsible for the
enhanced capacity for antibody-dependent cellular cytotoxicity (ADCC) observed in
CD56dim NK cells.
Additional subsets have been described which appear to be functionally discrete
from the peripheral CD56bright and CD56dim subsets.

Unique among these are the

decidual NK (dNK) cells which are found in the uterine lining during pregnancy. Gene
expression profiling demonstrates that these cells clearly represent a third subset and
differ markedly from both CD56bright and CD56dim NK cells (104). dNK are largely
uncharacterized, but may have evolved to perform specialized protective functions while
maintaining maternal-fetal tolerance. Very recently, functional intermediates directly
between CD56bright and CD56dim have been described based on surface expression of
NKG2A and KIR (105). These cells develop from CD56bright NK cells and secrete
intermediate levels of IFNγ in response to stimulation.

Furthermore, intermediate

populations based on surface expression of CD94 with similar functional overlap have
been described (106). These functional subsets are not entirely conserved between mice
and human, however, surface density of CD27 expression has recently been proposed to
segregate functional murine NK populations (107, 108).
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Mechanisms of NK Activation and Effector Function
Upon maturation, NK cells actively patrol in the peripheral circulation and can
become rapidly activated in response to a variety of environmental stimuli.

NK

activation is mediated through a variety of cell surface receptors that respond to
pathogens, “stressed” cells or cytokines. NK cells, unlike B and T cells, do not undergo
somatic hyper-mutation and clonal expansion in response to receptor stimulation.
Consequently, NK function is unperturbed in Rag-deficient mice. Instead, NK cells
express a broad range of both activating and inhibitory receptors, as well as numerous
cytokine receptors. NK cells are a relatively heterogeneous population and individual
cells possess discrete receptor expression profiles, often referred to as the receptor
repertoire.
The heterogeneity of receptor expression provides a source of functional diversity
and imparts the ability to balance the activating and inhibitory signals. This balance
forms the basis of the “missing self” hypothesis, originally proposed by Klaus Kärre in
the 1980’s. The original hypothesis stated that NK activity was directed against “self”
molecules that are altered in a manner that leaves them susceptible to NK-mediated
cytotoxicity and predicted the existence of inhibitory receptors. Experimental evidence
over the last several decades has largely born this out. It is now well-established that
killer cell immunoglobin recpetors (KIRs) and other receptors present on the surface of
NK cells recognize MHC class I molecules to mediate inhibitory signals. Conversely,
activating receptors, such as NKG2D, recognize stress-induced ligands and mediate
activating stimuli culminating with release of cytotoxic granules and increased secretion
of effector cytokines.
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Three structurally distinct families of NK receptors are expressed on human NK
cells: KIRs, C-type lectins and natural cytotoxicity receptors.

Several KIR family

members were originally cloned based on their ability to interact with HLA-B and HLAC to mediate an inhibitory signal (109). The KIR family contains 15 members which
show a high level of polymorphism among the population and differ in the number of
immunoglobin domains (two or three) and length of intracellular tail (short or long).
Although identified as inhibitory receptors, some short-tailed KIRs (e.g. KIR2DS)
mediate a DAP12-dependent activation signal through intracellular tyrosine activation
motifs (ITAM).

Members of the C-type lectin family, typified by NKG2A, share

homology to receptors for carbohydrates, but do not contain calcium binding domains.
These receptors can be either activating or inhibitory and recognize MHC Class I
molecules. Nearly all of them require heterodimerization with CD94 for functionality
(110). The distantly-related NKG2D molecule functions as a homodimeric activating
receptor that recognizes several stress-inducible, HLA-related molecules such as MICA
and MICB and signals through the adaptor DAP10 (111, 112). The natural cytotoxicity
receptors (NKp30, NKp44 and NKp46) are members of the Ig-superfamily and are
expressed exclusively on NK cells. These receptors trigger activation upon recognition
of their viral protein ligands, influenza hemagluttin and cytomegalovirus pp65 (113).
NK cells are also characterized by the expression of specific cytokine receptors.
All NK cell express the IL-2 receptor, with the CD56bright population preferentially
expressing the high affinity heterotrimeric form (102).

NK cells also express

heterodimeric receptors for IL-12 and IL-18 (Figure 6).

These cytokines can be

produced by mature DCs at sites of inflammation and within lymph nodes and are major
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mediators of NK activation (114).

NK cells also express a variety of chemokine

receptors and other ligands associated with mobility.

Significant differences in the

expression of molecules such as CCR7 and L-selectin (CD62L) likely account for the
differential localization of CD56bright and CD56dim NK cells in vivo (99, 103).

Figure 6: Cytokine receptors and signaling pathways utilized by NK cells. NK cells
express receptors for a variety of cytokines including, but not limited to: IL-2/IL-15, IL12, IL-18 and type I interferons. These molecules propagate signals through a variety of
distinct and converging pathways such as MAP kinase, JAK/STAT and NFκB.
Additionally, CD16 is capable of propagating activation signals upon interaction with the
Fc portion of antibodies. Currently, no signaling potential of CD56 has been described
and ligands have not been identified.
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In response to activating stimuli NK cells proliferate, increase cytotoxicity and
produce cytokines such as IFNγ, TNFα and GM-CSF (99).

IL-2 up-regulates the

expression of effector molecules and enhances natural cytotoxicity against a variety of
targets (115, 116). IL-2 modulates the expression of hundreds of transcripts in distinct
temporal waves, likely indicative of direct and indirect signaling modules (117). IL-2
appears to exert differential functions in NK cells and T cells. For instance, JAK2 and
STAT4 become phosphorylated in response to IL-2 in NK cells, but not in T cells (118).
Furthermore, the IL-2 “activation signature” in NK cells as determined by gene
expression profiling is largely divergent from that obtained with CD8+ cytotoxic T
lymphocytes (117). Long term culture of NK cells with IL-2 generates lymphokine
activated killer (LAK) cells that exhibit increased cytotoxicity and enhanced proliferative
capacity.
IL-15 exhibits significant functional overlap with IL-2. The molecules are highly
homologous and both signal through the common γc receptor to control proliferation. IL15 can maintain NK survival in vitro (119) and appears to be required for NK cells in
vivo (89, 120). This is supported by earlier observations that IL-2 deficient mice are not
devoid of NK cells (121, 122).
IL-12 and IL-18 were originally identified as cytokines capable of activating
lymphocytes. IL-12 was cloned as “NK-stimulating factor” and IL-18 as “interferon
gamma inducing factor” (123, 124).

These structurally-unrelated cytokines signal

through distinct heterodimeric receptor complexes to elicit increases in IFNγ and
cytotoxicity via several mechanisms, including increased transcription, message stability
and nuclear retention (125-127). They are produced by activated macrophages, DCs and
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liver-residing Kupffer cells. STAT4 is required for IL-12 signaling and NK cells derived
from Stat4-/- mice have impaired IFNγ production and display no enhancement of
cytotoxicity in response to IL-12 (128). IL-18 induces nuclear localization of NF-κB
p50/p65 which, cooperatively with AP-1, increases IFNγ and cytotoxicity (129).
Synergistic increases in cytotoxicity and IFNγ production are observed in response to costimulation with IL-12 and IL-18 (130, 131).
Upon activation NK cells participate in a variety of reciprocal interactions with immune
cells. Interactions between NK cells and DCs have been extensively studied and this
interaction allows NK-derived GM-CSF and TNFα to enhance DC maturation and DCderived IL-12 and IL-15 to further stimulate NK activation (Figure 7) (114). The
interaction requires cell-to-cell contact and is critically-dependent upon transpresentation of IL-15 by DCs to NK cells (132). Similarly, NK-derived IFNγ can drive
macrophage activation, thus increasing IL-12 and IL-18 production. NK cells can also
provide early IFNγ to shape CD4+ Th1 polarization, while in turn responding to T cellderived IL-2 and IL-21.

Thus, the early NK-dominated innate responses can be

“communicated” via cytokine stimulation to antigen-specific adaptive cells as they
expand. Virally-infected cells produce interferons which are known activators of NK
cells (133). Viral infection also leads to up-regulation of activating ligands such as
MICA and loss of MHC class I, rendering these cells more susceptible to NK receptormediated cytolysis. Thus, NK cells are critical regulators of both the adaptive and innate
arms of the immune response.
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Figure 7: NK cells mediate extensive crosstalk between innate and adaptive arms of
the immune system. Through the release of cytokines, NK cells serve as crucial
regulators of both innate and adaptive immune cells. Reciprocally, NK cells respond to
cytokines and other soluble factors produced by these cells.

Part III: Histone Methylation in Transcriptional Regulation
Nucleosome Organization
The compaction of DNA into chromatin within eukaryotic nuclei represents a
remarkably elegant solution that has evolved in order to overcome the spatial constraints
associated with packaging an enormous amount of material into a relatively tiny space.
Higher order structure of DNA is regulated at numerous levels, but the primary unit of
chromatin organization present in interphase cells is the nucleosome (134, 135). Each
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nucleosome consists of 146bp of DNA wrapped approximately 1.6 times around a
histone core (136). This core octamer consists of eight histone molecules, two copies
each of histones H2A, H2B, H3 and H4. Nucleosomes are separated from one another by
20-80bp with the “linker” histone H1 and other non-histone proteins interacting with the
DNA with varying affinities (137).
Structural data suggests that the nucleosome-DNA interaction has co-evolved to
impart important functionalities. The affinity between DNA and the core histone octamer
is likely dependent not only upon primary sequence motifs in the DNA, but also on an
“induced-fit” mode of interaction, which is supported by the observed deviations in
helical periodicity between free and histone-bound DNA (136). Importantly, the crystal
structure verified that the N-terminal tail of the core histone molecules H3 and H4 were
relatively un-structured and protruded from the histone core. Thus, these N-terminal tails
are available substrates for post-translational modification within the nucleus. It had
been known as early as the 1960’s that histones were subject to both acetylation and
methylation (138).

The identification of enzymes catalyzing these post-translational

modifications in the 1990’s and early 2000’s and the recognition that these molecules
were frequently present in complexes that regulate transcription led to the development of
the histone code hypothesis (139).

The Histone Code Hypothesis
According to the histone code hypothesis, specific modifications of histones are
associated with discrete biological outcomes.

For example, acetylated histones are

generally associated with transcriptional activation. The addition of acetyl groups to
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histone tails effectively neutralizes the basic, positively-charged character of the histone,
resulting in a decreased affinity for the negatively-charged phosphate backbone of DNA.
This results in an increase in the accessibility of DNA to polymerases and general
transcription factors, thus histone acetylation is positively correlated with transcriptional
activity.

Indeed, histone acetyltransferases co-purify with transcription activating

complexes and actively transcribed regions of the genome display increased levels of
acetylation.

Conversely,

histone deacetylase (HDAC) enzymes function as

transcriptional repressors and co-purify with repressive complexes such as N-CoR, SIN3,
NuRD and Co-REST (140, 141).
Distinct effects on transcriptional outcomes are associated with methylation of
specific amino acid residues of histones. Unlike acetylation, the addition of a methyl
group(s) does not result in an alteration of the electronegativity of the histone, but rather
provides novel docking sites for interacting effector proteins. For example, methylation
of H3K4 at promoter regions results in transcriptional activation via interactions with
positive regulators of transcription, while methylation of H3K27 results in recruitment of
the repressive polycomb complex PRC2/3 (142, 143). Furthermore, methyl groups can
be covalently attached to both lysine and arginine residues and multiple methyl moieties
can exist on individual residues; up to three per lysine, two per arginine (144).
Differential methylation has distinct functional consequences. H3K9 mono-methylation,
for instance, is permissive to transcription, while di- and tri-methylation are associated
with transcriptional repression.
Phosphorylation of histones is often cell cycle dependent. Phosphorylation of
H3S10 by Aurora kinase increases during cell cycle progression and levels are highest in

27

cells undergoing mitosis (145). Phosphorylation of H3S10 blocks methylation of H3K9,
imparting a further level of specificity to the histone code (146). Importantly, cell-cycle
dependent abrogation of methylation (via phosphorylation) provides a mechanism for
cell-cycle dependent transcriptional control. Numerous other modifications have been
documented

included

H2A/H2B

ubiquitination,

ADP-ribosylation

and

proline

isomerization. The functional consequences of multiple modifications and the effects of
cross-talk among different modifications are still being elucidated as the histone code
hypothesis is tested experimentally.

Methylation in Gene Silencing
The classic example of histone-mediated methylation leading to gene silencing is
the phenomenon of position-effect variegation, originally described in Drosophila
melanogaster. This phenotype results in variegated expression of a non-mutated allele of
the white gene, yielding eye color which is variegated among red and white pigments.
This process is considered epigenetic because it is both heritable and independent of
changes in the nucleotide sequence of the white gene. It is now known that both the
methyltransferase Su(var)3-9 and HP1, which binds methylated histones is required for
this process. Indeed, mutations within HP1 abrogate position effect variegation (147) and
structural evidence confirms that HP1 specifically interacts with tri-methylated H3K9 via
its chromodomain (148, 149). HP1 self-associates with other HP1 molecules and leads to
spreading of HP1 across large regions of the genome (150). Thus, methylation-specific
recognition of H3K9 mediates the formation of heterochromatin, which is highly compact
and remains untranscribed throughout cell divisions.
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Methylation of histones can also contribute to silencing of genes in euchromatic
regions. Indeed, the localization of Su(var)3-9 and HP1 correlate with heterochromatic
foci, while G9a and other histone lysine methyltransferases do not (151). Genome-wide
analysis of H3K9me2 indicates that this mark associates with regions of transcriptional
silencing at non-heterochromatic loci (152).

Thus, several levels of silencing are

mediated via histone methylation.

G9a Structure and Function
The histone methyltransferase G9a was originally cloned as an ankyrin-repeat
containing protein of unknown function from the MHC class III locus (153). The G9a
protein was later shown to contain 1,210 amino acids and exhibit primarily nuclear
localization (154). Although it was observed to share a region of homology with the
Drosophila SET domain-containing protein trithorax, its role in transcriptional regulation
was not initially appreciated. Only later was G9a shown to preferentially di-methylate
histones H3 (K9 and K27) and H1 (155). Furthermore, it plays critical roles in vivo as
G9a-/- embryos are not viable and G9a-/- ES cells display global hypomethylation of
H3K9 (156). G9a interacts with the highly-related G9a-like protein (GLP) to form
heterodimers, which forms the predominant, catalytically active species in vivo. GLP
knockout animals also display reduced H3K9me2 levels and double knockout animals
display no further abrogation, suggesting that G9a and GLP must act together in vivo
(157).
G9a interacts with a variety of molecules to mediate its functions. It is recruited
by PRDM1 in order to suppress IFNB and other genes as described earlier. Interaction
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with C2H2-type zinc finger transcription factors is a common modality as G9a interacts
with Gfi1, NRSF, PRISM/PRDM6, ZNF200, and ZNF217 (158). Another zinc-finger
containing molecule, Wiz, forms a complex with G9a-GLP and regulates the stability of
the heterocomplex. Knockdown of Wiz causes a concomitant reduction in G9a protein
levels (159). Thus, interactions with accessory proteins not only target G9a to specific
genomic regions, but also function in a regulatory capacity.
In yeast, the histone methylation and DNA methylation machinery are
functionally linked.

An interesting connection also exists between G9a and DNA

methylation in mammalian cells.

Knockdown of DNMT1 mediates a reduction in

H3K9me2 levels in both HeLa and HCT116 tumor cell lines (160, 161). Conversely,
knockdown of G9a results in global hypomethylation of DNA.

However, catalytic

activity is not required to restore DNA methylation levels, suggesting that the functional
effect is mediated through the formation of distinct complexes (162). DNMT1 requires
UHRF1 for targeting to hemi-methylated DNA. Indeed, G9a interacts with UHRF1,
which is capable of recognizing H3K9me2 (163). Thus, this bridging interaction may
functionally link the histone and DNA methylation systems in mammalian cells.
Knockout studies have demonstrated crucial roles for G9a.

Germline G9a-

deficient embryos are not viable and die via apoptosis by day 13.5 (156). Through the
use of conditional knockout strategies, numerous lineage-specific G9a functions have
been identified. G9a-deficient CD4+ T cells produce diminished levels of Th2 cytokines
IL-4, IL-5 and IL-13 and CD4 conditional knockout mice succumb to helminth infections
(164). In B cells, G9a regulates the composition of the B cell receptor through inhibition
of germline transcription, IgG Lambda light chain usage and V(D)J recombination (165).
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Conditional knockout results in a slight reductions in both proliferative capacity of
mature B cells and plasma cell generation in response to stimulation with IL-4 and LPS
(166). Recently, G9a was shown to mediate cocaine-induced transcriptional alterations
within the nucleus accumbens in response to repeated administration of cocaine (167).
Thus, G9a exerts control over a wide array of physiological functions.
The SET domain is the catalytic domain of the molecule and is found in nearly all
histone methyltransferases. G9a contains a carboxy-terminal SET domain, which is
flanked by “pre” and “post” SET domains, which are enriched in Cys residues and bind
zinc atoms (168). The first H3K9-specific methyltransferase to be crystallized was DIM5 from Neurospora crassa (169, 170). DIM-5 shares significant homology with G9a and
the structure reveals a conserved catalytic core of residues provides an aromatic cage
where H3K9 fits into a cleft and can be methylated using S-adenosyl-methionine (SAM)
which is bound to a separate module (Figure 8).

Surrounding residues define the

specificity of G9a for lysine 9 of the H3 tail. Within the catalytic domain, a “Phe/Tyr
switch”, controls methylation multiplicity. Presence of phenylalanine is required for diand tri-methylation and mutation to tyrosine renders G9a capable of only monomethylation (171). Ankryin repeats present within the central portion of the molecule are
required for interaction with methylated H3 and likely serve crucial tethering functions
(172). This tethering may contribute to H3K9me2 spreading and the establishment of
large regions of histone methylation, a mechanism analogous to HP1 spreading across
heterochromatic regions.
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Figure 8: Histone methyltransferase structure. The crystal structure of DIM5 reveals
conserved catalytic residues required for activity. The H3 peptide fits into a binding cleft
and methyl groups are transferred to the amino terminal of Lys 9 (shown in yellow) via
co-factor SAM, which binds on the rear-facing portion of the molecule. (PDB: 1PEG)
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CHAPTER II
MATERIALS & METHODS

Cell Lines
NKL cells were grown in RPMI, supplemented with 20% fetal bovine serum,
1mM sodium pyruvate, 1X non-essential amino acids and 100U/m IL-2. NK-92 were
grown in Alpha-MEM, supplemented with 20% fetal bovine serum, 1mM sodium
pyruvate, 1X non-essential amino acids and 100U/m IL-2. YT cells were grown in
RPMI, supplemented with 10% fetal bovine serum. NKL, NK-92 and YT cells were split
every 2 days. Jurkat and THP-1 were grown in RPMI, supplemented with 10% fetal
bovine serum. Jurkat and THP-1 cells were split approximately every 3 days to a density
of 2 x 105/ml. U2OS cells were grown in DMEM, supplemented with 10% fetal bovine
serum and split approximately every 3 days at a 1:10 ratio. All cell lines were grown in a
humidified incubator at 37ºC and were supplemented with 1% penicillin/streptomycin.

Primary Cell Isolation
Primary human NK cells were isolated via negative selection using the human
EZSep kit (StemCell Technologies) according to the manufacturer’s instructions. Purity
was verified by flow cytometry and routinely found to be 90 – 95% CD3-CD56+CD16+.
Cells were maintained in RPMI1640 (Gibco), supplemented with 10% FBS and 1%
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penicillin-steptomycin. For siRNA experiments, cells were grown in Accell Delivery
Media (Dharmacon) supplemented with 2% FBS. For stimulations, recombinant human
cytokines were used at the following concentrations: IL-2 100U/mL (Peprotech), IL-12
10ng/mL (Peprotech), IL-18 100ng/mL (MBL), TNFα 20−100ng/ml (BD Biosciences),
IFNγ 20−100ng/ml (BD Biosciences), IFN-α 10−50ng/ml (Sigma).

Mice
Mice were housed in accordance with Moffitt Cancer Center guidelines by the
laboratory of Esteban Celis, MD PhD. C57BL/6 mice (n=4) were immunized i.v. with
either 250 μg poly-IC (Oncovir, Inc., Washington, DC) or PBS. Mice were sacrificed at
48h post-injection and single-cell suspensions were prepared from pooled splenocytes.
Murine NK cells were isolated via negative selection using the Murine NK Enrichment
Kit (Stemcell Technologies) and maintained in RPMI1640, supplemented with 10% FBS
and 1% penicillin-steptomycin, when appropriate. Lysates were prepared from both
purified NK cells and total splenocytes and analyzed by immunoblot.

Flow Cytometry
Cells were collected and washed once with PBS. Cells (100,000/sample) were
resuspended in Flow Buffer (PBS, plus 0.5% BSA, mM EDTA). Antibody (5µl/test) was
added as per the manufacturer’s suggestion. Cells were incubated for 15 min. Samples
were collected on a Becton Dickinson FACs Calibur instrument using CellQuest
software. Data was analyzed either within CellQuest or using FlowJo.
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Immunoblotting
Whole cell lysates from 5 x 105 cells were prepared in lysis buffer (50mM tris pH
7.2, 150mM NaCl, 1% NP-40, 1% Na-deoxycholate, 0.1% SDS, 2mM EDTA) on ice for
20 min. Samples were then sonicated for 8 cycles (30 sec. “on”, 30 sec. “off”) in a
Diagenode Bioruptor.

Lysates were centrifuged at 13,000rpm for 10 min. at 4ºC.

Soluble lysates were mixed with Laemmeli dye and heated to 85ºC for 2 min. before
separation via 8% SDS-PAGE. Gels were transferred to PVDF, blocked with 5% skim
milk and probed using antibodies directed against PRDM1 (PRDI-BF1) (Cell Signaling)
1:1000, PARP1 (Cell Signaling) 1:1000 or β-actin (Sigma) 1:10,000.

Secondary

antibodies conjugated to HRP were used for detection: anti-rabbit (GE) 1:2000 and antimouse (GE) 1:10,000.

RNA Extraction and cDNA Synthesis
RNA was isolated using Qiagen RNeasy kit according to the manufacturer’s
instructions. On-column DNase treatment was performed after the initial binding to the
column. RNA was eluted in 30μl RNase-free H2 O and quantified using a Nanodrop UV
spectrophotometer. cDNA synthesis was carried using the qScript cDNA Synthesis kit
Quanta Biosciences per the manufacturer’s instructions. Within all experiments, starting
quantities were the same across all samples and varied between 0.2μg and 1μg depending
upon yield.
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Microarray Hybridization and Analysis
Two micrograms of total RNA served as the mRNA source for microarray
analysis. The poly(A) RNA was specifically converted to cDNA and then amplified and
labeled with biotin as described (173). Hybridization with the biotin labeled RNA,
staining, and scanning of the chips followed the prescribed procedure outlined in the
Affymetrix technical manual.

Scanned output files were visually inspected for

hybridization artifacts and then analyzed using Affymetrix GeneChip Operating Software
(GCOS). Heatmaps were generated using Heatmap Builder v1.1 using either signal
intensity or fold-change values for differentially expressed transcripts.

Enzyme Linked Immunosorbent Assay
Supernatants were collected from cells growing at 1 x 106/mL and stored at -20ºC
until use.

ELISA assay was performed using 100μl volumes in triplicate using

commercial kits for IFNγ and TNFα according to the manufacturer’s instructions (Ebiosciences). For some experiments, supernatants were diluted between 1:5 and 1:1000
(depending on experimental conditions and analyte) in order to obtain wavelength
readings within the dynamic range of the assay.

Plates were read at 450nm on a

Molecular Devices Spectramax Plus plate reader.
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Chromium Release Assay
NK cells isolated by negative selection were cultured for 72h prior to the assay.

K562 cells were labeled with 100μCi per 1 x106 cells for 1h, then were washed 3X with

36

warm PBS. NK cells were incubated with 5,000 K562 cells at various effector:target
ratios in triplicate in a total volume of 100μl for 4h. Supernatants were harvested and
c.p.m. determined using a Perkin Elmer 1470 automatic gamma counter.

Percent

cytotoxicity was calculated using the following formula: (experimental – spontaneous
release)/(total – spontaneous release) x 100.

siRNA-Mediated Knockdown
The Dharmacon Accell siRNA system was used for all knockdown experiments.
Accell siRNAs are modified via a proprietary mechanism that enables passive diffusion
into target cells, eliminating the requirement for transfection. Two PRDM1-specific
siRNAs (A-0093222-16 targeting CUCUCGACAGCAAAUGGUU and A-009322-18
targeting CAAUGGAUCCUUAAGAUUU) were used at a final concentration of 500nM
each. A non-targeting control siRNA (D-001910-01) was always used in tandem at a
final concentration of 1µM. Delivery was accomplished via incubation of cells in Accell
Delivery Media, supplemented with 2% FBS and 1% pen/strep at a density of 1-2 x106
cells/ mL. Knockdown experiments were conducted at 24, 48 and 72h time points.

Transient Transfection and Luciferase Assay
Transfections were performed using either 20μg of total plasmid into 107 cells or
10ug of total plasmid into 3 x 106 Jurkat T cells. Electroporation was conducted using a
BioRad Gene Pulser II at 250V, 1070µF in 300μl RPMI1640 containing 10% FBS
without antibiotics. Cells were cultured 36h at a density of 106/ml. Typically, ~60% of
cells remained viable after electorporation Luciferase activity assays were conducted
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using the Promega DLR kit. Lysates were prepared from 10 x 106 or 3 x 106 cells in
volumes of 500µl or 100µl, respectively. Cells were collected and washed once in cold
PBS before lysis in passive lysis buffer. Lysates were rotated at 4ºC for 15 min., then
centrifuged at 13,000G for 10 min. Firefly luciferase values from 10µ lysate, assayed
with 50µl LARI. Stop & Glo (50µl) was then immediately added to obtain renilla
luciferase values. All readings were performed on a Turner 20/20n luminometer with 10
sec. collection times for both firefly and renilla.

Data was expressed as “relative

luciferase activity” and was calculated by Firefly/renilla. Vector-only controls were set
to 100%.

Adenoviral Constructs and Transduction
Adenoviral constructs were created in the Ad5/F35 vector from previously
described constructs (15). This replication-deficient adenovirus utilizes the ubiquitouslyexpressed CD46 molecule to mediate high level transduction efficiency in a variety of
hematopoietic cells (174). Briefly, PRDM1a in the AdTrack vector was recombined with
Ad5/F35 to generate a bi-cistronic viral vector containing PRDM1a and GFP. Purified
stocks were obtained by infecting Ad293T cells for 48 hr. and concentrating via CsCl
banding according to standard protocols. Viral titers were calculated using the CellBio
Labs QuickTiter Adenovirus Quantitation Kit. For transduction experiments, Jurkat cells
were transduced using an MOI of 500 at a density of 1x106/ml for 44h before stimulation
with PMA (1μg/ml) and PHA (10ng/ml) for 4h.
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Real-time Quantitative PCR
RNA was isolated using Qiagen RNeasy kit according to the manufacturer’s
instructions. Eluted RNA was DNase-treated, converted to cDNA and 1/20th of the
cDNA reaction was analyzed by real-time PCR in duplicate using the BioRad iCycler (40
cycles, with primer-specific annealing temperatures between 55ºC and 60ºC).

For

expression analysis, data was analyzed by the ΔΔCt method, with normalization to either
18S or GAPDH. Primers were quality checked for single curve on melt curve and
efficiencies between 90% and 110%. Sequences of primers and Tm values are provided
below (Table 1).
Table 1: Oligonucleotide Primer Sets
Gene

FWD

REV

Tm

Application

BCL6

AACCTCTCGCTCCCTTTTGT

GGTCTGGGGCTAATTCCTTC

60

ChIP

CCR7

ATGTGTCAGTGCCTCCCATT

TGAGAGAAGTGTCCCCATCC

60

ChIP

CIIAp3

TCCCAACTGGTGACTGGTTA

CAAGGATGCCTTCGGATG

60

ChIP

CIITAp4

GGCCACAGTAGGTGCTTGGT

CTCGTCCGCTGGTCATCCT

55

ChIP

FOS

CCACAGGGAGAGTGCAAGT

CTGGGGATCCAAAAGTGAAA

55

ChIP

GZMK

CCTGAAAGTCCCCAAACTGA

ACCACAGGTGCTCTAGGGGT

55

ChIP

IBRDC3

AGGAGACAACCAGCAGCATC

GTCCTTGCAGTGTGTAAACG

60

ChIP

ID3

CCCATCTGTGCCTCCATATT

ACCCTCTGCCCCATAAACTC

60

ChIP

IFNB

TGCTCTGGCACAACAGGTAG

CAGGAGAGCAATTTGGAGGA

60

ChIP

IFNG I

CACCTGGGGTGACAAGAAAT

GCCAATCACAAGAGGGAAAA

55

ChIP

IFNG II

CTTCCGTAGGTTTGGCTTG

GGCGTAGATTTCTTCTTCCACTC

55

ChIP

IFNG III

TGGTGTGAAGTAAAAGTGCCTTCA

CGATGAGACAGACCCATTATGC

60

ChIP

IFNG IV

GACTGGGTGAGGGAGATTG

GGGAGTGACAGGTAGGGAGA

55

ChIP

IL12RB1

SA Biosciences (part# GPH1020516(-)01A

60

ChIP

IL18BP

TGGCCAGAGGGGCTAGGATGA

CCCAGGCTACCCACTCCCCC

55

ChIP

IL2

CCACGTGTGTCATACCCCCTGC

GGGATGGGGGTTGCCCTTTGA

55

ChIP

ITGAM

CTTGGGTGAAGAGCTTGAGG

AGGTGTGAGCCACTGCATC

55

ChIP

KIR2DL4

GGTGAGAGTGGGCATTCTTG

AGCCCTCAACAAGCTAAGCA

55

ChIP

KLRF1

AGGGGCATAATTTCCATTCC

AAAAGTTGCTTTCCCATGACA

55

ChIP

KLRG1

CATTTTGTTTGTTTTGCCTTCA

CATTGCCAAAAAGAGTCATCAA

55

ChIP

LMO2

TGGTGACTGCTGTGGGTAAG

GCCCACTCACTCTTGCTTTC

55

ChIP

LRMP

GCCAACGGCTGGAGGATGTGG

TGGTTTGCAGGGCATCTGAGGA

55

ChIP
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LTB IV

TCCATCCCACAAGATTCCAG

AGGTTTCCAATGTGGTTTGC

55

ChIP

MKI67

TACGGAAGTCTGGAAGGAAC

CTGGGTTTACAGGCGGTGA

55

ChIP

MB exon2

Diagenode (part# pp-1006-050)

60

ChIP

PAX5

GATTTGGGCGAGAACAGGAC

GAAGGCACCGTGAAATGATTA

55

ChIP

PCNA

CTGAGGAGCCACCATAAAGC

CGCCTCTTTGACTCCTGAAC

55

ChIP

PTK2

GCTAACCACAAGCCAGGAAG

GCTCCTAATGCAATGACG

55

ChIP

SELL

GGTGGGGAAAGAGGAAAGAG

GCTGTGCTGCAGGTAGACTG

60

ChIP

SLAMF7

GGCCAGGAAAGTGAAACAGA

TCAGAGCTTAAGTTTGCCATGT

55

ChIP

SOCS2

GGCTCACCTGGGCCACACAC

CCACCACCACACACAGCACCC

55

ChIP

SOX4

TGTTTGGGCTATGCAGGATT

GAAGGCAGGGAAGAGGACTT

60

ChIP

STAMBP

AGGCACACTGGGGCCTCAACT

TGGTTGATGGGCAGAAGCCCT

55

ChIP

STAT6

CGTGTTCCCCCACTCGGCAC

GCCCGCTGTTTCCGGCTTCT

55

ChIP

TNF

TACCGCTTCCTCCAGATGAG

TGCTGGCTGGGTGTGCCAA

55

ChIP

TNF I

CAACCTCCGAAACTGAGA

AGGAAGGAAGGGTAAGACTG

55

ChIP

TNF II

TACCGCTTCCTCCAGATGAG

TGCTGGCTGGGTGTGCCAA

60

ChIP

TNF III

TGCATCTGCCTCTTCTTGTG

GGTCCAGGGATCTTAAAGC

55

ChIP

TNFRSF10B

GGGGCGTTCTGTCCCCGTTG

AACCCCGCAATCTCTGCGCC

55

ChIP

UBR2

AGCCGTGTGCTCCTCCGACT

GCCTTCTTGGTGCCTGGGGC

VAV3

ACAGTTCCGAGCCTGACAGT

TGAGTGAGAGTGCGTGTGTG

55

ChIP

18S

GTAACCCGTTGAACCCCATT

CCATCCAATCGGTAGTAGCG

55

exp

DAP10

GGCTGCAGCTCAGACGAC

AGGAGCGGCAGAGAGG

58

exp

IFNG

GAAAAGCTGACTAATTATTCGGTAAC

GTTCAGCCATCACTTGGATGA

55

exp

LTA

CTGTCTGGCTGAGGATTTCA

CCCTCTCTCCATCCTCCATA

58

exp

PRDM1a

TCAAACTCAGCCTCTGTCCA

TCCAGCACTGTGAGGTTTCA

55

exp

PRDM1b

CCCGAACATGAAAAGACGAT

ATAGCGCATCCAGTTGCTTT

55

exp

ChIP

PTK2

GAGCCTTCTCTTCCTCCAG

TTGTCCTCCTACCCTCTACA

55

exp

TNF

TCCTTCAGACACCCTCAACC

AGGCCCCAGTTTGAATTCTT

58

exp

STAT6

ACTTTTTCTGGGGGCATCTT

AGAAGACAGCAGAGGGGTTG

exp

TNFRSF10B

CTCTCTGCTGGGGAGCTAGG

AAGACCCTTGTGCTCGTTGT

exp

BCL10

TTGCACGTAGATGATCAAAATGT

CGAGGAGGACCTCACTGAA

exp

SELL

CTAATTGCGTGCCACTCTGA

CCCCCTCACACACTTTGTCT

exp

LRMP

GTTGTTGAATTGCATCTGGC

GCACTTCAGCAGAAGACAAGG

exp

JAK2

CCATTCCCATGCAGAGTCTT

CAGGCAACAGGAACAAGA

exp

ITGA4

TGGCTGTCTGGAAAGTGTGA

AGACGTGCGAACAGCTCC

exp

IL18BP

AGGCCACACAGGATAAGCTC

CAGCAGCTAAGCAGTGTCCA

exp

KLRD1

CGGTGTGCTCCTCACTGTAA

AGCCTGCTTCAGCTTCAAAA

exp

IBRDC3

CTCACAAGTTAGCTTCGGGC

TACCTAGCCTCGGACCCC

exp

FBXO9

CAGACGCCATATTTCAGGGT

TCCGATGGGTGGTGTCTAGT

exp

UBR2

GCACTCCATGCACAAAACAC

CCTTCTCATCTTTGTGGTCGT

exp

DDX17

AAGTGGTCCGGTAACGAGAA

GAGGCCAATCAGGCTATCAA

exp
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Chromatin Immunoprecipitation
Cells (20 x 106) were crosslinked with 1% formaldehyde for 10 min. at room
temperature, then quenched via addition of 5M glycine to a final concentration of 0.125M
for 5 min. Cells were pelleted and washed in PBS. Nuclei were isolated in TX100/NP40
buffer (10mM Tris pH8.1, 10mM EDTA, 0.5mM EGTA, 0.25% Triton-X-100, 0.5%
NP40, 1mM PMSF, 0.5X Roche protease inhibitor cocktail) and washed in salt wash
buffer (10mM Tris pH8.1, 1mM EDTA, 0.5mM EGTA, 200nM NaCl, 1mM PMSF,
0.25X Roche protease inhibitor cocktail). After 10 min. incubation at 4ºC, nuclei were
pelleted and resuspended in 600µL (2 x 300µL) sonication buffer (10mM Tris pH8.1,
1mM EDTA, 0.5mM EGTA, 1% SDS, 1mM PMSF, 1X Roche protease inhibitor
cocktail) and sonicated for 8 cycles (30 sec. “on”, 30 sec. “off”) in a Diagenode
Bioruptor. Samples were centrifuged at 13,000rpm for 10 min. at 4ºC, then snap frozen
in LN2 and stored at -80ºC. 4.5 x 106 cell equivalents (135µl) were used for each
immunoprecipitation reaction. Primary antibodies were used at 0.5μg in each 900μl
reaction and incubated overnight. Antibodies used were: PRDM1 (PRDI-BF1) (Cell
Signaling) and normal rabbit IgG (Upstate). Immune complexes were captured with
protein A/G beads (Santa Cruz) and washed five successive times. First and second
washes were TSE150 (20mM Tris pH8.1, 150mM NaCl, 2mM EDTA, 0.1% SDS, 1%
Triton-X-100); third and fourth washes were TSE500 (20mM Tris pH8.1, 500mM NaCl,
2mM EDTA, 0.1% SDS, 1% Triton-X-100); fifth wash was LiCL250 (10mM Tris pH8.1,
250mM LiCl, 1% NP40, 1% sodium deoxycholate, 1mM EDTA). DNA was eluted from
beads using two successive elutions of 150µl elution buffer (10mM tris pH8.1, 1% SDS,
1mM EDTA). Eluted DNA was column purified (Qiagen) after reversal of crosslinks (4
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hr. 65ºC), RNase treatment and proteinase K treatment. PCR was performed using 1.5μl
of eluted DNA (~1/40th) in duplicate. Primers designed against the second exon of
Myoglobin (MB) (Diagenode) were used as a negative control locus. Percent input was
calculated by linearization of ΔCt (CtIP – Ct1%input) for both specific and IgG samples.

ChIP-chip
For each of three independent experiments, chromatin was prepared as described
above from 100 x 106 NKL cells at a density of ~5 x 105/ml. Ten immunoprecipitations
for PRDM1 were performed, with one IgG control immunoprecipitation and
immunoprecipitated DNA obtained as described above.

Quality was verified by

performing qPCR for PCNA and CIITApIV as positive controls and as positive controls
and MB and HLA-DR as negative controls. PRDM1 immunoprecipitations were pooled,
quantified using a Nanodrop 1000 spectrophotometer and amplified using the Sigma
Whole Genome Amplification kits according to the manufacturer’s instructions. Ten ng
were used to perform amplification in two steps using the WGA2 and WGA3 kits. In
both amplifications, only 14 cycles were used to prevent non-linear amplification. For
the second amplification, 20 ng were amplified in duplicate using dNTP mix containing
dUTP (provided by Moffitt Microarray Core Faciliy). An additional quality check was
performed using a 1:100 dilution of the amplified DNA (using primers to PCNA,
CIITApIV, MB and HLA-DR) to verify >10-fold enrichment. Six µg DNA for both
PRDM1 immunoprecipitation and input samples were submitted to the Moffitt
Microarray Core Facility for hybridization to Affymetrix GeneChip Promoter 1.0R Tiling
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Arrays. Separate arrays were run for each sample. Raw hybridization data was provided
as .cel files by the Core Facility.

ChIP-chip Data Analysis
Raw hybridization contained in .cel files was analyzed using two methods:
CisGenome and Model-based Analysis of Tiling Arrays (MAT) (175, 176).

Both

CisGenome and MAT analysis programs are freely available for download
(http://www.biostat.jhsph.edu/~hji/cisgenome/ and http://liulab.dfci.harvard.edu/MAT/).
For Cisgenome, .cel files were added and normalized via quantile normalization. Peaks
were annotated using default settings (PRDM1 > input; maximum gap < 300bp, peak >
100bp and peak contains > 5 continuous probes) and mapped to human genome version
18 (hg_18). Nearest single genes associated with peaks of enrichment were identified
within 15kb upstream of the transcription start site (TSS), 15kb downstream of the
transcription end site (TES) and within each gene. Based on these criteria, up to three
genes could be identified for each peak. For MAT, .cel files were first converted to .txt
files, input into the Linux-based MAT platform and peaks were annotated using settings
identical to those used for CisGenome. This analysis generated a .bed file containing the
annotated peaks which was then converted to a CisGenome file (.cod) and used to
identify the nearest genes as stated above. A total of six analyses were performed, two
for each of the three experiments.
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DNA Constructs
Flag-PRDM1
The full-length cDNA encoding PRDM1α was PCR cloned into pcDNA3.1,
modified to contain a FLAG epitope sequence.

This plasmid has been previously

described (5).
IFNG Promoter Luciferase Constructs
A fragment of the human IFNG promoter (-507 - +120) was PCR cloned from
human genomic DNA into pcr2.1. The fragment was then subcloned into pGL3basic
using the HindIII and SmaI restrictions sites to generate pGL3-IFNγ_WT.

pGL3-

IFNγ_mut was obtained via site-directed mutagenesis of the -254 site, changing residues
AAAAGT to TCTAGA, which created a novel XbaI site (Mutagenex, Inc). pGL3IFNγ_∆ was obtained by ligation of an XbaI-XbaI fragment obtained from pGL3IFNγ_mut with the XbaI-NheI fragment of the pGL3-Basic vector.
PTK2 Promoter Constructs
Plasmids encoding luciferase under control of the PTK2 promoter were obtained
from William Cance (Roswell Park, Buffalo, NY). Three plasmids were obtained with
progressive deletions of the promoter (spanning from +47 to -564, -1020 and -1173
realtive to the transcriptional start site) cloned upstream of luciferase in pGL3 as
described (177).

An additional construct pGL3-PTK2-1400 was created by PCR

amplifying a genomic 230bp and subcloning into the 1173.
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Recombinant G9a Expression and Purification
Using a portion of the murine G9a coding sequence cloned in-frame into pGEX3,
a catalytically-active fragment (amino acids 1 -439) was purified from bacterial lysates.
E.coli BL21 cells were inoculated and grown in large scale cultures (500ml) for 2-3h to
an OD450 of 0.5 – 0.6. Cultures were induced using 0.5 mM IPTG and incubated at 30ºC
for 90 min. Cells were collected, washed with cold PBS and lysed in bacterial RIPA
(20mM Tris pH 7.5, 500mM NaCl, 5mM EDTA, 1% NP-40, 0.5% Na-desoxycholate, 1X
Roche protease inhibitor cocktail, 5mg/ml lysozyme, 1mM PMSF) at 10mL per L of
culture. Viscosity was disrupted via 2 freeze/thaw cycles using a L2 bath and 6 pulses of
30s sonication using a Branson Sonifer set at 30% in the cold room. Lysates were
cleared by centrifugation at 13,000xG.

Supernatants were incubated with anti-

glutathione beads (800µl/10mL) and rotated for 2h at 4ºC. HMT-GST fusion proteins
were eluted in 4 fractions with glutathione elution buffer (50mM Tris pH 8.0, 150mM
NaCl, 15mM glutathione, 1X Roche protease inhibitor cocktail, 1mM PMSF). Fractions
were stored in 15% glycerol at -20ºC.

Radioactive In Vitro Histone Methyltransferase Assay
Recombinant G9a was incubated with histone substrate (4µg core histones,
isolated from calf thymus) and 1.5 3H-SAM (55-85 Ci/mmol) in a 40µl reaction
containing the following: 50mM Tris pH 9.0, 5mM Mg Cl2, 0.5mM DTT, 50µM PMSF.
Reactions were incubated at 30ºC for 1h and stopped by addition of 10µl 5X Laemmeli
dye. Reaction products were resolved on 16% SDS-PAGE gels and transferred to PVDF
membranes. Membranes were exposed to high sensitivity Kodak MS film at -80ºC for 2-
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14 days using an enhancer screen. Equal loading was monitored by amido black staining
of membranes.

MALDI-TOF Mass Spectrometry Analysis
Recombinant G9a was incubated with 1uM synthetic human histone H3 peptide
(N-terminal residues 1-20, ARTKQTARKSTGGKAPRKQL) in a 50µl reaction
containing the following: 50mM Tris pH 9.0, 5mM Mg Cl2, 0.5mM DTT, 50µM PMSF
and 1mM SAM. Reactions were initiated via addition of two equally buffered “master”
mixes, the first containing SAM and enzyme (40µl), the second containing peptide
(10µl). Reactions were carried out in 96-well plates and incubated 30 min. to 2h at room
temperature with slow rotation. Reactions were stopped via the addition of tri-fluoroacetic acid to a final concentration of 0.25%. Aliquots (0.2µl) were spotted on 192sample analytical plates.

Dried analyte spots were overlaid with 0.7µl α-cyano-4-

hydroxycinnamic acid matrix in 55% aqueous acetonitrile.

Matrix-assisted laser

desorption ionization – time-of-flight mass spectrometry (MALDI-TOF MS) was
performed with a tandem time-of-flight instrument (4700, Applied Biosystems,
Framingham, MA) in positive ion mode. Methylation was detected via shifts in the m/z
spectrum for the H3 peptide. Fragments corresponding to Δm/z 2183 (unmodified), Δm/z
2197 (mono-methylation), Δm/z 2211 (di-methylation) and Δm/z 2225 (tri-methylation)
were each quantified and used to assess the degree of modification based on signal-tonoise ratio for each peak. MALDI-TOF MS/MS was performed initially to verify that
Lysine at position 9 was the target of methylation.
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Small Molecule Screening to Identify Methyltransferase Inhibitors
Methyltransferase activity assays were carried out as described above using small
compound libraries arrayed across 96-well plates in 1µl DMSO at 5mM.

Reaction

volumes of 49µl generated a final small molecule concentration of 100µM. Each plate
contained 80 compounds with the first and last columns used for control wells. For each
plate, 8 wells (A1, B1, C1, D1, E12, F12, G12, H12) contained no enzyme controls and 8
wells (E1, F1, G1, H1, A12, B12, C12, D12) contained DMSO-only controls.

A

Beckman Biomek FX liquid handler was used to robotically pipette reaction components
into 96-well plates. Reactions were set up as described above, with 39µl containing the
enzyme added first, followed by addition of 10µl of solution containing the peptide
substrate. Thus, the enzyme was exposed to the small molecule before addition of the
peptide substrate. After each addition a “mixing” step was added, whereby 5µl was
pipetted up and down 3 times. Reactions were stopped by the addition of TFA as above,
bringing the total volume to 100µl. 0.2µl aliquots were analyzed by MALDI-TOF MS as
described above.
Average degree of methylation for DMSO-only controls (n =8) was considered
baseline methylation for each plate. Inhibitors were identified as “hit” if they resulted in
a decrease of > 2 standard deviations in degree of methylation.

Statistical Analyses
For statistical analyses, two-tailed paired t-tests were used. P-values less than
0.05 were considered significant. All calculations were performed in Microsoft Excel.
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CHAPTER III
PRDM1 REGULATES EFFECTOR CYTOKINE PRODCUTION IN NK CELLS

Introduction
NK cells play critical functions in both innate and adaptive immunity. Although
these lymphocytes were initially identified by their ability to lyse leukemia cells in a nonMHC restricted manner, subsequent studies have highlighted their role in cytokine
production. In response to activating stimuli, NK cells proliferate, increase cytotoxicity
and produce cytokines such as IFNγ, TNFα and GM-CSF (99). IL-2 up-regulates the
expression of effector molecules and enhances natural cytotoxicity against a variety of
targets. Furthermore, IL-2 and IL-15 both signal through the common γc receptor to
control proliferation, with IL-15 being uniquely required for survival in vivo (119). IL-12
and IL-18 signal through distinct heterodimeric receptor complexes to elicit increases in
IFNγ via several mechanisms, including increased transcription, message stability and
nuclear retention (125-127). Synergistic increases in cytotoxicity and IFNγ production
are observed in response to co-stimulation with IL-12 and IL-18 (130, 131).
Cytokine-mediated activation of NK cells proceeds through several wellcharacterized nuclear transcription factors, many of which are functionally conserved
between T and NK lineages (178).

However, relatively few negative regulators of

activation-induced transcription have been identified in NK cells. ATF3 was recently
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shown to down-regulate IFNγ levels and ATF-/- mice exhibit increased resistance to
MCMV infection (179). The transcription factor H2.0-like homeobox (HLX) negatively
regulates IFNγ production, primarily through degradation of phosphorylated STAT4, not
direct DNA-binding activity (180).
PR Domain containing 1, with Zinc Finger Domain 1 (PRDM1, also BLIMP1 or
PRDI-BF1) is a transcriptional repressor encoded by the PRDM1 gene on chromosome
6q21. It was originally identified as a post-induction suppressor of IFNB in virallyinfected osteosarcoma cells (1). Subsequent work revealed a pivotal role in the terminal
differentiation of antibody-producing plasma cells (2). PRDM1 exerts its repressive
functions through recruitment of histone-modifying enzymes (HDAC2, G9a, PRMT5 and
LSD1) and Groucho corepressors (15, 19, 181). Through silencing of direct (cMyc,
CIITA, Pax5) and indirect targets, PRDM1 is a master regulator of terminal
differentiation of B-lymphocytes, mediating cell cycle exit, repression of early B-cell
factors and induction of immunoglobulin secretion (46, 47).
More recently, a role for PRDM1 in T lymphocytes has emerged. PRDM1 is
expressed in both CD4+ and CD8+ T cell lineages and is critical for maintenance of
homeostasis.

Conditional knockout in T lymphocytes leads to increased effector

populations, resulting in severe colitis (64, 65). Upon activation, an auto-regulatory loop
exists whereby IL-2 induces PRDM1 expression which in turn negatively regulates IL-2
transcription (67, 68). During CD4 polarization, PRDM1 is preferentially expressed in
Th2 cells and reinforces commitment to this lineage through repression of Ifng, cfos and
tbx21 (66, 67).

Within the CD8 lineage, PRDM1 is expressed at higher levels in

exhausted subsets and promotes acquisition of the effector phenotype through
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suppr ession of memory potential (71-73). Thus, in addition to well-characterized B cell
specific functions, PRDM1 is also a critical regulator of T lymphocytes. The work
presented herein provides the first functional description of PRDM1 in NK cells.

Results
Human NK cells alter expression of multiple effector molecules and transcription factors
in response to cytokine stimulation

Natural killer cells are well known for their ability to up-regulate both the
production of effector cytokines and cytotoxic potential in response to IL-2 and other
cytokines such as IL-12, IL-15, and IL-18. However, the roles of sequence-specific,
DNA-binding transcription factors in the modulation of NK activity are incompletely
characterized. To directly address this, global gene expression profiling was conducted
using microarray analysis of RNA from NK cells isolated from peripheral blood of two
healthy donors either immediately upon isolation or after 24h stimulation in the presence
of IL-2, IL-12 and IL-18.

Purity of the NK population was determined by flow

cytometry to be greater than 92% in ungated populations and was further confirmed by
the absence of significant signals for transcripts associated with B cells, T cells, and
monocytes in the microarray (Figure 9A and 9B). Biological variance among donors
was quite low, yielding R2 value of .967 and .970 between donors in freshly isolated and
stimulated samples, respectively (Figure 9C). In total, 541 genes were increased 3-fold
or more in both donors, while 609 genes were decreased 3-fold or more following 24h
stimulation (Figure 10 and Appendix I).
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Figure 9: Cells utilized for microarray analysis display NK surface phenotype and
minimal donor-to-donor variability. A) FACS analysis of negatively-selected NK
cells obtained from PBMCs of two healthy donors. B) Average signal intensity obtained
from microarray analysis of RNA obtained from freshly isolated samples demonstrating
low to undetectable levels of transcripts associated with non-NK immune lineages. C)
Regression analysis of signal intensity values of resting and stimulated conditions for
each donor. R2 values indicate high correlation between donors.
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Figure 10: Top 75 up- and down-regulated transcripts upon stimulation. Heat-map
depicting top 75 genes sorted by signal intensity found to be up- or down-regulated at
least 3-fold in response to 24h stimulation with IL-2 (100U/mL), IL-12 (10ng/mL) and
IL-18 (100ng/mL) relative to time 0h. Pixel density (highest values in each are pure
black, lowest are white) represents average hybridization signal intensity from two
donors after and before stimulation for increased and decreased genes, respectively. Fold
changes are shown in parentheses. Presentation of expression data in this manner allows
appreciation of both magnitude of expression and increases/decreases in response to
stimulation.
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In response to stimulation, large transcriptional changes were observed in genes
encoding effector molecules. As previously reported, IFNG mRNA is detectable in
freshly isolated NK cells and is dramatically up-regulated upon stimulation (Figure 11).
Transcripts encoding the secreted cytokines GM-CSF and TNFα were also highly upregulated. Importantly, transcripts for cytokines not produced by NK cells (i.e. IL2) were
not detected, further indicating purity of cells used in the analysis. Decreased levels of
TGFB1, which is constitutively expressed in NK cells, were also observed in response to
stimulation, consistent with its role as a negative regulator of activation/proliferation.
Although NK cells are known to produce IL-10, transcripts of IL10 were not detected.

Figure 11: Up- and down-regulated effector molecules in response to stimulation.
Signal intensities were averaged from each donor before and after 24h stimulation with
IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are selected secreted
cytokines and tumor necrosis factor family members.

Numerous TNF family members were also found to be transcriptionally upregulated in response to stimulation. When present on the cell surface these molecules
facilitate induction of apoptotic programs upon engagement of ligands expressed on
target cells. FAS and TRAIL are both capable of mediating apoptosis via ligation with
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their receptors, present on target cells. 4-1BB (CD137) is a co-stimulatory molecule
whose expression increases upon activation and mediates activating signals upon
engagement with its cognate ligand (182). Similarly, OX40-OX40L interactions control
effector function via interactions with T cells (183). Thus, stimulation alters the
functional capacity of NK cells via transcriptional up-regulation of secreted cytokines
and surface-bound effector molecules.
In order to carry out effector function, NK cells must be able to respond to
signals. NK cells respond to a variety of cytokines produced by T cells, DCs and
macrophages. IL-2 and IL-15 are both crucial regulators of proliferation, which signal
through shared components of a heterodimeric or trimeric receptor. In response to
stimulation, NK cells up-regulate transcription of the IL-2 receptor α (encoded by IL2RA)
(Figure 12). The trimeric, high affinity IL-2 recep tor is comp osed of the α, β and γ
subunits and imparts

Figure 12: Up- and down-regulated cytokine receptor molecules in response to
stimulation. Signal intensities were averaged from each donor before and after 24h
stimulation with IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are
selected cytokine receptor molecules.
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the ability to respond to very low quantities of IL-2. Thus, in response to stimulation NK
cells quickly acquire increased sensitivity to IL-2 and are poised to rapidly proliferate.
Similarly, the IL-15 receptor is up-regulated and increases the ability to respond to IL-15,
which is often presented in trans by DCs (184). IFNγ has been reported to increase NK
cytotoxicity (185), yet the gene encoding one half of the dimeric IFNγ receptor (IFNGR1)
is significantly down-regulated in response to stimulation. Such a mechanism likely
prevents over-stimulation via an autocrine feedback loop involving NK-derived IFNγ.
NK activity is largely controlled by the repertoire of activating and inhibitory
receptors present on the cell surface. NK receptor families are broadly defined by their
shared structural motifs and propagate activating or inhibitory signals based upon the
presence of specific intracellular motifs. Transcripts for the killer cell immunoglobin-like
receptors (KIRs) are uniformly down-regulated in response to stimulation (Figure 13).

Figure 13: Up- and down-regulated NK receptors in response to stimulation. Signal
intensities were averaged from each donor before and after 24h stimulation with IL-2
(100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are selected members of
the KIR family, the killer-type lectins and the natural cytotoxicity receptors. KLRA1 =
psuedogene, KLRB1 = CD161, KLRC1 = NKG2A, KLRC3 = NKG2E, KLRC4 =
NKG2F, KLRD1 = CD94, KLRF1 = NKp80, KLRG1 = MAFA-L, KLRK1 = NKG2D,
NCR1 = NKp46, NCR2 = NKp44, NCR3 = NKp30.
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The killer lectin-like (KLRs) and natural cytotoxicity-triggering receptors (NCRs) remain
largely unchanged with the exception of KLRF1, which encodes NKp80 and is
significantly down-regulated upon activation. The inhibitory receptor NKG2A, which is
encoded by KLRC1, is the only NK receptor that is transcriptionally up-regulated in
response to stimulation.
The SLAM family consists of nine members all of which share homology to CD2.
These molecules are expressed on a variety of lymphocytes. In NK cells these molecules
are variably expressed with CD48 (SLAMF2) and CRACC (SLAMF7) strongly upregulated in response to stimulation (Figure 14). CD48 is a ligand for 2B4 (SLAMF4),
which is highly expressed in resting NK cells, but decreases upon stimulation.

Figure 14: Up- and down-regulated SLAM family members in response to
stimulation. Signal intensities were averaged from each donor before and after 24h
stimulation with IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are
SLAM family members. SLAM = signaling lymphocyte activation molecule. CD48 =
SLAMF2, LY-9 = SLAMF3, 2B4 = SLAMF4, CD84 = SLAMF5, NTB-A = SLAMF6,
CRACC = SLAMF7, BLAME = SLAMF8, CD84-H1 = SLAMF9.
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Modulation of these molecules has the potential to propagate activating signals via cellcontact. Interestingly, CRACC has been shown to function as an activating receptor in
NK cells, while playing an inhibitory role in CD4+ T cells (186). It should be noted that
surface level protein expression may not directly correlate with transcriptional changes.
Thus, conclusions about function must be made cautiously.
Transcriptional control of NK effector function is poorly defined relative to other
lymphocyte lineages. Unlike B and T cells, very few NK-specific transcription factors
have been defined. Of the top 150 transcripts found to be modulated after stimulation,
nearly 10% were sequence-specific DNA-binding transcription factors (Figure 15A). A
variety of transcription factors associated with lymphocyte function are induced upon

Figure 15: Up- and down-regulated transcription factors in response to stimulation.
A) Heat-map depicting top 15 up- and down-regulated DNA-binding transcription factors
as in Figure 10. B) Confirmation of up-regulation of six transcription factors in response
to IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL) by qRT-PCR. Data was
normalized using 18S as control gene, error bars represent s.d. from three independent
donors. C) Confirmation of NFκB (p105/p50) and STAT5 protein induction in response
to IL-2, IL-12 and IL-18 by immunoblot. D) Confirmation of IRF8 protein induction in
response to IL-2, IL-12 and IL-18 by immunoblot.
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stimulation, however, no data exist regarding their function in NK cells. BATF encodes
the B cell Activating Transcription Factor, which dimerizes with JunB, but lacks
transactivation activity. Thus, this factor whose expression is limited to hematopoietic
cells has the potential to abrogate AP-1 function via competition for Fos (187, 188).
EGR2, a zinc-finger transcription factor, is required for both positive selection of
thymocytes and differentiation of IL-10 producing CD4+CD25-LAG3+ Treg cells (189,
190). EOMES encodes the eomesodermin transcription factor which is critical for
effector function of CD8+ T cells (191). More recently, Eomes has been found to play a
role in murine uterine NK cells, which play crucial IFNγ-dependent functions during
pregnancy (192). NFKB1 encodes the p105 subunit of NFκB. In response to IL-12 and
IL-18, the p105 subunit is cleaved to form the p50 subunit, which dimerizes and enters
the nucleus. Thus, in response to stimulation a positive feedback exists where p50 levels
are increased via up-regulation of total p105 (Figure 15C). Similarly, STAT5A is upregulated in response to stimulation, resulting in higher levels of total STAT5, a major
mediator of IL-2 signaling. Finally, IRF8 levels are markedly increased in response to
stimulation (Figure 15D). This factor plays critical roles within the myeloid lineage, yet
has not been described in NK cells. Interestingly, the strong up-regulation observed for
STAT5A and IRF8 are quite specific, because other family members do not change
nearly as dramatically (Figures 16 and 17).
transcription factors to modulate effector function.
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Thus, NK cells utilize a variety of

Figure 16: Up- and down-regulated IRF family members in response to stimulation.
Signal intensities were averaged from each donor before and after 24h stimulation with
IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are IRF family
members (IRF1-IRF8).

Figure 17: Up- and down-regulated STAT family members in response to
stimulation. Signal intensities were averaged from each donor before and after 24 hr
stimulation with IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are
STAT family members (STAT1-STAT6).

Cytokine stimulation induces multiple PRDM1 isoforms in human NK cells
Among the up-regulated transcription factors, the transcriptional repressor
PRDM1 was increased in response to stimulation. PRDM1 has not been previously
identified in NK cells, however, within the immune system PRDM1 plays crucial roles in
both cell fate decisions and regulation of homeostasis. The role of PRDM1 in the
terminal differentiation of mature B cells into immunoglobin-secreting CD38+ plasma
cells is well established.

More recently, roles for PRDM1 in the maintenance of
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homeostasis and effector versus memory lineage commitment in T lymphocytes have
been reported (71-73).

The presence of PRDM1 and up-regulation upon activation

suggest that it may also have key functional roles in NK cells.
In order to directly establish PRDM1 activation, human NK cells were isolated by
negative selection and stimulated with multiple combinations of IL-2, IL-12 and IL-18.
Immunoblot analysis reveals that freshly isolated and unstimulated NK cells have barely
detectable levels of PRDM1 protein (Figure 18A).

Stimulation with IL-2 or a

combination of IL-12 and IL-18 results in increased levels of PRDM1 protein, which is
markedly enhanced by co-stimulation with all three cytokines. Cell lines derived from
malignant NK tumors constitutively express PRDM1 and exhibit distinct isoform
expression patterns (Figure 18B). YT and NK92 cell lines exclusively express the larger
α-isoform, while NKL most closely resemble the expression pattern observed in primary
human NKs.

Consistent with immunobloting experiments, analysis of the α and β

isoforms mRNA levels in primary NK cells indicates that cytokine stimulation upregulates both isoforms and that PRDM1β mRNA is present at approximately 20-fold
higher levels than PRDM1α (Figure 18C).
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Figure 18: Cytokine stimulation induces PRDM1 isoforms in human NK cells. A)
Western blot analysis of purified human NK cells stimulated for 24h with IL-2
(100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL) or combination. Blot shown is
representative of numerous experiments. B) Immunoblot analysis of lysates prepared
from human NK cell lines demonstrates differential expression of PRDM1 isoforms. C)
RT-PCR analysis of cDNA synthesized from freshly isolated or 24h stimulated NK cells.
Expression values were calculated using the ΔΔCt method with 18S as the control gene.
Upon linearization of Ct values, average Time 0 PRDM1α was arbitrarily set to “1” to
account for basal differences among donors and the consistently higher expression levels
of PRDM1β. Error bars represent SD from at least three biologically independent
samples isolated from different donors at different times. Paired two-tailed t-tests were
conducted, with (∗) representing p < .05 p-values were 0.016 and 0.023 for PRDM1α and
PRDM1β, respectively.

Human NK cell lines constitutively express high levels of PRDM1. In order to
assess changes in response to cytokine stimulation, two NK cell lines were stimulated for
24h or 48h with combinations of IL-2, IL-12 and IL-18 (Figure 19). NKL cells exhibit
relatively static expression of PRDM1, although stimulation with IL-2, IL-12 and IL-18
results in a moderate increase in PRDM1β. PRDM1 expression in NK-92 cells, unlike
NKL cells, is highly dependent on IL-2. In the absence of IL-2, PRDM1 expression is
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significantly diminished by 24h and is nearly absent by 48h. These data indicate that NK
cell lines do not recapitulate the cytokine responsiveness observed in primary NK cells.
In terms of PRDM1 expression, NKL and NK-92 cells differ markedly in basal isoforms
patterns and response to IL-2 withdrawal.

Figure 19: Human NK cells lines do not recapitulate dynamics of cytokine-induced
expression observed in primary NK cells. NKL cells (top) or NK-92 (bottom) were
stimulated with various combinations of IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18
(100ng/mL) for 24h or 48h. Immunoblot analysis was performed for PRDM1.

Primary NK cells express three distinct molecular weight forms of PRDM1. The
largest molecular weight band corresponds to the full-length PRDM1α isoform, however
this protein is significantly underrepresented compared to the smaller PRDM1 proteins.
The predominant and smallest form corresponds to the PRDM1β originally characterized
in multiple myeloma tumor cells and shown to have partially reduced repressive ability in
reporter assays (5). In addition, immunoblot analysis detected an intermediate-sized
isoform in primary NK cells. This protein migrating at ~85kD likely represents the
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human homologue of a previously-described murine splice variant, prdm1Δexon7 (6).
Indeed, RT-PCR analysis using primers spanning the analogous exon in humans (exon 6)
confirms the presence of this splice variant (Figure 20).

Figure 20: Identification of a PRDM1 splice variant lacking exon 6 in NKL cells.
NKL cells express a PRDM1 transcript variant corresponding to deletion of exon 6. RTPCR was carried out using primers specific for the fifth and seventh exons of the human
PRDM1 gene. Over-expression of cDNA obtained from either U2OS cells expressing a
flag-tagged PRDM1 construct or NK-92 cells yielded the expected 311bp product, while
cDNA obtained from NKL cells yielded both a 311bp and 182bp products.

Human NK cells can be divided into two subsets based on the surface density of
CD56 and the presence of CD16. The CD56brightCD16dim/- subset represents ~10% of the
human peripheral NK cell compartment and has been suggested to play a immunomodulatory role based on the increased ability to produce cytokines; the CD56dimCD16+
subset represents ~90% of human peripheral NK cells and is considered the primary
cytotoxic subset. In order to determine whether PRDM1 is restricted to specific subsets
or if it is broadly expressed, human NK cells were isolated from healthy donors via
negative selection followed by flow cytometric sorting into CD56bright and CD56dim
subsets. These cells were then stimulated with IL-12 and IL-18 for 24h before analysis.
Immunoblot and qRT-PCR analysis reveals that PRDM1 is preferentially expressed in
the CD56dim subset in response to stimulation (Figure 21). Furthermore, PRDM1β is the
predominant isoform present.
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Figure 21: PRDM1 is preferentially expressed in the CD56dim NK population. A)
CD56dim and CD56bright cells were obtained by FACs sorting of negatively-selected
human NK cells as described (193). Cells were stimulated for 24h with IL-12 (10ng/mL)
and IL-18 (100ng/mL) then analyzed by RT-PCR for expression of PRDM1 isoforms.
GAPDH was used as a housekeeping gene. Results are expressed as fold over U266
mRNA wh ich exp resses h igh levels of both PRDM1 α and PRDM1 β. B) Immunoblot
analysis of lysates prepared from CD56dim and CD56bright subsets obtained as in panel A,
but from different donors.

PRDM1 expression in NK cells appears to differ markedly from other immune
lineages. The characteristic isoform pattern is not observed in other cell types and
stimulations that induce PRDM1 are distinct. In B cells, using either CD19+ purified
lymphocytes or patient-derived CLL cells, IL-21 is involved in upregulation of PRDM1
protein expression (Figure 22A, B). In both experiments, the full-length PRDM1α is the
predominant isoform.

Similarly, during LPS-induced maturation of dendritic cells,

PRDM1α is induced with no detectable PRDM1β (Figure 22C).

Furthermore,

Bortezomib treatment induces only PRDM1α in mantle cell lymphoma cell lines (Figure
22D).

Conversely, multiple isoforms are consistently observed in NK cells.

Interestingly, IL-21 does not activate PRDM1 alone nor does it synergize with IL-12 or
IL-18 (Figure 22E). Thus, novel mechanisms of PRDM1 induction exist in NK cells.
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Figure 22: NK-specific expression of PRDM1 isoforms. Immunoblot analysis of
PRDM1 induced in various lineages. A) CD19+ B cells isolated from two healthy donors
+/- 7 day stimulation with IL-2, IL-4, IL-10, IL-21 and trimeric CD40 ligand as described
(194). B) Patient-derived CLL cells +/- 5 day stimulation with IL-21 (100ng/mL). C)
Human monocyte-derived DCs induced to mature with LPS as described (75). D) Mino
and Jeko cells +/- 5nM Bortezomib as described (195). E) Negatively-selected NK cells
treated for 2 days with combinations of IL-2, IL-12, IL-18 and IL-21.

Several lines of evidence suggest that the induction of PRDM1 in NK cells is not
associated with a terminal differentiation event as in B cells. First of all, NK cells in
peripheral circulation are mature cells, yet lack detectable PRDM1 protein expression in
the absence of stimulation. Constant cytokine stimulation is also required to maintain
PRDM1 expression, as indicated by “washout” experiments. In the absence of sustained
stimulation, PRDM1 protein and mRNA levels diminish to near background levels
(Figure 23A). Post-transcriptional mechanisms are involved in maintaining high levels
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Figure 23: PRDM1 induction is transient and is regulated via a post-transcriptional
mechanism. A) “Washout” experiments were conducted with primary NK cells
stimulated for 4h with IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Cells
were collected, washed in PBS and resuspended in fresh RPMI (w/o) or left under
stimulation (stim.) for up to 4 days. Lysates were collected at various time points and
analyzed by immunoblot for PRDM1 expression. B) Freshly isolated NK cells from two
healthy donors were stimulated for 4h in the presence of either DMSO, cyclohexamide or
actinomycin D. RT-PCR analysis was conducted of both PRDM1α and PRDM1β mRNA
levels, relative to 18S. C) LAK cells were either stimulated or left un-stimulated for 4h
and analyzed as in B. D) Model depicting putative labile repressor that regulates PRDM1
mRNA levels. This repressor has a high turnover rate and in the absence of new protein
synthesis, PRDM1 mRNA levels accumulate to high levels.

of PRDM1 expression in NK cells.

When protein synthesis is inhibited via

cyclohexamide, cytokine-stimulated NK cells express markedly higher levels of PRDM1
after 4h stimulation (Figure 23B, C). This effect is enhanced with cytokine stimulation
and indicates the presence of a labile negative regulator of PRDM1 mRNA. Furthermore,
expression profiles of transcription factors associated with plasma cell differentiation are
different in NK cells. In B cells, PAX5 and BCL6 decrease, while IRF4 and XBP1
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increase concomitantly with induction of PRDM1 during plasma cell differentiation. In
NK cells PAX5 is not expressed, BCL6 does not decrease and IRF4 does not increase
(Figure 24). Finally, when NK cells are stimulated to induce PRDM1, XBP1 is also upregulated, however, no splicing of XBP1 mRNA is observed in NK cells (Figure 25). In
B cells, XBP1 splicing accompanies PRDM1 induction during plasma cell differentiation
and is required for the proper regulation of the secretory pathway (48).

Thus,

stimulation-induced PRDM1 expression in NK cells is functionally distinct from B cells.

Figure 24: Plasma cell transcription factor expression diverges in NK cells. Signal
intensities were averaged from each donor before and after 24h stimulation with IL-2
(100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). Shown are major transcription
factors associated with plasma cell differentiation.
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Figure 25: XBP1 splicing is not associated with NK activation. RT-PCR analysis was
conducted for splicing of XBP mRNA. cDNA was prepared from RNA obtained from
two healthy donors at time of isolation or after 24h stimulation with IL-2 (100U/mL), IL12 (10ng/mL) and IL-18 (100ng/mL).

PRDM1 Expression is associated with NK activation
Given that PRDM1 is maximally induced in response to co-stimulation with IL-2,
IL-12 and IL-18, it is likely that levels of PRDM1 correlate with degree of activation.
Thus, mRNA levels of the effector cytokines IFNγ and TNFα were profiled in purified
human NK cells after 24h stimulation with various combinations of cytokines.
Quantitative RT-PCR analysis indicates that IFNγ and TNFα mRNA are synergistically
increased upon stimulation with IL-2, IL-12 and IL-18 stimulation (Figure 26A).
Consistent with this, IL-2, IL-12 or IL-18 alone each minimally alter PRDM1 expression
(Figure 26B). These data suggest that PRDM1 levels correlate with effector cytokine
transcription.
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Figure 26: PRDM1 induction is correlated with degree of activation. A) RT-PCR
analysis of cDNA synthesized from NK cells at time of isolation or after 24h stimulation
with IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL), alone or in combination.
Expression values were calculated using the ΔΔCt method with 18S as the control gene.
Upon linearization of Ct values, average Time 0 for each donor was arbitrarily set to “1”
to account for donor-to-donor variability of basal mRNA levels. Error bars represent
standard deviation from at least three biologically independent samples isolated from
different donors at different times. B) Immunoblot analysis of purified human NK cells
stimulated as in panel A.

As NK cells produce high levels of effector cytokines upon activation, the ability
of these effector cytokines to induce PRDM1 through autocrine or paracrine feedback
mechanisms was assessed. Treatment with either recomb in ant IFNγ or TNFα fails to
induce PRDM1. Stimulation with α-interferon is also insufficient to induce PRDM1,
suggesting that induction results primarily from cytokine receptor-mediated signaling and
likely requires multiple signaling events (Figure 27A, B). Ligation of CD16, the low
affinity Fc receptor, initiates activation of NK cells, resulting in ADCC and increased
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IFNγ production (196). However, no induction of PRDM1 was observed when surface
CD16 was activating with anti-CD16 antibodies (Figure 27C). Furthermore, although a
minor dose-dependent increase in PRDM1 expression was observed, IL-2 alone is
insufficient to drive high level PRDM1 expression in freshly isolated NK cells (Figure
27D). Thus, PRDM1 expression is not a “pan-activation” marker and NK cells require
stimulation with multiple cytokines to maximally induce PRDM1.

Figure 27: Autocrine and or paracrine feedback loops are not responsible for
PRDM1 induction. A) Immunoblot analysis of lysates prepared from purified NK cells
treated with recombinant human TNFα (20ng/mL or 100ng/mL), IFNγ (10ng/mL or
50ng/mL) for 24h. B) NK cells treated with recombinant human IFNα (10ng/mL or
50ng/mL). C) NK cells incubated with plate-bound anti-CD16. D) NK cells treated with
increasing concentrations of IL-2. In all experiments, stimulation with IL-2 (100U/mL),
IL-12 (10ng/mL) and IL-18 (100ng/mL) was used as a positive control for PRDM1
induction.

To determine if PRDM1 is induced in vivo, murine NK cells were activated by
tail vein polyI:C injections into C57/BL6 mice. PolyI:C is known to activate NK cells
indirectly through TLR3-mediated release of cytokines from dendritic cells and other
accessory cells. NK cells were purified by negative selection from the spleens of naïve
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and polyI:C treated mice. PRDM1 is robustly induced specifically in NK cells upon 48h
treatment (Figure 28). PRDM1 expression was also detected in total splenocytes and the
level did not change with polyI:C treatment. This is likely due to the presence of
PRDM1 in T cells and differentiating plasma cells within the spleen. Interestingly, only
the PRDM1α homologous isoform was detectable in murine NK cells. Although an
inability of the antibody to cross-react with other murine isoforms cannot be excluded, it
is possible that the expression and/or function of PRDM1 isoforms in murine cells may
be differentially regulated.

Figure 28: PRDM1 is induced in vivo. C57/BL6 mice were treated with 100μg polyI:C
via tail vein injection for 48h. NK cells from total splenocytes (right panel) or purified
via negative selection (left panel) and analyzed by immunoblot analysis.

PRDM1 is not involved in perforin-mediated cytotoxicity
The ability to lyse target cells in an antigen-independent manner is a hallmark of
NK cells. Cytotoxicity against heterologous target cells proceeds through the release of
perforin and granzymes and is markedly increased upon treatment with IL-2, IL-12 or IL18 (99, 197). To assess whether PRDM1 regulates cytotoxicity, NK cells were isolated
from healthy donors and stimulated with either IL-2 and IL-12 or the combination of IL2, IL-12 and IL-18 in the presence of either a non-targeting control or a PRDM1-specific
siRNA for 72h. Cytotoxicity against the K562 leukemia cell line was assessed in a 4h
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Chromium release assay. As expected, cytokine-activated NK cells exhibit significant

cytotoxicity against K562 targets (Figure 29A). Knockdown of PRDM1 expression did

Figure 29: Perforin-mediated cytotoxicity is not affected by PRDM1 knockdown. A)
4h 51Chromium release assays were performed in triplicate from two donors. Purified
NK cells were incubated for 72h in the presence of either a non-targeting (NT) or
PRDM1-specific (KD) siRNA and stimulated with combinations of IL-2 (100U/mL) and
IL-12 (10ng/mL), with or without IL-18 (100ng/mL). % 51Chromium release was
calculated as described in Materials & Methods. Error bars represent SD of triplicate
wells. B) Western blot analysis to confirm knockdown in cells used in cytotoxicity assay.
IL-2-only sample was not assayed in cytotoxicity assay and is only included to avoid
cropping of gel. C) Purified NK cells were incubated for 48h or 72h in the presence of
either a non-targeting (NT) or PRDM1-specific (KD) siRNA. Cells were stimulated with
combinations of IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL) and analyzed
by western blot for PRDM1 induction and PARP cleavage.

not alter cytolytic activity across several effector:target ratios. Distinct from experiments
that revealed increases in IFNG and PRDM1 mRNA levels with the addition of IL-18 to
IL-2 and IL-12, no additive effect of IL-18 was observed in cytotoxicity assays, further
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demonstrating that cytotoxicity and PRDM1 levels are not directly linked. Knockdown
of PRDM1 protein was confirmed by immunoblotting to be highly efficient and had no
effect on viability as assessed by trypan blue staining (Figure 29B , data not shown). No
activation-induced cell death was detected in stimulated NK cells as measured by PARP
cleavage (Figure 29C).

Furthermore, no defects in cytokine-induced clustering were

observed in response to PRDM1 knockdown (Figure 30). Collectively, these results
show that PRDM1 does not have a significant role in regulating perforin-mediated
cytotoxicity in NK cells.
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Figure 30: Clustering phenotype observed upon cytokine activation is not
diminished with PRDM1 knockdown. Primary NK cells were stimulated with either
IL-2 (100U/mL) and IL-12 (10ng/mL) or IL-2, IL-12 and IL-18 (100ng/mL) in the
presence of either a non-targeting or PRDM1-specific siRNA. Cells were analyzed by
light microscopy at 24h, 48h and 72h.
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PRDM1 binds promoters in multiple target genes
As PRDM1 is well-documented as a DNA-binding transcriptional repressor we
sought to characterize its function in NK cells by identifying DNA elements to which
PRDM1 specifically binds.

To this end, chromatin immunoprecipitation (ChIP)

experiments were performed using primary NK cells isolated from healthy donors. Cells
were stimulated for 24h with IL-2, IL-12 and IL-18 to induce PRDM1 expression prior to
isolation of chromatin and immunoprecipitation with either anti-IgG or anti-PRDM1
antibodies. Initially, promoter regions of genes known to be regulated by PRDM1 were
analyzed (Figure 31). A well-documented PRDM1 target gene is CIITA, the master
regulator of MHC class II expression which is transcriptionally silenced as mature B cells

Figure 31: PRDM1 binds CIITApIV, but not other B cell target genes. Chromatin
immunoprecipitation experiments were performed with chromatin isolated purified NK
cells stimulated for 24h with IL-2 (100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL).
Induction of PRDM1 was confirmed by western blot. Percent input was calculated as
described in Materials & Methods. Error bars represent SD from three biologically
independent experiments performed at different times with chromatin preparations from
different donors. Two-tailed t-tests between IgG and PRDM1 immunoprecipitated
samples, * p-value = 0.035.
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differentiate into antibody-producing plasma cells. PRDM1 binding was observed at the
IFNγ-inducible CIITApIV promoter, but not the lymphoid-specific CIITApIII promoter.
Although human NK cells can increase surface MHC Class II expression in response to
activation (198) and have been reported to exhibit antigen presentation capacity (199),
they express low to undetectable levels of CIITA. Binding of PRDM1 to the CIITApIV
promoter may function to reinforce this repressed state and prevent IFNγ-mediated
autocrine induction of CIITA.
No binding was detected at the promoters of PAX5 and IFNB, both of which have
previously been shown to be directly regulated via binding of PRDM1 to promoters in B
cells and Sendai virus-infected osteosarcoma cell lines, respectively. Furthermore, no
binding was detected at the promoter of SLAMF7, which encodes the NK activating
receptor CRACC and contains a potential PRDM1 binding motif within its proximal
promoter. This indicates that PRDM1 binds target gene promoters in a selective and cell
type specific manner. As expected, no binding was detected using primers to the second
exon of Myoglobin, which was used as a negative control locus.
In murine T cells, Blimp-1 has been shown to bind to a distal, conserved
regulatory site within the Ifng locus in in vitro polarized CD4+ Th1 lymphocytes (66). As
NK cells are potent producers of IFNγ during the early innate immune response and
induction is correlated with PRDM1 expression, its binding to the human IFNG locus in
cytokine-stimulated primary NK was evaluated. Four genomic locations were assayed
across the IFNG locus, which are highly conserved between rodents and humans and
have been demonstrated to regulate IFNG expression (200). Binding was detected at the
distal regulatory site, which has been demarcated as CNS -22 based on the genomic
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distances relative to the transcriptional start site in the mouse (Figure 32). This site is
analogous to the PRDM1 binding site detected in T cells. Additionally, through

Figure 32: PRDM1 binds known regulatory loci within the IFNG locus. A)
Chromatin immunoprecipitation experiments were performed as in Figure 31 using
primers across several known regulatory regions of the IFNG locus. Error bars represent
SD from three biologically independent experiments performed at different times with
chromatin preparations from different donors. Two-tailed t-tests between IgG and
PRDM1 immunoprecipitated samples, ** p-value = 0.0009. B) Locations of the primer
sets, relative to a portion of the IFNG locus region of chromosome 12.

bioinformatic analysis two potential PRDM1 binding sites were identified within the
minimal promoter, located 370bp and 254bp upstream of the IFNG transcriptional start
site. Robust PRDM1 binding was detected in this proximal promoter region which has
not been identified in T cells. Consistent with the absence of potential PRDM1 binding
sites, no binding was detected at CNS -6 or CNS +18-20. Collectively, these data
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demonstrate that PRDM1 binds both proximally and distally to multiple sites across the
IFNG locus in human NK cells.
TNF is coordinately induced with IFNG upon cytokine stimulation of NK cells.
Thus, we sought to determine if this locus was also bound by PRDM1. To this end, we
assayed four distinct locations across the ~12kB TNF locus by chromatin
immunoprecipitation. The TNF locus contains three genes, each of which contains four
exons (Figure 33). LTA and TNF are separated by ~1kB and transcribed from the same
strand while LTB is transcribed from the opposite strand and separated from TNF by

Figure 33: PRDM1 binds known regulatory loci within the TNF locus. A) Chromatin
immunoprecipitation experiments were performed as in Figure 31 using primers across
several known regulatory regions of the TNF locus. Error bars represent SD from three
biologically independent experiments performed at different times with chromatin
preparations from different donors. B) Locations of the primer sets, relative to a portion
of the TNF locus region of chromosome 6.
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~3kB. PRDM1 binding was measured at the proximal promoter regions of LTB and
TNF, the intergenic region between TNF and LTB and a recently identified regulatory site
located ~3.5kB upstream of LTA. This upstream enhancer element coordinately regulates
the LTA and TNF genes but not the opposing LTB gene (201, 202). PRDM1 binding was
clearly detected at this upstream regulatory site, but not at either proximal promoter or
the intergenic region. Furthermore, bioinformatic analysis detected a consensus PRDM1
recognition sequence in the bound enhancer element. These data indicate that PRDM1
specifically associates with defined regulatory sequences of the TNF locus.

Blockade of cytokine-induced PRDM1 expression increases effector cytokine production
PRDM1 is coordinately induced with effector cytokines upon stimulation and
occupies specific regulatory regions within the IFNG and TNF loci. To investigate the
functional effects of PRDM1 in NK cells, gene expression knockdown experiments using
primary human NK cells were performed. Cells were stimulated with IL-2 and IL-12 in
the presence of either a non-targeting control or PRDM1-specific siRNA. mRNA was
isolated after 48h and analyzed by real-time RT-qPCR. Significantly higher mRNA
levels of IFNG, TNF, and LTA were observed when PRDM1 induction was abrogated via
siRNA, yet no significant differences were found for DAP10 (Figure 34).
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Figure 34: Knockdown of PRDM1 increases levels of effector cytokine mRNA:
Purified NK cells were incubated for 48h in the presence of either a non-targeting (NT)
or PRDM1-specific (KD) siRNA and stimulated with IL-2 (100U/mL) and IL-12
(10ng/mL). RT-PCR was conducted for several genes on cDNA synthesized from RNA
isolated from three different donors at different times using 18S control gene. For each
donor, NT was normalized to “1”. Data are presented as the mean, with error bars
representing SEM from three biologically independent experiments.

In order to determine whether increases in mRNA levels observed with PRDM1
knockdown resulted in detectable changes in protein expression, ELISA experiments
were performed. Secreted IFNγ and TNFα were consistently increased in multiple donors
in response to PRDM1 expression knockdown (Figure 35). Consistent with this
silencing, PRDM1 expression remains elevated over a four day post-stimulation time
course, while IFNG and TNF levels decline (Figure 36). Together, these data indicate
that PRDM1 negatively regulates production of these cytokines in response to NK cell
activation.
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Figure 35: Knockdown of PRDM1 increases levels of secreted effector cytokines:
ELISA assay was conducted on supernatants harvested at 48h from samples in Figure 34
above. Data represent the mean of three independent wells. For each analyte, two-tailed
paired t-tests demonstrated p-value < 0.05 among all three donors for NT vs. KD.

Figure 36: Time course of cytokine mRNA and PRDM1 protein levels. A) Primary
NK cells stimulated with IL-2 and IL-12 for up to 4 days. RT-PCR was conducted for
several genes on cDNA synthesized from RNA isolated from different times using 18S
control gene. B) Representative immunoblot for PRDM1 expression at various
timepoints.
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Over-expression of PRDM1 mediates repression of activation-induced expression of
IFNG and TNF
Because PRDM1 occupancy at effector cytokine loci and increased production in
the context of PRDM1 knockdown were observed, the ability of PRDM1 to block
activation-induced transcription of IFNG and TNF was assessed. The Jurkat T cell line
was transduced with adenovirus expressing either GFP alone or GFP and PRDM1α prior
to stimulation. After PMA/PHA stimulation, RT-qPCR analysis was performed to assess
induction of IFNG and TNF. GFP-transduced cells showed significant up-regulation of
IFNG and TNF upon stimulation, which was nearly abolished in PRDM1α-transduced
cells (Figure 37). Thus, introduction of PRDM1 prior to stimulation was sufficient to
block stimulation-induced transcription of IFNG and TNF, providing further support that
PRDM1 is a negative regulator of effector cytokine production.

Figure 37: Over-expression of PRDM1 suppresses activation of target genes. Jurkat
cells were transduced for 40h, and then stimulated with PMA (50 ng/mL) and PHA (1
µg/mL) for 4h prior to RNA isolation. After correction using 18S, relative expression for
IFNG and TNF were determined by assigning a value of 100% to the stimulated GFPtransduced treatment. Data are presented as mean of three independent experiments, with
error bars representing SD, * p-value .0002, ** p-value .0005.
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PRDM1 mediates repression of IFNG via elements in the proximal promoter
To directly assess the functionality of PRDM1 binding to the newly identified
elements within the proximal promoter of the IFNG gene, we cloned the region
comprising -507 to +121 of the human IFNG gene and inserted it upstream of a luciferase
reporter (pGL3-IFNγ_WT). This promoter region contains the two potential PRDM1
binding sites, located at -370 and -254. Co-transfection of PRDM1 was sufficient to
repress luciferase activity driven by the wild type IFNG promoter by approximately 50%
(Figure 38). To assess the relative contributions of the two potential PRDM1 binding
motifs, a deletion of approximately 300 base pairs encompassing both of these sites

Figure 38: Promoter-proximal elements in the IFNG promoter are required for
PRDM1-mediated repression. Luciferase assays were conducted in Jurkat cells, 36h
post-transfection. Data are presented as the mean of four independent transfections +/SD, with each reporter transfected with empty vector set to 100%. Two-tailed paired ttests showed p-value of .005 for wild-type, indicated by *.
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(pGL3-IFNγ_Δ) was created. This deletion eliminated the ability of PRDM1 to repress
transcription from the construct.

This repression was similarly eliminated by point

mutations at the -254 site (pGL3-IFNγ_mut) demonstrating that this location is critical
for PRDM1-mediated repression. Thus, PRDM1 represses IFNG through binding to this
previously uncharacterized motif.

PRDM1 accumulates during LAK expansion and associates with functional exhaustion
PRDM1 expression is associated with terminal differentiation in a variety of cell
types. Recent evidence demonstrates that PRDM1 accumulation in CD8+ effector T cells
is associated with exhaustion. After an initial lag phase, human NK cells can be induced
to proliferate robustly in vitro for several weeks (in the presence of IL-2 and activating
stimuli such as anti-CD335 beads) before reaching exhaustion. These stimuli do not
induce PRDM1 expression after 48h in culture, but high levels are observed by day 19
(Figure 39). Interestingly, the full-length PRDM1α is the predominant isoform induced,
unlike short-term stimulation with IL-2, IL-12 and IL-18, which induce the truncated
PRDM1β and the putative PRDM1αΔexon6 isoform more abundantly.
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Figure 39: PRDM1 expression and function in LAK cells. A) LAK cells were
generated from three healthy donors in the presence of IL-2 (500U/mL) and activating
beads (anti-NKp46, anti-CD2). Immunoblot analysis at various timepoints. B) Primary
NK cells from three donors were isolated and stimulated for 48h with IL-2, IL-12 and IL18. C) ChIP analysis of the IFNG locus in LAK cells derived from one donor.

Discussion
The data presented here provides the first functional description of PRDM1 in
natural killer cells. PRDM1 accumulates upon cytokine-mediated activation and acts as a
negative regulator of activation, attenuating inflammatory cytokine production. Such a
negative feedback loop has important implications in the context of inflammation and
immune homeostasis.
Using global gene expression profiling, PRDM1 was identified as a highly
expressed transcription factor in stimulated NK cells. This data complements previous
studies (100, 101, 104, 117) providing the first global gene expression profile of NK cells
utilizing a physiologically-relevant combination of cytokines to achieve activation.
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During the early phases of the innate immune response IL-12 and IL-18 are produced by
monocytes and epithelial cells, while IL-2 is primarily produced by activated T cells,
typically a later event. Another early monocyte-derived cytokine, IL-15, signals through
the shared IL-2 receptor and can substitute for IL-2 to induce PRDM1 in the presence of
IL-12 and IL-18 (unpublished data). Consistent with this, maximal induction of murine
NK cells in response to Salmonella-infected macrophages has recently been shown to
require: 1) IL-2 and/or IL-15, 2) macrophage-derived IL-12 and IL-18 and 3) direct NKmacrophage cell contact (130). Thus, the exposure of freshly isolated NK cells to these
cytokines ex vivo can mimic the milieu present in vivo during the early innate immune
response and can provide insight into the physiological gene expression changes
occurring.
The ability of NK cells to produce a variety of cytokines in response to
stimulation provides a crucial mechanism of cross-regulation between the innate and
adaptive arms of the immune system. In order to maintain homeostasis, regulatory
control must be exerted not only upon the activation phase, but also during the recovery
phase to restrain the degree of activation. While activation events have been thoroughly
investigated, molecular events regulating dampening or recovery remain poorly
characterized. The studies herein now show that PRDM1 is an important mediator of this
phase. PRDM1 attenuates production of multiple effector cytokines in a coordinate
manner via direct binding to specific DNA sequences in known regulatory regions. At
the TNF locus, PRDM1 binds specifically to a highly conserved regulatory element
~3.5kB upstream of the transcriptional start site of LTA. This region exhibits DNaseI
hypersensitivity and contains binding sites for inflammatory activators such as NFκB and
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NFAT (201). Furthermore, this site has been shown to be crucial for activation-induced
looping (202). This three-dimensional looped chromatin structure mediates interaction
between distally- and proximally-bound NFAT at the TNF promoter forming an
enhanceosome resulting in transcriptional activation of TNF and (to a lesser extent) LTA
in response to stimulation. Consistent with the notion that this region imparts specific,
localized control at the TNF locus, knockdown of PRDM1 results in increases in both
LTA and TNF, but not LTB which is located further downstream and encoded on the
opposite DNA strand.
The IFNG locus is also subject to PRDM1-mediated regulation in NK cells.
Studies in the T cell compartment identified an upstream regulatory region in murine
CD4+ T cells (CNS-22) with enhancer activity which contributed to Tbet-dependent Ifng
expression in in vitro polarized Th1 cells (200). This site was later shown to be bound by
the murine homologue Blimp1 (66). The functionality of this distal site was confirmed in
human NK cells. In addition to this distal element, we have identified a novel promoterproximal element within the IFNG promoter to which PRDM1 binds. This novel
proximal site is required for silencing of a reporter gene driven by the human IFNG
promoter. Freshly isolated, resting NK cells differ substantially from T cells with respect
to the kinetics of IFNG mRNA induction. Indeed, NK cells induce IFNG rapidly upon
stimulation without the requirement for chromatin modifications because the entire locus
is poised in a hyperacetylated state under basal conditions (203). Thus, PRDM1 binding
directly upstream of the transcriptional start site may facilitate potent silencing in NK
cells without necessarily requiring long-range chromatin modifications.
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Human NK cells exist in at least two functionally divergent subsets based on the
surface density of CD56 and CD16.

Several groups have demonstrated that

CD56dimCD16+ NK cells are the major population in peripheral blood, while
CD56brightCD16-/dim NK cells represent less than 10% of peripheral NK cells and
primarily localize to lymph nodes (204). The CD56bright population has been described as
a “regulator” population. These cells express the high-affinity IL-2 receptor, are highly
proliferative in response to stimuli and localize at inflammatory sites. Accumulating
evidence suggests that CD56bright cells may, in fact, be developmental precursors to the
more mature CD56dim “effector” population (106, 205).

Conversely, the CD56dim

“effector” population exhibits increased natural cytotoxicity, but produces lower levels of
inflammatory cytokines relative to the CD56bright population. Consistent with its role as a
negative regulator of cytokine production, PRDM1 is preferentially expressed in the
CD56dim population.

Thus, PRDM1-mediated transcriptional repression likely

contributes to the functional divergence observed in these populations.
NK cells exhibit a unique pattern of PRDM1 protein isoform expression. In
addition to the full-leng ht PRDM1 α, NK cells exp ress h gi h levels of two smaller
molecular weight species. Expression of the PRDM1β-isoform has previously only been
documented in myeloma cell lines and samples from myeloma and T cell lymphoma
patients, and is always present at lower levels than the full-length protein (5, 206). NK
cells represent the first non-transformed cell type with PRDM1β expression; furthermore,
it is consistently observed at higher levels than the larger PRDM1α. The β-isoform is
transcribed from an alternate promoter and utilizes a distinct transcriptional start site
present in the third intron of the full-length protein. The resulting protein has a disruption
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of the highly conserved PR-domain. It was previously shown that the β-isoform localizes
to the nucleus and maintains capacity for DNA-binding, albeit, its repressive activity is
dampened relative to PRDM1α.

All of the cytokine combinations tested activate

transcription of both isoforms in NK cells, although there remains the potential that
isoform-specific activation signals may exist.

An intermediate-sized isoform

(PRDM1αΔ6) corresponding to a deletion of the amino acids encoded by exon 6 is also
consistently observed. This isoform is generated via splicing to exclude exon 6 resulting
in a deletion of the 2nd zinc finger as well as disruption of a portion of the 1st and 3rd zinc
finger. An analogous splice variant was recently described in naïve CD19+ murine B
cells, although it was present at very low levels (6). The first two zinc fingers of PRDM1
have a role in DNA binding and are required for recruitment of the histone
methyltransferase G9a, but are dispensable for interaction with HDAC2 (14, 15).
Interestingly, no induction of apoptosis or evidence of cell cycle exit concomitant with
PRDM1 induction in NK cells was observed. Furthermore, IL-2-expanded LAK cells
continue to proliferate despite acquisition of high level PRDM1 expression (unpublished
data). Thus, the presence of these lower molecular weight isoforms which have altered or
impaired activity may provide a cytoprotective effect, whereby NK cells are protected
from the anti-proliferative and apoptotic effect of PRDM1, but retain the ability to repress
selective target genes. Characterization of the contribution of each isoform will be an
important area of future investigation.
The PRDM1 allele is encoded on chromosome six within a region that is known
to be frequently associated with B-, T- and NK-derived malignancies. A recent report
used high resolution comparative genomic hybridization arrays to precisely map regions
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deleted within NK lymphomas and identified a minimal common region spanning
approximately 2Mb of the 6q21 deletion, which is present in roughly 40% of cases (62).
Within this region, the authors identified three genes which were down-regulated in
tumor specimens harboring the 6q21 deletion: ATG5, PRDM1 and AIM1. More recently,
PRDM1 expression levels were shown to be highly variable and found to be independent
of the 6q21 deletion in an independent study of six primary NK lymphoma patient
samples (207). This data clearly establishes a functional role for PRDM1 in normal NK
cell function. Thus, while PRDM1 can act as a tumor suppressor in Diffuse Large B Cell
lymphoma, its contribution to the transformed phenotype in NK-derived malignancies
remains controversial.
The experiments herein add NK cells to the expanding list of immune lineages in
which PRDM1 has a key functional role.

Until very recently, PRDM1 has been

described in plasma cells, multiple T cell subsets, dendritic cells and myeloid cells.
Subsequent to the publication of these studies, a second group working in a murine
system has published complementary data, confirming most of the findings presented
here (208). Although lineage-specific regulation of target genes exists, a significant
commonality is that PRDM1 regulates final effector function. For instance, negative
regulation of Il2 and tbx21 by Blimp1 promotes Th2 polarization in CD4+ T cell
differentiation, yet differential expression of these genes does not play a role in either B
or NK effector function. Coordinate regulation of IFNG and TNF, on the other hand, is
critical to both T and NK effector function. Characterization of overlapping and nonoverlapping functions of PRDM1 across multiple lineages will be an important area of
focus in future experiments.

For example, Lanier and colleagues recently provided
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evidence for a “memory” phenotype in murine NK cells using an MCMV infection
model wherein they demonstrated that antigen-specific Ly49H+ NK cells underwent a
prolonged contraction period, but were subsequently activated to higher levels upon restimulation (209). PRDM1-mediated restriction of memory potential has recently been
described in CD8+ T-cells (72). Given that PRDM1 is induced in vivo during NK
activation, it will be interesting to ascertain if PRDM1 has such a role in NK memory
commitment.
In summary, the data suggest that PRDM1 plays a crucial role in the postactivation phenotype of NK cells by negatively regulating cytokine transcription in a
coordinate manner, without compromising perforin-mediated cytotoxicity or inducing
exit from cell-cycle. Such a mechanism may have important implications in innate
immunity and tumor surveillance.
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CHAPTER IV
IDENTIFICATION OF PRDM1 TARGET GENES IN NK CELLS

Introduction
Transcriptional control of cellular function is mediated through the combined
action of transcriptional activators and repressors. PRDM1 is a master regulator of the
terminal differentiation of activated B cells into antibody-producing plasma cells.
PRDM1 mediates this phenotypic change via direct binding to regulatory sequences of
target genes, which are subsequently repressed. CIITA, PAX5, and cMYC are major
targets of PRDM1-mediated repression in B cells, while PRDM1 regulates a distinct set
of target genes including FOS and IL2 in T cells (181). In NK cells, the IFNG and TNF
loci were found to be targets of coordinate repression via a candidate ChIP approach.
However, this candidate approach was not ideal to discover novel genomic loci to which
PRMD1 binds.
Recent advances in hybridization technologies have facilitated the de novo
discovery of target genes. Using traditional ChIP coupled to promoter-tiled microarrays,
all genes bound by a particular transcription factor can be identified. This approach,
termed ChIP-chip or ChIP-on-chip was pioneered by the laboratory of Peggy Farnham
and has recently become a widely-used technique (210). Affymetrix is one of several
companies that now manufacture promoter tiling arrays which can be utilized by
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microarray core facilities at a reasonable cost to investigators. More recently, ChIP-seq
protocols have been developed whereby immunoprecipitated DNA is analyzed by highthroughput sequencing platforms. However, ChIP-seq procedures require equipment and
computer capabilities that remain cost prohibitive to many investigators.
In order to define the interaction network of PRDM1 in NK cells, two microarray
approaches were utilized. First, ChIP-chip experiments were conducted using the NKL
cell line to identify genomic regions bound by PRDM1. Next, mRNA expression arrays
were used to assess transcriptional changes associated with knockdown of PRDM1 in
primary NK cells. These data were used to define both the direct and indirect targets of
PRDM1 in NK cells. To date, no ChIP-chip or ChIP-seq analyses have been reported in
NK cells. Thus, these experiments are the first to use global approaches to transcription
factor analysis in NK cells.

Results
PRDM1 is constitutively-bound to numerous target genes in the NKL cell line
Through the use of a candidate approach with traditional chromatin immunoprecipitation (ChIP) experiments several bona fide PRDM1 targets were identified,
several of which were described in the previous section. This approach, however, is
associated with a low “success” rate because relatively few potential PRDM1 binding
motifs were found to be bound in vivo. Less than five percent of in silico-identified
PRDM1 binding sites exhibited binding when assayed by ChIP. Thus, the presence of
the motif within the promoter region alone was a poor predictor of promoter occupancy.
Furthermore, PRDM1 occupancy was not routinely found at the promoters of known B
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cell target genes indicating that occupancy of target genes may vary widely among cell
types.
In order to circumvent the low discovery rate associated with a candidate
approach, ChIP-chip experiments were performed.

This technique expands upon

traditional ChIP and utilizes hybridization to microarrays containing tiled genomic DNA
sequences. A screening approach can then be taken facilitating the de novo identification
of target genes. The Affymetrix Promoter 1.0 array contains over 4.6 million probes tiled
over 25,500 human promoters. Typical coverage for each promoter is approximately
7.5kb upstream and 2.5kb downstream from the transcription start site (TSS), while
promoter coverage for nearly 1,300 cancer-associated genes extends to 10kb upstream.
The requirement for large amounts of starting material (10ng immunoprecipitated DNA)
precluded the use primary NK cells for ChIP-chip analysis. Thus, the NKL cell line had
to be used. These cells constitutively express PRDM1 and exhibit an isoform expression
pattern that is highly similar to activated primary NK cells as described earlier.
Three independent chromatin preparations were used to perform ChIP-chip
experiments. Multiple immunoprecipitations were performed and analyzed by traditional
ChIP using primers for two positive loci (CIITApIV and PCNA) and two negative loci
(MYOB and HLA-DR) to verify ChIP efficiency (data not shown). Immunoprecipitated
DNA from each chromatin preparation was then separately pooled and subjected to
whole genome amplification in order to obtain sufficient quantity for hybridization. A
second efficiency check was performed on amplified DNA to ensure that negative and
positive loci remained easily distinguishable. Three hybridizations were performed using
the amplified DNA and regions of enrichment for PRDM1 binding were identified using
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two recently-described analytical algorithms: Cisgenome and Model-based Analysis of
Tiling-arrays (MAT) (175, 176).
Because ChIP-chip datasets are characteristically large and heterogenous,
accurate determination of transcription factor binding to DNA can be challenging. In
order to separate signal from noise (referred to as “peak calling”), CisGenome and MAT
make use of distinct statistical algorithms in order to calculate enrichment over
background. Cisgenome utilizes TileMapv2 to call peaks after quantile normalization.
This algorithm relies on a Bayesian shrinkage to analyze variance in hybridization values
between specific and control samples, then applies either a Hidden Markov Model or a
moving average to score for enrichment (175, 211). MAT analysis differs in the method
used for initial normalization of hybridization intensities and it also applies a modelbased statistical algorithm to correct for non-specific hybridization. This is based on the
assumption that much of the observed “signal” is actually “noise” due to intrinsic
properties of specific probe sets on the array (176). Importantly, each program allows the
user to define the minimum peak lengths, number of probe sets required to define a peak
and tolerable gap sizes so that only the underlying algorithms are different when
analyzing an individual experiment each way.
Peak lists were created for each PRDM1 ChIP-chip experiment with both analysis
methods using raw hybridization data for both PRDM1 immunoprecipitation and input
(.cel files). MAT analysis consistently produced a lower number of peaks per experiment
(mean = 100) than CisGenome (mean = 483) using identical parameters: a minimum peak
size of 100bp, a minimum of five probe sets per peak as thresholds for detection and a
separation of > 300bp between individual peaks (Figure 40). In order to identify genes
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associated with these peaks (potential targets of PRDM1 regulation), peak lists generated
by both MAT and CisGenome were annotated with CisGenome using settings such that

Figure 40: CisGenome consistently identifies more PRDM1-enriched peaks. Graph
plotting number of peaks identified in each experiment using both CisGenome and MAT
analysis algorithms.

the single closest gene within 15kb of either the transcription start site (TSS) or
transcription end site (TES) was identified.

Thus, depending on the local gene

architecture of the genome, it is possible to have multiple genes identified for each peak.
Consequently, a total of 1,695 unique annotated genes were identified in the six analyses
(three experiments, analyzed two ways). The PRDM1-enriched peaks were localized
upstream, within and downstream of target genes, with approximately half of the peaks
mapping upstream of the TSS (Figure 41A). Interestingly, for the 892 genes to which
PRDM1 was bound upstream of the TSS, peaks were equally represented across the
probes (sized 7,500bp) with no enrichment observed at the minimal promoter regions
(Figure 41B).
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Figure 41: Distribution of PRDM1 binding locations across the genome. A) 1,695
unique genes were identified within 15kb of PRDM1-enriched peaks in three
experiments. Approximately half were located upstream of the gene, while the other half
were located both within the gene and downstream. B) Binning analysis of the 895 genes
for which PRDM1 was located upstream of the TSS. Equal distribution was observed
across the 7,500bp represented by most of the probe sets.

Due to the potentially high false discovery rate associated with genome-level
binding experiments, a subset of annotated genes was evaluated further.

Using the

criteria that a gene must be identified in at least two analyses, a total of 292 unique genes
were identified. Validation testing with independently-prepared chromatin yielded a
confirmation rate of 83% (19/23) using percent input of PRDM1 immunoprecipitation
relative to IgG immunoprecipitation (Figure 42). Genes such as STAT6, PTK2 and
LMO2 gave robust signal, while genes such as BCL10, IBRDC3 and IL2 demonstrated
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more modest enrichment over control, consistent with variability in peak magnitude
observed by ChIP-chip. Of the four genomic loci that did not validate, all were identified
by both CisGenome and MAT analysis indicating that neither algorithm is solely
responsible for the false positives.

Figure 42: Confirmation of selected ChIP-chip target genes. Chromatin was prepared
from NKL cells and analyzed by ChIP for PRDM1 occupancy at 23 genomic loci
identified by ChIP-chip. Gene names represent the nearest gene within 15kb of the
region. Confirmation rate was 83% (19/23).

Motif analyses were conducted to evaluate whether the identified genomic regions
were enriched for putative binding sites for PRDM1. Two approaches were utilized to
accomplish this. First, de novo motif searches were conducted for each of the six data
sets (three MAT, three CisGenome) to identify significantly enriched sequence motifs
present within the regions of PRDM1 binding. A PRDM1 motif was identified as highly
enriched sequence in both MAT and CisGenome data sets in two of three experiments
(Figure 43A). Next, a PRDM1 sequence matrix (MAGYGAAAGYK) was used to
search for the presence of this motif within each peak region. This motif was found in
the peaks associated with 84 of the 292 genes (29%). The frequency of this motif was
significantly higher than a scrambled motif (p-value = .009) (Figure 43B). Of the 23
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genes used for validation testing, 13 contained a PRDM1-binding site and all 13 could be
confirmed to be bound by PRDM1. This suggests that the presence of a defined binding
motif is not absolutely required for binding, but is associated with a lower false discovery
rate.

Figure 43: Motif analysis of associated peaks. A) The Gibbs motif sampler module of
CisGenome was used to identify statistically-enriched motifs present in the sequences of
annotated peaks for both the MAT and CisGenome data sets. The motif was found in
two out of three experiments using both data sets. B) A known PRDM1-binding motif
(MAGYGAAAGYK) or a scrambled motif was used to identify the presence of the motif
in all sequences associated with PRDM1-enriched peaks. The frequency of the
scrambled motif was significantly lower (p-value = .009). Although motifs were found in
both MAT and CisGenome in experiment three, they were not identified as statisticallyenriched, thus they do not show up in A).

Expression changes associated with ChIP-chip target genes
Of the 292 genes identified, expression data was available for 278 genes using the
24h IL-2, IL-12 and IL-18 stimulation microarray described in Chapter III. Using a
cutoff of 1.3 fold in both donors, 161 were found to be differentially expressed with
cytokine stimulation (76 decreased, 85 increased) (Table 2 and Appendix II). Genes
that decrease coordinately with PRDM1 induction are likely early targets of PRDM199

mediated direct repression.

Several of these down-regulated genes are intracellular

signaling adaptors likely important for NK function, including ZAP70, BCL10 and
STAMBP. ZAP70 is a cytoplasmic tyrosine kinase that is activated in response to CD16
ligation and therefore contributes to ADCC (212). In response to activating stimuli such
as NKG2D ligation, BCL10 signals in cooperation with CARMA1 to induce NF-κB
resulting in up-regulation of effector cytokine production (213). STAMBP binds to
STAM (signal transduction associated molecule) and abrogates JAK-STAT signaling
downstream of the IL-2 receptor (214). Repression of these signaling molecules is
consistent with PRDM1’s roles as a post-activation attenuator of NK activation.
Table 2: Changed ChIP-chip target genes in response to stimulation (Top 30)
Decreased
Gene ID
LRMP
GCHFR
ZAP70
WHDC1L1
ATM
NR4A3
AK1
RGS14
NEK1
SREBF1
BCL10
MAPK7
BTF3
C20orf32
C14orf43
PPP1R9A
SSBP1
BRD3
SMARCA2
STAMBP
C9orf55
NCOA2
CRAMP1L
PCSK7
CDKN1B
RUNX1
IL18BP
HECTD1
BTN3A3
EIF2B5

Donor 1
-42.8
-20.7
-11.4
-9.4
-7.7
-7.4
-6.8
-5.9
-5.2
-4.2
-4.2
-4.1
-3.7
-3.6
-3.6
-3.5
-3.3
-3.2
-3.2
-3.2
-3.2
-3.0
-3.0
-2.9
-2.9
-2.7
-2.7
-2.7
-2.6
-2.6

Increased
Gene ID
LTA
HAS2
ZNRF1
MTHFD1L
CTLA4
CDGAP
RAB6IP1
NFE2L1
BIRC3
RAB10
STX3A
GBP2
WDR59
STK6 (AURKA)
STCH
IBRDC3
BCL2L11
FARSLA
TTK
BIRC4
EIF3S1
C1orf77
CEP76
LUZP1
ZNF672
ZNF146
ZC3H12A
KPNA4
RMI1
ANKRD12

Donor 2
-77.0
-24.3
-10.9
-17.0
-14.9
-15.1
-5.8
-41.1
-6.9
-2.5
-6.6
-2.3
-2.6
-14.9
-3.3
-2.4
-4.4
-2.4
-2.6
-2.4
-11.1
-5.7
-5.6
-1.7
-3.7
-4.2
-3.1
-4.4
-3.6
-2.2

100

Donor 1
4213.9
815.2
39.2
38.7
12.9
10.4
9.5
8.2
6.0
6.0
5.3
5.1
4.9
4.9
4.8
4.7
4.3
4.1
4.1
3.9
3.7
3.7
3.6
3.6
3.4
3.1
3.1
3.0
3.0
2.9

Donor 2
1686.3
63.2
367.5
26.7
3.3
7.1
11.1
12.2
4.0
8.2
3.9
3.2
2.6
6.3
3.9
6.3
1.7
4.8
4.8
3.2
4.3
3.6
3.0
3.2
3.1
2.7
4.7
1.7
3.5
2.9

For the genes that increased with stimulation, it is likely that the 24h time point
used in the microarray represents a window that is too early for repression to be observed.
Indeed, LTA which encodes TNFβ, is one of the most highly up-regulated transcripts at
24h, but PRDM1-dependent repression is observed at 48h as previously revealed by
knockdown experiments (Figure 34). Other molecules associated with NK activation
and bound by PRDM1 likely behave in a similar manner. IBRDC3 (also known as NKlytic associated molecule) is a RING domain-containing E3 ligase that is expressed at
low levels in resting NK cells, but induced upon activation (215-217).
Numerous transcripts show either no change in expression levels or are not
expressed in NK cells. For instance, IL2 has been documented as a PRDM1 target gene
in T cells (67), but is not expressed in NK cells. PRDM1 binding to regulatory regions of
the IL2 locus may serve to reinforce its silencing in NK cells. Another target gene that is
expressed at very low levels in NK cells is LMO2. This gene encodes the Lim-only
domain protein which is normally down-regulated during the transition of germinal
center B cells to plasma cells and expression levels are predictive of survival in diffuse
large B cell lymphoma patients (218).
Numerous genes that are targets of PRDM1 regulation in other lymphoid lineages
(such as PAX5, IFNB and SPIB) are not bound by PRDM1 in NK cells. A recent ChIPchip analysis in the U266 myeloma cell line identified 282 unique target genes (219), of
which only 13 (~5%) were found to overlap with the NK target genes identified in this
study. This study utilized a different immunoprecipitating antibody and a different peak
detection algorithm, which likely contribute to the low degree of overlap. However,
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despite these experimental differences, binding patterns are likely highly divergent across
cellular lineages.

Identification of PRDM1-regulated genes by microarray analysis
ChIP-chip analysis is useful for the de novo identification of PRDM1 binding
sites, but does not facilitate characterization of the associated changes in gene expression
of the target genes. In order to identify genes that are responsive to PRDM1, a second
gene expression profiling microarray analysis was conducted. NK cells were isolated
from two healthy donors and treated with either IL-2 and IL-12 or IL-2, IL-12 and IL-18
for 48h. For both sets of stimulations, cells were incubated with either a PRDM1-specific
siRNA or a non-targeting siRNA. Samples containing IL-2 alone were also included for
each donor for a total of ten samples. Immunoblotting was performed on an aliquot of
each sample to confirm PRDM1 induction and knockdown efficiency. As expected, IL-2
and IL-12 induced PRDM1, with the addition of IL-18 further increasing PRDM1
expression and the presence of PRDM1-specific siRNA significantly down-regulated
protein expression in both conditions (Figure 44).

Figure 44: Immunoblots of PRDM1 knockdown used for microarray analysis. NK
cells isolated from two donors were stimulated with either IL-2, IL-2 + IL-12 or IL-2 +
IL-12 + IL-18 for 48 h. For IL-2 + IL-12 and IL-12 + IL-12 + IL-18, samples were
treated with either a non-targeting or PRDM1-specific siRNAs. PRDM1 expression was
analyzed by immunoblot.
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A large number of genes were found to be differentially expressed concomitantly
with PRDM1 knockdown.

Using IL-2 and IL-12 stimulation, a total of 56 unique

transcripts were up-regulated, while 77 were down-regulated more than 1.3 fold in both
donors. Of the up-regulated transcripts, three (5.4%) were also ChIP-chip targets (Table
3 and Appendix III). When IL-2, IL-12 and IL-18 were used for stimulation, a larger
number of transcripts were differentially expressed. A total of 174 transcripts were upregulated, while 82 were down-regulated 1.3 fold or more in both donors with PRDM1
knockdown. Of the up-regulated transcripts, 13 (7.5%) were found to be ChIP-chip
targets. The three transcripts changed with IL-2 + IL-12 treatment were also up-regulated
in response to PRDM1 knockdown with IL-2, IL-12 and IL-18 treatment. Many of the
expression changes associated with PRDM1 knockdown are not associated with ChIPchip regions and likely result from indirect mechanisms.

This is consistent with

microarray experiments conducted in plasma cells, where only a small fraction of the
hundreds of differentially expressed transcripts have been demonstrated to be direct
targets of PRDM1 binding (46, 47).
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Table 3: Target genes increased > 1.3 fold with PRDM1 knockdown (Top 30)
2+12 Up
Gene ID

2+12+18 Up
Donor 1

Donor 2

Donor 1

Donor 2

FLJ25791

4.72

1.78

Gene ID
C10orf97

8.64

1.31

HBA1

3.29

1.31

HIPK3

5.82

1.91

CXCL10

2.69

1.61

RAB8B

5.31

1.70

IL1R1

2.52

2.10

LRAP

4.96

2.04

DLL1

2.19

1.35

PSMA3

4.70

1.45

FAM26F

2.07

1.54

WHDC1L1

4.61

2.29

PTK2

2.03

2.12

RINZF

4.05

1.44

CD160

1.99

2.78

CXCL11

4.02

2.30

IPO11

1.93

1.65

SCOC

3.92

1.84

VNN2

1.87

1.53

SP1

3.91

1.42

DDX17

1.75

3.22

SGPP1

3.88

1.81

SLC16A7

1.73

1.50

MAF

3.88

1.37

DMRTA2

1.71

1.42

MLSTD2

3.85

1.92

HBA2

1.66

1.41

ZNF230

3.77

1.49

TNFRSF10B

1.64

1.88

NR4A3

3.70

1.32

CBX3

1.64

1.67

PDCD4

3.47

1.71

CLK4

1.57

1.35

FLI1

3.43

1.57

BCAR3

1.53

1.54

MBNL1

3.42

2.00

VEGF

1.51

1.49

MST4

3.33

1.33

JAK2

1.50

1.31

ITGA4

3.09

1.89

GART

1.50

1.38

NEDD1

3.08

1.43

ZAK

1.49

1.76

CAPRIN1

3.06

1.33

PHOSPHO2

1.46

1.47

B4GALT6

3.05

1.70

ZNF238

1.46

1.54

JAK1

3.03

1.41

FBXO8

1.45

1.37

MGC33214

2.98

1.59

FLJ37034

1.45

1.53

PSAT1

2.94

1.55

SOCS1

1.44

1.32

EIF4A2

2.92

1.35

TRFP

1.43

1.33

NCK1

2.89

1.57

IDH1

1.43

1.45

IGJ

2.86

1.84

TFAM

1.43

1.32

MCL1

2.79

1.44

This analysis has led to the identification of a variety of direct targets of PRDM1mediated repression that likely contribute to NK function. Importantly, levels of these
transcripts are altered in the absence of PRDM1 (Table 4). KLRD1, better known as
CD94, heterodimerizes with members of the NKG2 family via disulfide bonding to form
biologically-active killer cell lectin-like receptors.

CD94 can participate in both

activating and inhibitory signaling depending upon the NKG2 family member present
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(110). For instance, CD94:NKG forms an activating receptor, while CD94:NKG2A
forms an inhibitory receptor (220, 221). BCL2L11 encodes the pro-apoptotic molecule
Table 4: Direct PRDM1 target genes: increased > 1.3 fold
Gene ID

Donor 1

Donor 2

BCL2L11

2.10

1.82

Bim; pro-apoptotic molecule

Protein Function

ETV6

1.73

1.40

Ets family transcription factor; hematopoiesis

FLCN

1.68

1.35

folliculin; tumor suppressor

KLRD1

1.87

1.44

CD94; heterodimerization with NKG2 family members

LRMP

1.70

1.71

lymphoid-restricted membrane protein; endosomal sorting, recycling

MBNL1

3.42

2.00

RNA processing

NR4A3

3.70

1.32

NOR1; nuclear receptor; tumor suppressor, hematopoiesis

NUMA1

1.89

1.56

mitotic spindle assemble

PTK2

1.80

1.46

FAK; response to integrin signaling

RAB6IP1

1.70

1.54

modification of guanine exchange factor activity

SH2B3

2.34

1.59

LNK; adaptor molecule, negative regulation of JAK-STAT signaling

STAT6

2.68

1.76

IL-4-induced IFNg production in NK

4.61
2.29
homologous to WASp; cytoskeletal rearrangement
WHDC1L1
* bold genes were also changed with PRDM1 knockdown using IL-2 and IL-12 stimulation

Bim, which has been shown to be up-regulated during apoptosis driven by IL-15
withdrawal in murine NK cells (222). BCL2L11 is up-regulated in response to IL-2, IL12 and IL-18 signaling, therefore, post-induction repression by PRDM1 may prevent
stimulation-induced apoptosis. STAT6 is required for IL-4 induced IFNγ production in
vitro and in vivo (223, 224). PTK2 encodes FAK, which mediates up-regulation of
cytotoxicity via cytoskeletal rearrangements in response to integrin signaling. Finally,
WHDCL1 is a poorly-characterized gene, however, it shares significant homology with
the Wiskott-Aldrich syndrome protein (WASp) which functions at the NK immune
synapse and is critical for F-actin accumulation (225). Thus, PRDM1 modulates NK
function through the transcriptional modulation of extracellular receptors, signaling
molecules and regulatory components of the cytoskeleton.
A variety of other direct target genes have not been attributed directly to NK
function, yet their regulation may be crucial in order to maintain homeostasis. LRMP
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encodes an ER-resident protein that is involved in TAP-independent MHC Class I
processing and is normally silenced as activated germinal center B cells differentiate into
plasma cells (226, 227). LNK, encoded by SH2B3, is a lymphoid-specific signaling
adaptor molecule that negatively regulates proliferation in response to a variety of
cytokines (228, 229). Both NR4A3 and ETV6 encode transcription factors that are
required for hematopoiesis. NR4A3 is also induced in response to LPS in activated
macrophages, suggesting a role in inflammatory responses (230). ETV6 is an ETSfamily transcription factor that normally functions in hematopoiesis and vascular
development. Also known as TEL1, ETV6 is an oncogene and numerous fusion proteins
(eg. ETV6-RUNX1, ETV6-PAX5, ETV6-ABL) have been identified in both lymphoid
and myeloid-derived malignancies (231).
In order to confirm the transcriptional changes associated with PRDM1
knockdown, qRT-PCR analysis was conducted for genes which changed with PRDM1
knockdown or were ChIP-chip targets. For these experiments, NK cells obtained from
three additional donors were stimulated with either IL-2 and IL-12 or IL-2, IL-12 and IL18 and treated with either non-targeting or PRDM1-specific siRNAs for 48h exactly as in
the knockdown microarray experiment (Figure 45). Immunoblotting confirmed efficient
knockdown in all donors using both stimulations. Consistent with results obtained in the
microarray experiment, a larger number of genes was differentially expressed when IL-18
was present. In both experiments, CXCL10, TNFRSF10B and PTK2 were up-regulated in
response to PRDM1 knockdown.

Based upon microarray results comparing freshly

isolated to 24h stimulated NK cells, expression of CXCL10 is strongly up-regulated,
while the expression of its receptor CXCR3 is down-regulated. Thus, PRDM1 may help
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Figure 45: Knockdown of PRDM1 increases mRNA levels of selected PRDM1 target
genes. A) NK cells from three donors were stimulated for 48h in the presence of IL-2
and IL-12, treated with either PRDM1-specific siRNA or non-targeting siRNA. Relative
levels of target gene mRNA were determined by qRT-PCR, with normalization to 18S.
Error bars represent SD. B) Same analysis using IL-2, IL-12 and IL-18 for stimulation.

restore the CXCL10:CXCR3 ratio to attenuate stimulation-induced migration. Indeed,
sustained CXCL10 expression by NK cells is associated with chronic colitis (232).
TNFRSF10B encodes a TRAIL receptor, also known as DR5 or KILLER, which is
capable of transducing a pro-apoptotic signal due to the presence of an intracellular death
domain upon ligand engagement.

Down-regulation of this molecule may be a

mechanism to prevent fratricidal killing of NK cells via TRAIL-DR5 interaction. PTK2
was also up-regulated and is covered in more detail in the next chapter. Up-regulation of
SELL, which encodes L-selectin, was observed with IL-2, IL-12 and IL-18 stimulation
and may have functional consequences in terms of migratory capacity. BCL10, LRMP,
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KLRD1, ITGA4 and IBRDC3 were also all slightly up-regulated in these experiments.
Thus, knockdown of PRDM1 leads to differential expression of a variety of genes
involved in modulating NK activity.

Discussion
The experiments conducted in this chapter aimed to define the global interactions
of PRDM1 in NK cells and examine the transcriptional changes associated with PRDM1
knockdown. Numerous novel PRDM1 target genes were identified, which modulate
function through well-characterized mechanisms such as NK receptors, cytokine
signaling and regulation of apoptosis. Additionally, many PRDM1 target genes may
regulate NK biology through mechanisms not previously associated with NK function.
Using ChIP-chip in NKL cells to identify PRDM1 target genes has several
caveats that must be taken into consideration.

The NKL cell line is considered to

phenotypically mimic activated NK cells and does express the PRDM1 isoform pattern
observed with primary cells. However, NKL cells are an immortalized tumor cell line
derived from a patient with LGL-leukemia, have numerous karyotype abnormalities and
are “addicted” to IL-2 signaling (233). NKL cells may have adapted novel mechanisms
to regulate gene expression to maintain continuous growth. Furthermore, the response to
stimulation with IL-12 and IL-18 is vastly attenuated in NKL cells. For example, upregulation of IFNG transcription as measured by qRT-PCR is > 1,000 fold lower in NKL
cells when compared to primary cells.

Consistent with this, PRDM1 is not found

associated with chromatin at the IFNG promoter in NKL cells. Thus, dynamic changes in
PRDM1 target changes may not be recapitulated in culture.
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The binding of a transcription factor to specific regions near genes can have
several potential outcomes. Generally, one would expect that a transcriptional repressor,
such as PRDM1, would be associated with gene silencing and that removal of the factor
(via knockdown) should result in increased expression. At least four functional outcomes
for target gene expression in response to PRDM1 binding exist: 1) silencing of genes
expressed in the resting state, 2) post-induction silencing, 3) repression of non-NK genes
(maintenance) and 4) non-productive binding (no silencing). Over a quarter of the ChIPchip target genes (27.6%; 77/278 genes, for which expression data was available)
decreased upon stimulation, consistent with PRDM1 silencing genes normally expressed
in resting NK cells. A similar number of PRDM1 target genes were increased upon
stimulation (30.6%). Among these, LTA is one of the most highly induced genes at 24h
stimulation. However, at 48h expression differences were observed when PRDM1 was
abrogated via siRNA knockdown. IFNG also behaves in a similar manner, although it is
only bound by PRDM1 in primary NK cells. IL2 and LMO2 are two examples of genes
that are known PRDM1 targets in other lineages, but are not expressed in NK cells.
The observation that only 4.6% (13/278) of the ChIP-chip target genes exhibited
increased expression in the absence of PRDM1 is consistent with many published reports
(210). Indeed, only a subset of PRDM1 target genes were dynamically expressed in
response to PRDM1 knockdown in U266 cells (219).

A variety of technical and

biological factors may be involved in this phenomenon. On the technical side, it is
possible that the remaining fraction of PRDM1 after knockdown is sufficient to maintain
biological activity. Another possibility is that despite the presence of a robust band on
immunoblots, PRDM1 may only be induced in a subset of NK cells. Thus, RNA lysates
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from the total population may be biased by the non-PRDM1 expressing fraction. It may
be possible to address this issue by the development of a FACS-based assay utilizing
intra-cellular staining for PRDM1. Co-staining for effector cytokine targets IFNγ and
TNFα could be performed simultaneously using this approach. Finally, because the
microarray experiments were conducted using purified primary NK cells, some
experimental variability is unavoidable due to inherent differences existing among
donors.
In terms of biological explanations for lack of response to PRDM1 knockdown,
there are several possibilities.

First of all, removal of a repressor may simply be

insufficient to re-activate transcription. For example, PRDM1 binds the ZAP70 promoter
and its expression decreases as PRDM1 is activated. However, ZAP70 levels do not
change in response to PRDM1 knockdown. Another factor, such as NFAT or AP-1, may
be required in order to activate expression. It has also been suggested that IRFs compete
for PRDM1 binding sites (13, 219) and the presence of IRFs may abrogate silencing by
PRDM1. NK cells specifically up-regulate IRF8 in response to IL-2, IL-12 and IL-18
stimulation. In dendritic cells, PRDM1 and IRF8 directly compete for regulatory sites
present within the myeloid-specific CIITApI (75). Whether or not such a mechanism
exists in NK cells remains to be determined as no data is available for IRF8 function in
NK cells. Finally, cytokine stimulation is required to induce PRDM1 expression, but also
leads to massive changes in the global NK transcriptional profile.
complicating factor and may mask PRDM1-mediated changes.

This adds a

Consistent with this

notion, in the PRDM1 knockdown microarray far fewer genes change with IL-2 and IL12 stimulation when compared to IL-2, IL-12 and IL-18 stimulation.
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In the ENCODE project, a large portion of sequence-specific transcription factors
were found outside of what would typically be referred to as promoter regions (234).
This promiscuity in binding has several important correlates with potential biological
functions. First of all, the classical minimal promoter models in which activators and
repressors bind to discrete regulatory elements present < 1,000bp upstream of the
transcriptional start site (TSS) are most certainly oversimplified. Binding of transcription
factors to DNA is likely a relatively widespread phenomenon. Even using an array that
contains almost exclusively promoter sequences, PRDM1 binding shows nearly uniform
binding across the entire tiled region with no increased enrichment at locations < 1kb
upstream of the TSS. Similarly widespread binding has recently been reported for ChIPchip studies in Drosophila with the heat shock factor HSF wherein the authors observed
that only 11% of the 454 identified regions were found within 1,250bp of the TSS (235).
Additionally, no correlation exists between genes that were changed in response to
PRDM1 knockdown and distance of binding peak from the TSS because only three of the
thirteen changed genes demonstrated enrichment in the region between the TSS and -1kb
upstream. The presence of a PRDM1 binding motif (defined as MAGYGAAAGYK)
may not be required for binding as many of the validated PRDM1 target genes did not
contain this consensus sequence. However, eight of the thirteen genes differentially
expressed upon knockdown did contain matches to the motif.
In NK cells, PRDM1 appears to act as a modulator of effector response rather
than a master regulator of a differentiation program. Thus, PRDM1 function in NK cells
appears to be more similar to its role in T cells, than B cells (181). PRDM1 target genes
are not generally fully silenced in NK cells. This may be explained by the fact that
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multiple isoforms are uniquely present in NK cells and knockdown experiments often
result in no more than a two- to three-fold increase in expression of the target gene in the
absence of PRDM1. The truncated PRDM1β-isoform is known to exhibit somewhat
diminished repressive capacity and the PRDM1Δexon6 is predicted to have a disrupted
zinc finger domain. Thus, genes may not be completely silenced due to these isoforms
competing with the full-length PRDM1α, the only isoform observed in B cells. It is also
possible that the disruption of the zinc fingers in PRDM1Δexon6 alters the affinity for
specific recognition motifs, contributing to the large divergence in target genes between
lymphoid lineages.
Modulation of expression levels of a large number of target genes through both
direct and indirect mechanisms may be a key feature of PRDM1 in NK cells. In previous
chapters, effector cytokines were identified as targets of regulation and here a key NK
receptor (KLRD1), signaling adaptors (ZAP70, SH2B3, STAT6, BCL10) and a variety of
other factors (eg. IBRDC3, LRMP) were identified. Diminished expression of a number
of these genes may allow PRDM1 to serve as a rheostat to fine-tune the activated
phenotype. In murine cells (which only express the full-length PRDM1α), ablation of
PRDM1 expression was recently shown to increase proliferative capacity and increase
NK-mediated clearance of RMAS target cells in vivo (236). Given the prevalence of the
6q21 deletion in NK lymphomas, it will be important to determine the mechanisms by
which PRDM1 suppresses growth potential. Silencing of genes with oncogenic potential
may be an important function of PRDM1 in NK cells.
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CHAPTER V:
PRDM1-MEDIATED REGULATION OF FOCAL ADHESION KINASE

Introduction
Integrin signaling plays a critical role in numerous cellular processes such as
proliferation, migration and differentiation. Integrins on the cell surface function as
receptors for various components of the extra cellular matrix (ECM). Fibronectin, a
major component of the ECM, specifically interacts with α and β integrin receptors via
the Arg-Gly-Asp sequence present in the central portion of the molecule. Human NK
cells are functionally responsive to fibronectin-mediated signaling because they express
β1 and α4/α5 integrin receptors (237). Thus, integrin signaling has the potential to
modulate NK function.
Focal adhesion kinase (FAK) is a tyrosine kinase that was originally identified as
a 125kD protein which was phosphorylated in response to fibronectin (238, 239). FAK
was later shown to integrate multiple signal transduction pathways in a variety of cell
types. FAK is encoded by the PTK2 gene on chromosome eight. FAK is phosphorylated
on several tyrosine residues including Tyr397, Tyr576/577 and Tyr925 in response to integrin
signaling (240). These phosphorylation events increase enzymatic activity and create
novel binding sites for SH2 domain-containing proteins. FAK interacts with a variety of
adaptor molecules that eventually lead to the cytoskeletal rearrangements via actin-
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mobilization through several alternative pathways.

Several important intermediate

molecules in the FAK signaling cascade include: SRC, p130CAS, calpain and paxillin.
FAK signaling is crucial for adhesion, migration and survival. Consequently, it is
associated with metastatic potential in a variety of tumors and FAK is over-expressed in a
variety of solid tumors (240). Knockdown of FAK expression disrupts lamellipodia
forming the “leading edge” resulting in defects in directional migration (241). FAK also
mediates survival in response to inflammatory stimuli. This process requires both NF-κB
and ERK signaling and FAK-/- fibroblasts display increased sensitivity to TNFα-induced
apoptosis (242).
FAK activity also mediates a variety of functions within the adaptive immune
system. In T cells, FAK signaling in response to β1 integrin ligation increases migration,
but does not affect adherence to fibronectin (243). FAK signaling is independent from
CD3/TCR signaling, although some downstream substrates such as CAS-L are shared
among these pathways (244). In B cells, FAK is phosphorylated in response to integrin
signaling downstream of Rap GTPases.

This phosphorylation is enhanced by BCR

signaling and is required for actin-dependent morphological changes associated with
activation (245). FAK likely also plays critical functions in early development of both T
and B lymphocytes via α4β1 intregrin:fibronectin interactions in the thymus and bone
marrow (246, 247).
In NK cells, FAK has been shown to increase cytotoxic capacity and has been
implicated in survival.

Exposure of NK cells to full-length fibronectin or “active”

fragments containing integrin-interacting domains result in the phosphorylation of
paxillin and several higher molecular weight proteins, one of which was later identified
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as FAK (248).

Fibronectin exposure increases the association of FAK with the

intracellular kinases Fyn and ZAP70 suggesting the existence of an active signal
transduction pathway (249). Furthermore, fibronectin dose-dependently increases NK
cytotoxicity against a variety of target cells (250). Incubation with fibronectin also
maintains the survival of murine NK cells in the absence of IL-2 or IL-15 (251).
Collectively, these data suggest that fibronectin signaling mediated through integrins and
FAK may be an important regulator of NK activity and survival.

Mechanisms of FAK

expression in NK cells have not been elucidated. Here, a role for PRDM1 in the negative
regulation of PTK2 mRNA and FAK protein levels is established.

Results
PRDM1 binds to the FAK promoter
By ChIP-chip analysis PRDM1 was found to bind to a distal region of the PTK2
promoter at approximately 1,200bp upstream of the TSS. (Figure 46A). The defined
peak region spans approximately 400bp and contains two potential PRDM1 binding sites
at –1120 to –1110 and -1290 to -1279 upstream of the TSS, respectively. Both of these
motifs are closely-related to the MAGYGAAAGYK consensus sequence used to identify
potential PRDM1 target genes. Primers spanning this region were designed and used in
ChIP analysis in several types of NK cells. PRDM1 was found to occupy this region in
the NKL cell line using independent chromatin preparations, thus confirming the ChIPchip results (Figure 46D). Furthermore, PRDM1 was found to bind this region in both
primary NK cells stimulated for 24h to induce PRDM1 and LAK cells derived from three
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different donors (Figure 46B, C). Thus, PTK2 is a PRDM1 target gene within the NK
lineage.

Figure 46: PRDM1 occupies the distal PTK2 promoter. A) Representative ChIP-chip
result for PRDM1 binding to regions upstream of PTK2. B) Chromatin was prepared
from primary NK cells isolated from three healthy donors after 24h stimulation with IL-2
(100U/mL), IL-12 (10ng/mL) and IL-18 (100ng/mL). ChIP analysis was performed
using primers amplifying a region approximately 1,200bp upstream of the transcriptional
start site. C) Similar analysis in LAK cells generated from three healthy donors. D)
Similar analysis in triplicate from the NKL cell line.

PRDM1 regulates FAK expression
Given that PRDM1 binds the PTK2 promoter in vivo as revealed by ChIP,
knockdown experiments were undertaken to evaluate whether PTK2 mRNA and FAK
protein levels were elevated in the absence of PRDM1. Primary NK cells were isolated
and treated with either IL-2 and IL-12 or IL-2, IL-12 and IL-18 for 48h in the presence of
116

either a PRDM1-specific or non-targeting siRNA. During a four day culture period,
PTK2 mRNA levels are increased concomitantly with PRDM1 knockdown, consistent
with PRDM1’s role as a negative transcriptional regulator (Figure 47).

Figure 47: Knockdown of PRDM1 increases PTK2 mRNA expression. Purified NK
cells from multiple donors were incubated for 48h in the presence of either a nontargeting (NT) or PRDM1-specific (KD) siRNA. Cells were stimulated with IL-2
(100U/mL) and IL-12 (10ng/mL) with or without IL-18 (100ng/mL). RNA was isolated
and analyzed by RT-CR. Data was normalized to 18S and fold change calculated by the
ΔΔCt method, with the non-targeting sample for each donor set to “1”. Data represent the
mean of four (2+12) or three (2+12+18) donors +/- SD.

The observed increase in PTK2 mRNA with PRDM1 knockdown was greater
with IL-2 and IL-12 stimulation than for the combination of IL-2, IL-12 and IL-18.
Consistent with these results, protein levels for FAK were also increased when NK cells
were subjected to siRNA-mediated knockdown of PRDM1 during IL-2 and IL-12
stimulation (Figure 48). In several experiments, FAK protein levels showed minimal
response to PRDM1 knockdown when IL-2, IL-12 and IL-18 was used for stimulation
(data not shown). It is likely that the addition of IL-18 results in substantially higher
levels of NF-κB activation. NF-κB has been shown to positively regulate FAK promoter
activity (177) and thus may override the repressive potential of PRDM1.
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Figure 48: Knockdown of PRDM1 increases FAK protein expression. Purified NK
cells from three donors were incubated for 48h in the presence of either a non-targeting
(NT) or PRDM1-specific (KD) siRNA. Cells were stimulated with IL-2 (100U/mL) and
IL-12 (10ng/mL) and analyzed by immunoblot for PRDM1 and FAK expression. β-actin
served as loading control.

Time course experiments were conducted to analyze the kinetics of PTK2
expression during ex vivo stimulation. NK cells were isolated and stimulated for up to
four days with IL-2 and IL-12. qRT-PCR was conducted on samples harvested at 24h,
48h, 72h and 96h.

In multiple donors, PTK2 mRNA levels decreased in a time-

dependent manner (Figure 49A). Consistent with changes at the mRNA levels, FAK
protein levels also diminish while PRDM1 levels remain elevated (Figure 49B). In order
to support these findings, over-expression studies were carried out in the Jurkat T cell
line.

Transduction for 48h with PRDM1-GFP adenovirus diminishes both PTK2 mRNA

and FAK protein levels, relative to GFP-only adenovirus (Figure 50). Consistent with
these findings, FAK is not expressed in LAK cells after two to three weeks in culture
(data not shown).

Collectively, these data confirm an inverse relationship between

PRDM1 and FAK, further supporting PRDM1’s role as a negative regulator of FAK.
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Figure 49: Time-dependent reduction in PTK2 mRNA and FAK protein levels. A)
Primary NK cells stimulated with IL-2 (100U/mL) and IL-12 (10ng/mL) for four days.
RT-PCR was conducted for PTK2 mRNA on cDNA synthesized from RNA isolated at
different time points using 18S control gene. B) Representative immunoblot for PRDM1
expression at various timepoints.
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Figure 50: Over-expression of PRDM1 decreases FAK expression. Jurkat cells were
transduced for 48h with adenovirus expressing either PRDM1 and GFP or GFP alone. A)
RT-PCR analysis of PTK2 mRNA levels. B) Representative immunoblot analysis
demonstrating that FAK levels are diminished in the presence of PRDM1.

PRDM1 suppresses PTK2 promoter activity
In order to directly assess the ability of PRDM1 to mediate transcriptional control
over FAK levels, luciferase experiments were carried out. Based on the presence of two
potential PRDM1 binding sites upstream of the PTK2 TSS, constructs with progressive
deletions of the 5’ promoter region cloned upstream of luciferase were utilized to monitor
PRDM1-mediated repression. Co-transfection of PRDM1 resulted in ~30% reduction in
luciferase activity from the pGL3-PTK2-1400 construct (Figure 51).

This level of

repression was consistent with repression observed with a known PRDM1 target gene,
CIITA.

Deletion of 227bp to generate pGL3-PTK2-1173 diminished, but did not

eliminate, the repressive ability of PRDM1. Further deletion of an additional 153bp to
generate pGL3-PTK2-1070 completely blocked repression by PRDM1. Thus, multiple
elements likely contribute to PRDM1-mediated suppression because step-wise deletion of
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these regions results in additive loss of repressive ability. As expected, no effects of
PRDM1 were observed using pGL3-PTK2-564. Importantly, luciferase assay results
confirm the functionality of the region identified by ChIP-chip.

Figure 51: PRDM1 mediates repression through regulatory elements upstream of
PTK2. Deletion constructs were used in luciferase experiments. Jurkat T cells were
transfected with either empty vector or PRDM1, harvested at 36h and analyzed by
luciferase assay. Potential PRDM1-binding sites are shown as dashes. Data shown are
averages of three independent experiments +/- SD.

Discussion
Data presented in this chapter define PTK2 as a direct target of PRDM1
regulation in human NK cells. PRDM1 is bound to two sites in the distal promoter in NK
cell lines, stimulated primary NK cells and LAK cells.

Furthermore, reduction of

PRDM1 via siRNA results increased PTK2 mRNA and FAK protein, while over
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expression represses PTK2 mRNA and FAK protein. Finally, luciferase assays establish
that PRDM1’s repressive effects are mediated through two regions in the distal promoter.
Repression of FAK by PRDM1 in response to stimulation is consistent with
PRDM1’s role as a negative regulator of activation. In response to stimulation, PRDM1
is induced leading to reduction in FAK levels. Consistent with this, LAK cells which
acquire high levels of PRDM1 lose FAK expression during culture. A higher level of
repression is observed when IL-18 is not included in the stimulation cocktail likely
because IL-18 activates NFκB, a known activator of PTK2 (177). Thus, it is possible that
PRDM1-mediated repression of FAK may be over-ridden via an NFκB-dependent
pathway. Nonetheless, such a mechanism may still serve to diminish responsiveness to
integrin signaling during the attenuation phase of activation under specific stimulation
conditions.
It has been difficult to experimentally elucidate the functional consequences of
FAK down-regulation in human NK cells.

Initial functional experiments using

adenoviral-mediated transduction of PRDM1 failed to demonstrate a difference in
fibronectin-mediated survival as assessed by flow cytometry.

Low transduction

efficiency and non-specific cytotoxicity associated with adenoviral infection represent
significant technical hurdles. It may be possible to utilize a FAK-specific siRNA or a
FAK-specific inhibitor to assess functional changes; however, these approaches
circumvent PRDM1. It is also possible that NK cells can functionally compensate for
diminished FAK expression via PYK2/FAK2 encoded by PTK2B. Indeed, this closelyrelated kinase is known to be activated in response to integrin signaling (252).
Furthermore, by microarray analysis PTK2B is expressed at considerably higher levels

122

than PTK2 and is further up-regulated two- to three-fold in response to stimulation.
Thus, the functional role of FAK in NK cells requires further investigation.
Interestingly, a microRNA (miR-151) resides within intron 22 of PTK2. This
microRNA has not been extensively studied, but appears to be associated with malignant
progression.

In hepatocellular carcinoma (HCC), miR-151 mediates increases in

migratory capacity and metastatic potential (253). Levels of PTK2 mRNA correlate with
levels of miR-151, indicating that both gene products are co-regulated. Consistent with
this, FAK over-expression is associated with metatastasis and poor survival rates in HCC
patients (254, 255). miR-151 targets the Rho GTP disassociation inhibitor RhoGDIA,
which blocks GTPase activity via disruption of nucleotide exchange activity and subcellular localization. Knockdown of miR-151 increases RhoGDIA mRNA and protein,
resulting in significantly fewer metastatic nodules within the liver in vivo (253).
Suppression of miR-151 by PRDM1 may be an important tumor suppressive
mechanism.

miR-151 is expressed in acute lymphoblastic leukemia (ALL) and is

specifically down-regulated in patient samples of T cell origin relative to those of B cell
origin. Among the several thousand potential target genes, miR-151 is predicted to target
ITK, ZAP70 and several interferon-related genes (256). Other potential targets identified
in MIRBase include: IL2Rγ, IL12Rβ2, RELA and KIR2DL1. It will be interesting to
determine the levels of miR-151 in NK-derived malignancies, as well as in normal NK
cells in response to stimulation.

It will also be important to determine whether a

correlation exists between 6q21 deletion (PRDM1 loss) and over-expression of miR-151
in patient samples of various hematological malignancies. Thus, in addition to down-
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regulation of protein-coding genes, PRDM1 may regulate miR-151 (and other
microRNAs) to modulate cellular functions.

124

CHAPTER VI
HIGH-THROUGHPUT SCREENING IDENTIFICATION OF SMALL
MOLECULE INHIBITORS OF THE G9A HISTONE METHYLTRANSFERASE

Introduction
A substantial portion of the human genome is devoted to transcriptional
regulation and an estimated 1,400 genes encoding proteins that function as sequencespecific transcription factors have been identified (210). The ability to directly regulate
transcriptional activity through the use of small molecule inhibitors is a long-standing
goal of the pharmaceutical industry, yet transcription factors are largely considered to be
“undruggable” targets.

It is now widely accepted that transcription factors do not

function in isolation and frequently require the recruitment of histone-modifying enzymes
to mediate both transcriptional activation and repression. Thus, by targeting enzymes
which are recruited by transcription factors it may be possible to modulate transcription
via disruption of the associated enzymatic activity with small molecule inhibitors.
The development of inhibitors of DNA methyltransferases and histone
deacetylases has established that “epigenetic” therapy is a viable therapeutic stategy. The
nucleoside analog 5’-Aza-cytidine (Decatabaine), a competitive inhibitor of DNA
methyltransferase I (DNMT1), has been evaluated for efficacy in a variety of
hematological disorders and is FDA-approved for the treatment of myelodysplastic
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syndrome (257). Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase
inhibitor and was approved by the FDA in 2006 for the treatment of cutaneous T cell
lymphoma (258). SAHA treatment leads to growth arrest and apoptosis of transformed
cells through several mechanisms, including up-regulation of pro-apoptotic proteins of
the Bcl-2 family (259). Novel histone deacetylase inhibitors, some of which exhibit
isoform selectivity, are in development for the treatment of a variety of disorders and
numerous clinical trials are ongoing.
Inhibition of histone methyltransferases represents an attractive target for
epigenetic therapy.

However,

relatively

few small

molecule

inhibitors of

methyltransferases have been described. At the outset of this project, the only described
methyltransferase inhibitor was a compound identified from a natural product library,
chaetocin (260). This compound preferentially inhibits the Suv(var)3-9 enzyme, which
tri-methylates histone H3K9.

However, this compound exhibits high toxicity in

mammalian cells and is difficult to synthesize due to its complex chemical structure.
Thus, a need exists for the identification of novel inhibitors of histone methyltransferases.
Alterations in epigenetic patterns normally maintained through histone and DNA
methylation are characteristic of human malignancies. Therapeutic approaches which
modulate the activity histone methylating enzymes may, alone or in combination with
other epigenetic modifiers, contribute to phenotypic reversion (261). G9a is the major
enzyme responsible for H3K9me2, is functionally linked with the DNA methylation
machinery and is over-expressed in a variety of tumors. siRNA-mediated knockdown of
G9a reduces proliferation, diminishes anchorage-independent growth and induces
apoptosis in a lung cancer cell culture model (262). G9a is also required to maintain the
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malignant phenotype in vitro and in vivo (263). In breast cancer cells, 5’-Aza-cytidine
treatment reduces G9a levels and decreases global H3K9me2 levels leading to
reactivation of the tumor suppressor gene MASPIN (264). In colorectal cancer cells,
H3K9me2 is a crucial component of silencing the tumor suppressor MHL1 and loss of
H3K9me2 is critical to achieve re-activation in response to 5’-Aza-cytidine.
Given that G9a plays a critical role in cancer progression and is known to be
recruited by PRDM1 to silence its target genes, a screen was developed to identify novel
small molecule inhibitors of G9a activity. Data presented here describe the development
of a high throughput screening assay and the identification of a novel in vitro inhibitor.

Results
G9a assay development
PRDM1 recruits the histone methyltransferase G9a to mediate silencing of target
genes. Identification of a G9a-specific inhibitor could potentially provide a means to
selectively regulate gene expression due to its specific targeting to promoters via
transcription factors such as PRDM1.

Typically, methylation of histones has been

monitored in vitro using incorporation of radio-labeled S-adenosyl methionine (SAM)
into core histone substrates (265). These assays are time-consuming, poorly quantitative
and incompatible with large sample numbers. Thus, a mass spectrometry approach was
developed to assay histone methylation with the aim of conducting a small molecule
inhibitor screen.
The histone methyltransferase G9a preferentially catalyzes the di-methylation of
histone H3 lysine 9 (H3K9) and to a lesser extent H3K27 (156). Bacterially-expressed
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recombinant G9a was used to methylate a synthetic 20-mer peptide, representing the
amino-terminal tail of human histone H3 (ARTKQTARKSTGGKAPRKQL).

By

utilizing residues 1-20 as the substrate, the preferred methylation site is approximately
centered within the peptide and the K27 is not present. Although other lysine residues
are present within the peptide (K4, K14, K18), they are not targets of G9a-mediated
methylation as confirmed by MS/MS analysis (data not shown). As the methylation
reaction proceeds, the H3 peptide (m/z 2183) initially accumulates mono-methylation
(m/z 2197), then di-methylation (m/z 2211) and finally tri-methylation (m/z 2225) if
incubated for extended time periods (Figure 52). Using signal-to-noise ratios, each
species can be quantified and relative methylation levels determined. Mono-methylation
is the first product formed.

However, mono-methylated peptide levels were never

observed to accumulate above approximately 40% of the total peptide signal.
Components of the reaction were optimized in titration experiments to identify optimal
concentrations of each (Figure 53). Optimal conditions were determined and used for
scaling up the assay to 96-well plate format.
substrates were used at saturating concentrations.
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Importantly, both SAM and peptide

Figure 52: MALDI-TOF MS analysis to monitor methylation. A) Example of MS
analysis of HMT reaction. Reaction was quenched via addition of TFA after 2h
incubation and analyzed by MALDI-TOF MS. MALDI-TOF mass spectrum indicates
accumulation of methylated species. B) Same reaction, incubated for 24h.
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Figure 53: Optimization of HMT assay conditions. Titration experiments were
performed for individual reaction components. MALDI-TOF analysis was conducted to
determine the degree of methylation. These values were used to optimize conditions for
high throughput screening.

High-throughput screening
Using the reaction conditions established above, screening was carried out at the
High-throughput Screening Core Facility using the ChemDiv Chemical Diversity Set
small molecule library. This library consisted of approximately 20,000 small molecules,
representing hundreds of chemical backbones. The components of this library were
resuspended in DMSO and arrayed across 96-well plates.

Using robotic pipetting,

individual histone methyltransferase reactions were conducted in the presence of small
molecules and analyzed by MALDI-TOF MS to assess the degree of inhibition. To
account for experimental variability, data were analyzed using normalization for each
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plate. Several representative plate results are shown below (Figures 54 and 55). Each
data series consists of three points, showing the percent contribution to the overall MS
spectra for the unmodified, mono-methylated and di-methylated peptide species. Each
plate contains 96 samples (80 candidate compounds, 8 DMSO-only controls, 4 no
enzyme controls and 4 no SAM controls).

Figure 54: Raw data from four selected plates. Blue lines represent un-modified
peptide. No enzyme controls were included in the first four and last four wells of all
plates and typically show nearly exclusive unmodified peptide. Magenta and yellow
represent mono- and di-methylation, respectively. Loss of mono- and di-methyaltion
signals and gain of unmodified signal indicates enzymatic inhibition.
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Figure 55: Analyzed data from four selected plates. Data from the four plates above
was analyzed in Excel. SD was determined for DMSO-only control wells on each plate
(n = 8). Experimental samples were then graphed as deviations from control SD,
expressed as the absolute value of the fold change. Large shifts (e.g. Sample A10, on
plate 85) were considered “hits”.

After the initial rounds of screening and analysis, 8,320 small molecules had been
analyzed and numerous potential G9a inhibitors were identified. A total of 59 small
molecules were found to result in > 50% reduction in levels of di-methylation,
representing a 0.7% “hit” rate. In order to streamline the process of screening the
remainder of the library (11,680 small molecules), in silico docking studies were carried
out by the Molecular Modeling Core.

Because the crystal structure of G9a was

unavailable, a homology model was constructed based on the crystal structure of the
closely-related SET domain-containing methyltransferase, DIM5, from Neurospora
crassa. Chemical structures of the 20,000 compounds in the library were docked into the
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homology model and a docking score was generated. This value was an approximation
of the free energy associated with interactions between the small molecule and the
enzyme, with higher scores predicted to indicate higher affinity. These docking scores
were ranked and used as a predictor of inhibition. Using the top 20% of these scores,
4,000 small molecules were identified.

Of these, 2,316 were from the remaining

unscreened portion of the library, while 1,684 had been previously screened. 1,600 of
these 2,316 small molecules (representing 13.8% of the remaining library) were
robotically spotted across 20 plates and screened at 50µM for inhibitory activity. No
additional “hits” (as defined by > 50% inhibition) were found using this “cherry picking”
approach.

A total of 9,920 small molecules were screened; 8,320 via an unbiased

approach and 1,600 using a structure-guided approach.

In vitro inhibitors of G9a
Of the 59 “hit” compounds identified, 35 were ordered from ChemDiv for further
testing. IC50 values were determined by MALDI-TOF analysis, using di-methylation
levels as an endpoint; IC50 values were defined as the concentration at which dimmethylation levels were half of the DMSO-only control levels. A relatively small
percentage of these compounds demonstrated significant inhibition when assayed at
concentrations lower than 100µM. In fact, only seven showed activity at 50µM. One
compound that did exhibit reproducible inhibition was HLM-02414. This compound is a
sulfamethazine derivative with a difluoro-substituted phenyl moiety on the opposite end
of the molecule (Figure 56). This chemical backbone is a suitable pharmacophore
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because sulfamethazine derivatives have been used previously as antibacterials in a
variety of formulations.

Figure 56: Chemical structure of HLM-2414. Chemical structure of 4-(4-(2,4difluorophenyl)-thiazol-2-ylamino)-N-(4,6-dimethylpyrimidin-2-yl)benezensulfonamide.
The left portion of the molecule represents the sulfamethazine backbone.

HLM-2414 exhibited an initial IC50 value in the range of 50µM by MALDI-TOF
MS assay using a synthetic peptide substrate, even though it was not one of the strongest
inhibitors identified in the screen. However, inhibitory activity was significantly higher
using radioactive assays monitoring

3

H-incorporation into core histones, a more

physiologically-relevant substrate. Also, the chemical structure was found to be highly
amenable to combinatorial chemistry approaches. Therefore, in collaboration with the
Chemistry Core Facility, a focused library of chemical derivatives was created based on
this chemical backbone with the goal of improving inhibitory activity.

Initial

experiments demonstrated that the sulfamethazine backbone alone had no inhibitory
activity (data not shown). Therefore, chemical modifications were targeted to the phenylthiazol portion of the molecule. A total of 17 derivatives were synthesized and IC50
values were determined using MS analysis of the original compound (synthesized “in-
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house” as YL1-132) and the derivatives. The recently-published G9a inhibitor BIX01294 (synthesized as YG2-018) was also included for comparison (Figure 57).

Figure 57: IC50 values for various derivatives of HLM-2414 (YL1-132). Small
molecules are shown above in concentric circles representing IC50 values. The outermost
ring represents compounds with IC50 > 50µM, the middle ring represents compounds
with IC50 between 25µM and 50µM, while the innermost ring represents compounds with
IC50 < 25µM.

Modifications of the phenyl thiazol portion of the molecule resulted in significant
improvement of inhibitory activity. Substitution of the 2,4-difluorophenyl with 3,4dichlorphenyl (YL1-148-1) significantly improved inhibitory activity, resulting in a
compound with an IC50 value as low as 15µM. Alterations to the thiazol portion of the
molecule by addition of a methyl moiety (YL2-157) or removal of methyl groups from
the pyrimidine ring of the sulfamethazine (YG2-101) did not abrogate inhibitory activity.
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Other structure-function relationships, however, were difficult to elucidate. For example,
it was surprising that the ortho diphenyl substitution (YL1-116-1) maintained good
inhibitory activity and suggested that the elctronegativity associated with the
dichlorophenyl moiety was not critical for inhibition. Importantly, five of the derivative
molecules consistently inhibited G9a enzymatic activity to a greater extent than the BIX01294 compound. In silico docking experiments suggested that YL1-148-1 interacted
strongly with the peptide-binding cleft, indicating a potential for substrate inhibition
(Figure 58). Furthermore, in methyltransferase assays YL1-148-1 inhibited HA-purified

Figure 58: In silico docking of YL1-148-1 to H3 peptide binding cleft. YL1-148-1
was “docked” into a homology model of G9a based on the crystal structure of Dim5 with
the assistance of the Moffitt Molecular Modeling Core Facility. Docking suggests that
YL1-148-1 may lie at the top of the catalytic cleft where the Lys residue (H3K9) must be
inserted in order to receive the methyl group from the SAM co-factor. Binding at this
site would displace the H3 N-terminal tail, consistent with YL1-148-1 acting as a
substrate competitor.
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human, full-length G9a with an IC50 of approximately 3-5µM as detected by radioactive
incorporation into core histones and immuoblotting for di-methylation of GST-H3 tails
(Figure 59).

Figure 59: YL-148-1 inhibits in vitro methylation of core histones. A) Histone
methylation was monitored in vitro to determine IC50. Recombinant G9a was incubated
with core histones (4µg) and a 3H-labeled SAM substrate. Reaction products were
separated via SDS-PAGE and exposed to radiographic film. Results shown are from
three independent experiments. B) Similar assays were conducted, using non-radioactive
SAM and GST-H3 tails as substrates. Reactions were incubated with wither YL-148-1 or
sulfamethazine, which lacks the pharmacophore. H3 tails were resolved by SDS-PAGE
and analyzed by immunoblot using an antibody specific for H3K9me2.
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G9a inhibitors fail to abrogate cellular functions
In order to further characterize the efficacy of these small molecule in vitro
inhibitors, cell-based assays were carried out. Several approaches were attempted to
demonstrate ability of the small molecules to abrogate G9a-dependent processes within
cells. First of all, reporter assays were employed in which G9a was targeted upstream of
luciferase via insertion of Gal4 binding sites upstream of the thymidine kinase promoter
(266). Co-transfection of a G9a-Gal4 fusion protein strongly represses luciferase activity
using this system. Significant repression was observed with co-transfection of a G9aGal4 fusion protein, yet no de-repression was observed at doses significantly higher than
the in vitro determined IC50 (Figure 60A). Next, histones were acid-extracted from
U2OS cells that had been treated with increasing doses of YL1-148-1. These histones
were analyzed via immunoblotting in order to monitor alterations in H3K9me2 levels in
response to treatment. By pre-treating U2OS cells for 24h with SAM-deficient media, a
reduction in H3K9me2 levels was observed, but treatment with YL-148-1 did not
abrogate the recovery of H3K9me2 levels (Figure 60B).
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Figure 60: YL-148-1 fails to inhibit G9a-dependent methylation in cell-based assays.
A) U2OS cells were co-transfected with a G9a-repsonsive luciferase reporter with GAL4binding sites upstream of the tk promoter. Luciferase assays were conducted at 24h posttransfection. B) U2OS cells were incubated 24h with SAM-deficient media, then media
was replaced in the presence of increasing concentrations of YL1-148-1 for 24h.
Histones were acid-extracted and H3K9me2 levels assessed by immunoblot. C) U2OS
cells were induced to express IFNB by electroporation with 50µg pI:C. Samples were
analyzed at 5h and 24h by qRT-PCR with normalization to 18S. D) THP-1 were
“tolerized” by 16h treatment with LPS (1µg/ml) or left “responsive” by treatment with
PBS. After 1h secondary LPS stimulation (1µg/ml), samples were analyzed by qRTPCR. Experiments in A-D are representative of two to three independent experiments.

Given that G9a is required for silencing of numerous genes, two endogenous
reporter systems were utilized to assess the ability of YL1-148-1 to interfere with G9amediated repression. G9a is required for post-induction silencing IFNB in response to
polyI:C stimulation (15). Thus, inhibition of G9a enzymatic via a small molecule should
result in the sustained expression of IFNB. When U2OS cells were treated with polyI:C,
IFNB were markedly elevated at early timepoints and diminished by 24 h, however,
treatment with YL1-148-1 resulted in only marginal de-repression of IFNB (Figure 60C).
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Similarly, THP-1 cells become “tolerized” to LPS stimulation and fail to induce TNF in
response to secondary stimulation via a mechanism that requires G9a and histone
methylation (267). However, no significant abrogation of tolerance was observed in the
presence of YL1-148-1 (Figure 60D). Collectively, these data suggest that although
YL1-148-1 inhibits G9a-mediated methylation in vitro, it does not inhibit histone
methylation within a cellular context.

Discussion
Data presented here describe the development of a mass spectrometry-based
screening assay of G9a activity, which was subsequently used to identify in vitro
inhibitors of enzymatic activity. The use of mass spectrometry allowed a relatively quick
and sensitive readout of methylation levels in a format that was amenable to processing a
large number of samples. Using this approach, nearly 10,000 small molecules were
evaluated for their ability to inhibit G9a activity at 100µM. From this screen an in vitro
inhibitor of G9a was identified with an IC50 of approximately 3-5µM. Furthermore, this
assay was utilized to functionally validate an interaction of MDM2 with an H3K9specifiic methyltransferase activity (268).
While

small

molecule

inhibitors

of

histone

deacetylases

and

DNA

methyltransferases have made their way into clinical practice, the development of histone
methyltransferase inhibitors has proceeded at a slower pace, making this an attractive
area to conduct screening for novel small molecule inhibitors. When this project began
the only known selective inhibitor of histone methylation was the natural product
chaetocin. This fungal metabolite selectively inhibited drosophila SU(VAR)3-9 with an
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IC50 of 0.6µM, but exhibited extremely high toxicity in mammalian cell culture
experiments (260).

This molecule has a complex chemical structure and has only

recently been synthesized (269).
During the course of this work, a series of several small molecule inhibitors of
G9a was reported IC50 values < 10µM (270). BIX-0194 was the most potent molecule
and was reported to decrease levels of H3K9me2 at several G9a target genes, although
expression levels were not modulated for all target genes analyzed. BIX-0194 has been
shown to abrogate some G9a-dependent cellular processes (267), but controversy exists
regarding BIX specificity in vivo. Furthermore, structural and in vitro kinetic analysis
indicates that G9a-like protein GLP likely is inhibited to a greater extent than G9a. Other
groups have also reported that BIX-0194 inhibition is markedly diminished when total
histones are used as substrates in place of H3 tails, further fueling the controversy (158).
Additional structural analogs of BIX-0194 with improved activity and in vitrodetermined IC50 values in the low nM range have recently been reported, but have not
been tested in cells (269). In the experimental conditions described here, YL1-148-1
inhibits G9a more potently in vitro. However, cellular-based assays failed to demonstrate
specific inhibition of G9a using a variety of approaches for either compound.
There are several potential explanations as to why YL1-148-1 failed to mediate
detectable changes in H3K9me2 levels and G9a-dependent functions within cells. First
of all, the possibility exists that the compound either did not enter cells or was quickly
metabolized. Both appear to be unlikely because treatment at doses of 50µM were
sufficient to alter cellular morphology and growth rate. However, this defect was not
overcome by ectopic expression of G9a in MTT assays, suggesting that the effects were
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not directly attributable to inhibition of G9a. It is also possible that the in vivo interaction
of G9a-GLP heterodimers alters the ability of YL1-148-1 to abrogate enzymatic activity.
G9a immunoprecipitated from cells is inhibited in vitro, however, indicating that coprecipitating proteins do not abrogate YL1-148-1 activity.
It is quite likely that YL1-141 acts as a substrate competitor and that the extreme
abundance of histone molecules within cells significantly dilutes activity of the small
molecule. Assuming two copies of histone H3 per 200bp of DNA based on the known
structure of the nucleosome unit, each human cell will contain approximately 3 x 107
histone H3 molecules. This number will be even higher in transformed cell lines such as
U2OS, which display complex karyotypes and multi-nucleation. There is some evidence
for this competition effect. In silico docking indicated that the compound likely interacts
with the portion of the enzyme involved with substrate recognition.

Furthermore,

competition experiments with increasing concentrations of peptide, but not SAM,
abrogate YL1-148-1 activity.
Although YL1-148-1 in its current formulation is not effective in eliciting
changes in G9a-dependent processes within cells, the identification of this small molecule
has several potential applications. It may be useful as a chemical probe, by enabling in
vitro inhibition of G9a in a variety of experimental settings (271). For example, blocking
G9a enzymatic activity in nuclear extracts may be beneficial in deciphering the role of
G9a in DNA methylation and for examining the functional interdependence of other
histone modifications. It may also be possible to further modify this scaffold, which
clearly has activity against G9a. Modifications to improve bioavailability, stability or
affinity to G9a may result in more potent compounds. Since the completion of these
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studies, the crystal structures of both G9a and GLP have been deposited in the Protein
Data Bank, which will facilitate structure-guided modification strategies in the future.
The approach taken here could also be applied to future screens. These efforts may focus
on larger compound libraries or structure-guided libraries in order to identify not only
inhibitors, but also small molecules capable of altering substrate and/or product
specificity for a variety of histone modifying enzymes.
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CHAPTER VII
DISCUSSION AND SCIENTIFIC SIGNIFICANCE

The studies presented in this dissertation have led to the discovery of novel
functions for PRDM1 in human NK cells and described the identification of an in vitro
inhibitor of G9a. PRDM1 is a zinc finger transcriptional repressor that mediates its
repressive effects via the recruitment of G9a methyltransferase and other histone
modifying enzymes. PRDM1 is highly conserved throughout metazoan species and has
evolved to carry out a wide array of functions in embryonic development, lineage
commitment and effector regulation of differentiated cells. Its critical ability to both
restrain cell growth and limit effector function is highlighted by its role as a tumor
suppressor. Indeed, it is the founding member of a large family of proteins characterized
by the presence of a PR domain, many of which have been implicated in differentiation
events and tumor suppression.
PRDM1 is induced coordinately with NK activation. Knockdown experiments
performed at 48h time points demonstrate that PRDM1 mediates a post-induction
repression of IFNG, TNF and LTA, but cytotoxicity against NK-sensitive targets remains
unaffected. Consistent with this, ChIP data confirm binding to regulatory loci and overexpression suppresses activation of IFNG and TNF (272). Recent data published after
completion of this work largely confirm the findings presented here. In murine NK cells,
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combinations of IL-12 and IL-18 induce only a single isoform of PRDM1 and mRNA
expression was significantly higher in CD56dim from human samples (236). The authors
demonstrate that in vivo tumor clearance is enhanced in NK cells derived from lethally
irradiated Rag2-/- mice reconstituted with fetal liver cells derived from Prdm1-deficient
embryos and that this effect was due to enhanced proliferation of Prdm1-deficient NK
cells. However, no negative regulation of Ifng was observed. This may be explained in
part due to technical variations in experimental set-up (different stimulating cytokine
cocktails, different culture times, etc.) or species-specific regulation differences between
murine and human NK cells. Compensatory mechanisms may also be in play as total
absence of Prdm1 in the murine system is achievable, while human NK cells require
stimulation to induce PRDM1 followed by subsequent siRNA-mediated knockdown.
PRDM1 exerts both overlapping and non-overlapping functions in NK cells and
other immune lineages. Significant similarities exist between PRDM1’s role in NK cells
and T cells. Regulation of IFNG appears to be conserved as PRDM1 binding was
detected at the distal CNS-22 site, previously identified in murine CD4+ T cells (66).
Binding of PRDM1 to the promoter of IL2 is detected in NK cells as in T cells, but this
cytokine is not expressed by NK cells. In Prdm1-deficient CD8+ T cells, higher levels of
IFNγ, IL-2 and TNFα are produced in response to influenza challenge, consistent with
PRDM1’s role as a negative regulator of effector cytokines (71). However, in CD8+ T
cells, Prdm1-deficient cells have a defect in cytotoxicity due to diminished expression of
cytolytic molecules Gzmb, Gzmk and Prf1, which is not observed in NK cells. The
ability of PRDM1 to restrict memory potential in NK cells may also be conserved.
Recent data has implicated NK cells in the maintenance of immunological memory using
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both hypersensitivity and viral infection models (209, 273). In response to haptenmediated contact hypersensitivity, hepatic NK cells exhibit an increased “memory-like”
phenotype relative to splenic NK cells (274). It would be feasible to test a role whether
these hepatic NK cell “memory” populations express lower levels of Prdm1 and/or have
altered patterns of PRDM1 induction in response to hapten exposure. However, it is
currently still unclear if human NK cells exhibit this memory potential as all studies to
date have been performed exclusively in murine systems (274).
PRDM1 was identified as one of several transcription factors up-regulated in NK
cells in response to IL-2, IL-12 and IL-18. It will be of interest to determine how
PRDM1 interacts with other immune-regulatory transcription factors such as EOMES,
IRF8 and BATF which are also strongly induced with stimulation.

Conversely,

transcripts encoding a number of transcription factors are down-regulated with
stimulation, including: RUNX3, GATA3, GILZ and PLZF. RUNX3 and GATA3 are wellknown for their roles in CD4+ T cell differentiation, while PLZF has recently emerged as
the master regulator of NKT effector function (275, 276). GILZ is a glucocorticoidresponsive transcription factor that exhibits dual functionality; it negatively regulates T
cell proliferation, but enhances NK proliferation in response to IL-15 and hydrocortisone
treatment (277). Virtually nothing is known about the expression and function of these
factors within the NK lineage. Furthermore, published data (236) and microarray data
presented here suggest that the transcriptional network in activated NK cells is markedly
different than the well-defined transcriptional cascade that accompanies plasma cell
differentiation. It is likely that these transcriptional changes represent a stimulation-
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specific activation signature and cooperate to shape the NK effector phenotype. Furhter
characterization of these factors may provide important insight into NK function.
In NK cells, PRDM1 is induced in response to activating stimuli and its levels at
early time points correlate with mRNA levels of effector cytokines IFNG and TNF.
PRDM1 mRNA is readily detectable in freshly isolated NK cells and increases upon
stimulation with IL-2, IL-12 and IL-18. PRDM1 protein, however, is expressed only
very weakly in freshly isolated cells, but is markedly up-regulated with stimulation. The
requirements for induction appear to be relatively specific because CD16 ligation or
treatment with recombinant cytokines (IFNγ, IFNα or TNFα) fails to induce PRDM1.
Interestingly, when new protein synthesis is inhibited via cycloheximide concomitantly
with stimulation, PRDM1 mRNA levels increase dramatically, analogous to the wellestablished phenomenon of “super-induction” observed for IFNγ (278). This effect is
potentially mediated by a negative regulator that is itself labile and subject to constant
turnover. When de novo protein synthesis is blocked, the factor is rapidly degraded
resulting in a diminished repression of PRDM1. It is currently unclear whether this factor
actively represses transcription of PRDM1 or acts at a post-transcriptional level to control
message stability. The 3’ untranslated region (UTR) of PRDM1 contains numerous AUrich elements and has a half life of less than one hour, one of the shortest of all known
genes (279). This suggests that post-transcriptional mechanisms are critical for PRDM1
protein expression.
NK cells are unique in the expression of multiple PRDM1 isoforms. To date, NK
cells are the first example of a non-transformed cell that expresses high levels of
PRDM1β. Also, an intermediate isoform PRDM1αΔ6 is consistently detected at similar
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levels. Expression levels of these two lower molecular weight isoforms are always equal
to or greater than the full-length PRDM1β. Surprisingly, protein species corresponding
to PRDM1βΔ6 are not detected, despite the fact that, if present, they should be observed
with the antibody used in immunobloting experiments. Previously, PRDM1β has only
been detected in myeloma cell lines and samples obtained from myeloma and lymphoma
patients. Although lacking an intact N-terminal PR domain, PRDM1β still localizes to
the nucleus and can mediate transcriptional repression (albeit this activity is diminished
relative to that of PRDM1α) (5). PRDM1αΔ6, however, likely has an altered capacity for
DNA-binding due to disruptions in the zinc finger domain. It is possible that this isoform
either does not interact with DNA or recognizes distinct sequence motifs.
Collectively, the two lower molecular weight isoforms may exhibit endogenous
“dominant negative” functionality. B cells express p red omin antly PRDM1α as they
terminally differentiate into plasma cells and exit the cell cycle. NK cells, on the other
hand, induce multiple isoforms in response to stimulation. This may allow NK cells to
continue to proliferate, but at a reduced rate. Consistent with this, PRDM1 induction in
NK cells is not accompanied by an increase in apoptosis as is observed in mantle cell
lymphoma cells, which induce only full-length PRDM1α in response to Bortezomib
(195). Furthermore, PRDM1 expression in LAK cells increases during a two to three
week culture period and is characterized by an increased PRDM1α:PRDM1β ratio as
cells approach exhaustion. Similarly, PRDM1 accumulates in murine CD8+ T cells as
they become exhausted (73). In lymphoma cells, treatment with the chemotherapeutic
agent doxorubicin in combination with Rituximib leads to a decrease in PRDM1β levels,
which is correlated with their survival (280). Thus, an increased PRDM1α:PRDM1β
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ratio is associated with decreased proliferation and apoptosis. NK cells have likely struck
an evolutionary balance in terms of PRDM1 expression, sacrificing some potency in the
ability to repress target genes, but avoiding full repression of proliferation.
These studies identify numerous novel targets of PRDM1-mediated regulation in
NK cells. In fact, relatively few ChIP-based experiments have been performed in NK
cells to date and there are no published ChIP-chip or ChIP-seq data sets for any
transcription factors in NK cells. The target gene list identified shares some limited
overlap with known targets of PRDM1 in other lineages, but is substantially divergent
overall. In these studies, a criterion was applied whereby an annotated gene had to
appear in two different analyses to be considered a true target gene. This relatively
arbitrary approach represents a “best-fit” approximation to describe the NK-specific
“PRDM1 target interactome”.

Indeed, genes such as PCNA and CIITApIV are

consistently strongly positive in qPCR-based ChIP, but were not identified by ChIP-chip.
Technical

differences

between

detection

by

PCR-based

amplification

versus

hybridization of post-amplified material surely accounts for some of this divergence.
Furthermore, many genes were identified in only one experiment, while a small group
was identified in five or more analyses, suggesting that some targets may be
constitutively-bound, while others are more transient in nature.
PRDM1’s function in NK cells is mediated via the binding of numerous target
genes. PRDM1 affects expression of genes that are constitutively expressed in resting
NK cells and also functions as a post-induction suppressor of genes that are induced upon
stimulation. By regulating the expression of a large number of target genes, PRDM1
shapes the effector phenotype, functioning as a rheostat to control the degree of NK
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activation. For example, regulation of ZAP70, KLRD1, STAT6 and others allows for a
diminished response to certain activating stimuli, while leaving other signaling pathways
largely intact. Other target genes such as LRMP and BCL2L11 may facilitate receptor
recycling and protection from stimulation-induced apoptosis, respectively. Importantly,
PRDM1 binding is not limited to proximal regions of the promoter as binding was not
enriched at or near the TSS of genes. PRDM1 also mediates its control over effector
function via indirect mechanisms as transcript levels for a large number of genes that are
not direct targets of PRDM1 binding are altered upon knockdown of PRDM1.
In order to repress its target genes PRDM1 recruits several co-repressors and
histone modifying enzymes which mediate changes in the chromatin structure. PRDM1
mediates epigenetic silencing via increases in di-methylation of H3K9 (H3K9me2) and
decreases in histone acetylation at target promoters.

Thus, the use of epigenetic

modifying agents has the potential to modulate transcription of specific genes based upon
selective recruitment of histone modifying enzymes to target genes. In NK cells, the use
of HDAC inhibitors leads to increased lysis of a variety of target cells via up-regulation
of NKG2D ligands, MICA and MICB (281-284).

Yet, relatively few data exist

concerning the NK-intrinsic effects of epigenetic modifying agents and little is known
about the connections between chromatin structure and effector functions.

HDAC

inhibitors have been reported to interfere with IL-2 mediated activation, but effects on
cytolytic activity are less clear (285, 286).

Inhibition of histone methyltransferase

function may have the potential to mediate similar functional alterations. Presumably,
NK differentiation requires significant alterations in chromatin structure. However, a
paucity of NK-specific knockout targeting strategies and the relatively low number of NK
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cells per animal make it exceedingly difficult to experimentally address questions of this
nature.
PRDM1’s role as a tumor suppressor is well-established within lymphomas. In
DLBCL numerous mutations have been identified and deletion of 6q21 occurs with
relatively high frequency. Recent in vitro and in vivo studies verify mechanistically that
abrogation of PRDM1 results in increased incidence of several hematopoietic
malignancies (10, 59). A role for PRDM1 as a tumor suppressor in NK malignancies is
suggested by the high frequency of a minimal deletion region on 6q21 that includes
PRDM1. Interestingly, lymphomas originating from the NK lineage exhibit a distinct
geographical distribution, with markedly higher incidences observed in Asia and South
America. A secondary genetic locus or environmental interaction may partially explain
the wide discrepancies in incidence of these highly aggressive and often fatal neoplasms.
Deletions and silencing of PRDM1 have been documented in these patients (62).
However, data linking disruption of PRDM1 to NK-specific functional defects is
currently lacking, due in no small part to the difficulty involved in obtaining primary
patient samples. Likewise, the contribution of microRNAs to NK lymphomagenesis
remains unexplored. It will be of interest to assess the expression of miR-155 (as well as
other potential PRDM1 targets) in this process.
Collectively, the data within this dissertation establish PRDM1 as a negative
regulator of NK effector function.

PRDM1 is induced during cytokine-mediated

activation and acts as a post-induction attenuator of effector cytokine production, but
does not impede cytotoxic activity. Through modulating the expression of a wide variety
of target genes PRDM1 shapes the phenotype of human NK cells (Figure 61). PRDM1
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is a highly conserved transcription factor and orthologs have been identified in numerous
metazoan phyla, indicating an ancient evolutionary history.

Evolution of PRDM1’s

functionality likely predates the emergence of the adaptive immune system, which
occurred roughly 500 million years ago.

Consistent with this notion, these studies

position PRDM1 as a common regulator of both the adaptive and innate immune
response.

Figure 61: Model of PRDM1 function in NK cells. Schematic demonstrating
functionality of PRDM1 in response to cytokine stimulation and LAK culture.
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Appendix I: Genes changed 4-fold in stimulated NK cells
Genes up-regulated with 24h IL-2 + IL-12 + IL-18
Un-annotated transcripts removed.
Data filtered based on a “present” call and hybridization signal of >500 after cytokine
stimulation (T24hr).
Duplicate probe sets excluded.
•
•

541 genes up-regulated 3-fold or more
305 genes up-regulated 4-fold or more
Fold
Change
2950.10
2529.17
918.23
852.71
563.02
436.34
399.46
351.10
298.32
289.36
277.55
252.64
211.41
203.36
175.35
170.62
167.31
143.31
115.95
85.42
77.37
76.15
74.33
64.95
64.87
63.99
62.85
62.61
59.19
57.60
57.20
55.64
55.10
54.57

Gene Symbol
LTA
CSF2
IL26
EBI3
ZBTB32
GPR84
IL2RA
ETV5
MFSD2
TNFRSF9
ITGA1
PTGER3
STEAP1
ZNRF1
SLCO4A1
ADM
HK2
CPXM
DPP4
IL1A
TNFSF4
NETO2
LAG3
P2RX5
LGALS3
TNF
RGS16
CCR5
MYC
EGR2
SLC27A2
ICOS
FREQ
LIMK2

Gene description
lymphotoxin alpha (TNF superfamily, member 1)
colony stimulating factor 2 (granulocyte-macrophage)
interleukin 26
Epstein-Barr virus induced gene 3
zinc finger and BTB domain containing 32
G protein-coupled receptor 84
interleukin 2 receptor, alpha
ets variant gene 5 (ets-related molecule)
major facilitator superfamily domain containing 2
tumor necrosis factor receptor superfamily, member 9
integrin, alpha 1
prostaglandin E receptor 3 (subtype EP3)
six transmembrane epithelial antigen of the prostate 1
zinc and ring finger 1
solute carrier organic anion transporter family, member 4A1
adrenomedullin
hexokinase 2
carboxypeptidase X (M14 family)
dipeptidylpeptidase 4 (CD26)
interleukin 1, alpha
tumor necrosis factor (ligand) superfamily, member 4
neuropilin (NRP) and tolloid (TLL)-like 2
lymphocyte-activation gene 3
purinergic receptor P2X, ligand-gated ion channel, 5
lectin, galactoside-binding, soluble, 3 (galectin 3)
tumor necrosis factor (TNF superfamily, member 2)
regulator of G-protein signalling 16
chemokine (C-C motif) receptor 5
v-myc myelocytomatosis viral oncogene homolog (avian)
early growth response 2 (Krox-20 homolog, Drosophila)
solute carrier family 27 (fatty acid transporter), member 2
inducible T-cell co-stimulator
frequenin homolog (Drosophila)
LIM domain kinase 2

186

52.00
51.07
49.18
48.95
47.73
47.00
45.41
43.26
42.30
38.88
38.43
37.64
37.63
37.45
35.50
33.01
32.25
30.91
30.50
29.08
28.99
28.82
27.44
26.66
25.29
25.27
25.01
24.40
24.30
22.68
21.85
21.58
21.58
20.44
20.22
19.72
19.08
18.76
18.65
18.48
18.43
18.33
18.15
18.11
17.91
17.89
17.32
17.24
16.75

SOD2
MYB
CHAC1
PHLDA1
IFNG
PSAT1
CXCL10
AMID
CCR1
PDCD1L1
CCND2
CYP1B1
NDFIP2
MTHFD1L
IER3
BCAR3
SLAMF1
DUSP4
CDC6
HBEGF
HAS2
CD274
CLIC4
HAPLN3
CXCL16
TNFSF10
TSPAN33
EPS8
ADAM19
NFE2L3
CISH
ICAM1
TNFRSF18
DKFZP434B0335
TNFRSF25
PBEF1
BATF
TRIP10
SLC7A1
CD83
SLC31A1
ST8SIA4
CDKN1A
SLC1A5
PPIF
CHEK1
APOARGC
MAR3
GBP1

superoxide dismutase 2, mitochondrial
v-myb myeloblastosis viral oncogene homolog (avian)
ChaC, cation transport regulator-like 1 (E. coli)
pleckstrin homology-like domain, family A, member 1
interferon, gamma
phosphoserine aminotransferase 1
chemokine (C-X-C motif) ligand 10
(AIF)-like mitochondrion-associated inducer of death
chemokine (C-C motif) receptor 1
programmed cell death 1 ligand 1
cyclin D2
cytochrome P450, family 1, subfamily B, polypeptide 1
Nedd4 family interacting protein 2
methylenetetrahydrofolate dehydrogenase 1-like
immediate early response 3
breast cancer anti-estrogen resistance 3
signaling lymphocytic activation molecule family member 1
dual specificity phosphatase 4
CDC6 cell division cycle 6 homolog (S. cerevisiae)
heparin-binding EGF-like growth factor
hyaluronan synthase 2
CD274 antigen
chloride intracellular channel 4
hyaluronan and proteoglycan link protein 3
chemokine (C-X-C motif) ligand 16
tumor necrosis factor (ligand) superfamily, member 10
tetraspanin 33
epidermal growth factor receptor pathway substrate 8
ADAM metallopeptidase domain 19 (meltrin beta)
nuclear factor (erythroid-derived 2)-like 3
cytokine inducible SH2-containing protein
intercellular adhesion molecule 1 (CD54)
tumor necrosis factor receptor superfamily, member 18
DKFZP434B0335 protein
tumor necrosis factor receptor superfamily, member 25
pre-B-cell colony enhancing factor 1
basic leucine zipper transcription factor, ATF-like
thyroid hormone receptor interactor 10
solute carrier family 7), member 1
CD83 antigen
solute carrier family 31 (copper transporters), member 1
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
solute carrier family 1, member 5
peptidylprolyl isomerase F (cyclophilin F)
CHK1 checkpoint homolog (S. pombe)
apolipoprotein (a) related gene C
membrane-associated ring finger (C3HC4) 3
guanylate binding protein 1, interferon-inducible, 67kDa

187

16.73
16.61
16.51
16.36
15.69
15.61
15.47
14.99
14.93
14.92
14.39
14.30
14.07
13.98
13.95
13.73
13.37
13.21
13.15
12.82
12.78
12.55
12.50
12.35
12.31
12.13
12.04
11.96
11.58
11.56
11.43
11.41
11.36
11.20
11.19
11.11
11.09
11.05
10.92
10.83
10.68
10.66
10.64
10.58
10.54
10.29
10.22
10.21
10.18

STX11
SHMT2
PAICS
NFKB2
SNCA
WARS
EBI2
BCL2A1
PBEF
CSDA
UBE2T
TRPV1
SAMSN1
KLRA1
MTHFD2
E2F1
CDK6
MT1E
SOCS1
SEH1L
SART2
MDFIC
CDT1
DUSP5
UHRF1
TRAF1
FRMD4B
PKM2
NFKBIZ
STK3
VEGF
GPR171
IRAK2
LIG4
NME1
IL12RB2
SLAMF7
CD48
DTL
SLC43A3
BYSL
PIM2
SLC16A1
CMAH
TANK
RAB6IP1
MYO1B
RPP40
NFE2L1

syntaxin 11
serine hydroxymethyltransferase 2 (mitochondrial)
phosphoribosylaminoimidazole succinocarboxamide synthetase
nuclear factor of kappa light enhancer in B-cells 2 (p49/p100)
synuclein, alpha (non A4 component of amyloid precursor)
tryptophanyl-tRNA synthetase
Epstein-Barr virus induced gene 2
BCL2-related protein A1
pre-B-cell colony-enhancing factor
cold shock domain protein A
ubiquitin-conjugating enzyme E2T (putative)
transient receptor potential cation channel, subfamily V, 1
SAM domain, SH3 domain and nuclear localisation signals, 1
killer cell lectin-like receptor subfamily A, member 1
methylene tetrahydrofolate
E2F transcription factor 1
cyclin-dependent kinase 6
metallothionein 1E (functional)
suppressor of cytokine signaling 1
SEH1-like (S. cerevisiae)
squamous cell carcinoma antigen recognized by T cells 2
MyoD family inhibitor domain containing
DNA replication factor
dual specificity phosphatase 5
ubiquitin-like, containing PHD and RING finger domains, 1
TNF receptor-associated factor 1
FERM domain containing 4B
pyruvate kinase, muscle
nuclear factor of kappa light enhancer in B-cells inhibitor, zeta
serine/threonine kinase 3 (STE20 homolog, yeast)
vascular endothelial growth factor
G protein-coupled receptor 171
interleukin-1 receptor-associated kinase 2
ligase IV, DNA, ATP-dependent
non-metastatic cells 1, protein (NM23A) expressed in
interleukin 12 receptor, beta 2
SLAM family member 7
CD48 antigen (B-cell membrane protein)
denticleless homolog (Drosophila)
solute carrier family 43, member 3
bystin-like
pim-2 oncogene
solute carrier family 1, member 1
cytidine monophosphate-N-acetylneuraminic acid hydroxylase
TRAF family member-associated NFKB activator
RAB6 interacting protein 1
myosin IB
ribonuclease P 40kDa subunit
nuclear factor (erythroid-derived 2)-like 1

188

10.15
10.03
9.83
9.79
9.61
9.59
9.54
9.47
9.41
9.20
9.17
8.97
8.96
8.76
8.70
8.52
8.45
8.43
8.43
8.35
8.31
8.19
8.18
8.15
8.07
8.06
8.06
7.99
7.97
7.92
7.87
7.80
7.75
7.66
7.59
7.57
7.44
7.37
7.32
7.28
7.26
7.17
7.15
7.09
7.06
7.03
7.02
6.99
6.98

CHAC2
FAS
STAG3
MIRN21
RAB33A
GPR34
TWSG1
PIGV
PTTG1
TMEM49
ADORA2A
ABTB2
GMPPB
SHCBP1
IRF8
SLC35F2
IL15RA
SDC4
NFKB1
JMJD3
NUPL1
STIP1
SLC7A5
CBX5
TNFRSF4
FNBP2
TAX1BP3
PHGDH
FASLG
FABP5
SRPRB
CSE1L
PRDX3
PIM1
BCOR
GADD45B
TARS
METTL1
POLR3D
BCL2L1
TRIB3
GPR174
LACTB
RAB10
EXOSC3
GART
SQLE
SKB1
TAP1

ChaC, cation transport regulator-like 2 (E. coli)
Fas (TNF receptor superfamily, member 6)
stromal antigen 3
microRNA 21
RAB33A, member RAS oncogene family
G protein-coupled receptor 34
twisted gastrulation homolog 1 (Drosophila)
phosphatidylinositol glycan, class V
pituitary tumor-transforming 1
transmembrane protein 49
adenosine A2a receptor
ankyrin repeat and BTB (POZ) domain containing 2
GDP-mannose pyrophosphorylase B
SHC SH2-domain binding protein 1
interferon regulatory factor 8
solute carrier family 35, member F2
interleukin 15 receptor, alpha
syndecan 4 (amphiglycan, ryudocan)
nuclear factor of kappa light enhancer in B-cells 1 (p105)
jumonji domain containing 3
nucleoporin like 1
stress-induced-phosphoprotein 1 (Hsp70/90-organizing protein)
solute carrier family 7, member 5
chromobox homolog 5 (HP1 alpha homolog, Drosophila)
tumor necrosis factor receptor superfamily, member 4
formin binding protein 2
Tax1 (human T-cell leukemia virus type I) binding protein 3
phosphoglycerate dehydrogenase
Fas ligand (TNF superfamily, member 6)
fatty acid binding protein 5 (psoriasis-associated)
signal recognition particle receptor, B subunit
CSE1 chromosome segregation 1-like (yeast)
peroxiredoxin 3
pim-1 oncogene
BCL6 co-repressor
growth arrest and DNA-damage-inducible, beta
threonyl-tRNA synthetase
methyltransferase like 1
polymerase (RNA) III (DNA directed) polypeptide D, 44kDa
BCL2-like 1
tribbles homolog 3 (Drosophila)
G protein-coupled receptor 174
lactamase, beta
RAB10, member RAS oncogene family
exosome component 3
phosphoribosylaminoimidazole synthetase
squalene epoxidase
SKB1 homolog (S. pombe)
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)

189

6.98
6.97
6.96
6.89
6.88
6.85
6.83
6.83
6.83
6.77
6.72
6.69
6.65
6.64
6.62
6.61
6.59
6.50
6.49
6.48
6.48
6.46
6.45
6.36
6.32
6.28
6.27
6.26
6.23
6.23
6.22
6.19
6.18
6.16
6.05
5.97
5.95
5.93
5.90
5.90
5.90
5.89
5.88
5.80
5.79
5.79
5.78
5.76
5.76

FLOT1
SYNCRIP
HIVEP2
SMS
LMAN1
SPHK1
PPIL1
NUDCD1
CDK4
SNAPC1
SEC24D
HSPA1A
XCL1
NANS
GFPT1
MOSPD2
TYMS
PLAGL1
SAR1B
KLHL6
DLEU2
CCDC6
ECGF1
GPR18
FH
SLC39A14
PGD
TFRC
VASP
ACVR1B
SFXN4
AK2
KCNA3
WDR12
MT1H
HM13
APMCF1
LARP4
SUV39H2
STAT5A
MT1G
PPAN
TUBB
BET1
RBBP8
HAVCR2
E2F6
GADD45G
GOT1

flotillin 1
synaptotagmin binding, cytoplasmic RNA interacting protein
human immunodeficiency virus type I enhancer binding protein 2
spermine synthase
lectin, mannose-binding, 1
sphingosine kinase 1
peptidylprolyl isomerase (cyclophilin)-like 1
NudC domain containing 1
cyclin-dependent kinase 4
small nuclear RNA activating complex, polypeptide 1, 43kDa
SEC24 related gene family, member D (S. cerevisiae)
heat shock 70kDa protein 1A
chemokine (C motif) ligand 1
N-acetylneuraminic acid synthase (sialic acid synthase)
glutamine-fructose-6-phosphate transaminase 1
motile sperm domain containing 2
thymidylate synthetase
pleiomorphic adenoma gene-like 1
SAR1 gene homolog B (S. cerevisiae)
kelch-like 6 (Drosophila)
deleted in lymphocytic leukemia, 2
coiled-coil domain containing 6
endothelial cell growth factor 1 (platelet-derived)
G protein-coupled receptor 18
fumarate hydratase
solute carrier family 39 (zinc transporter), member 14
phosphogluconate dehydrogenase
transferrin receptor (p90, CD71)
vasodilator-stimulated phosphoprotein
activin A receptor, type IB
sideroflexin 4
adenylate kinase 2
potassium voltage-gated channel, shaker-related subfamily, 3
WD repeat domain 12
metallothionein 1H
histocompatibility (minor) 13
APMCF1 protein
La ribonucleoprotein domain family, member 4
suppressor of variegation 3-9 homolog 2 (Drosophila)
signal transducer and activator of transcription 5A
metallothionein 1G
peter pan homolog (Drosophila)
tubulin, beta
BET1 homolog (S. cerevisiae)
retinoblastoma binding protein 8
hepatitis A virus cellular receptor 2
E2F transcription factor 6
growth arrest and DNA-damage-inducible, gamma
glutamic-oxaloacetic transaminase 1, soluble
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5.75
5.72
5.71
5.71
5.61
5.57
5.52
5.50
5.49
5.44
5.37
5.37
5.35
5.33
5.31
5.26
5.24
5.24
5.24
5.18
5.17
5.17
5.17
5.16
5.13
5.13
5.12
5.09
5.04
5.03
5.03
5.02
5.02
5.02
5.02
4.97
4.95
4.95
4.95
4.91
4.90
4.90
4.86
4.86
4.84
4.81
4.79
4.79
4.74

PFKFB3
FAM89A
SFXN1
TUBG1
PDIA5
LTB
SNX10
WDR4
IBRDC3
MCM4
PPP1R15A
TM6SF1
TIMM10
PNPT1
CREM
SERPINB8
DAPK1
WARS2
IDH3A
ETS2
EIF2S1
JARID1B
ETNK1
ACSL1
BCCIP
MCM6
HTPAP
LMNB2
KIF3B
HSPD1
BIRC3
NAB1
IARS
AARS
ABHD2
NDUFAF1
TMEM64
PSMB5
CYB5
BXDC1
SOCS3
MT1X
SPRED2
CSTF2
EED
FTH1
PELO
IL4R
EIF2S2

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
family with sequence similarity 89, member A
sideroflexin 1
tubulin, gamma 1
protein disulfide isomerase family A, member 5
lymphotoxin beta (TNF superfamily, member 3)
sorting nexin 10
WD repeat domain 4
IBR domain containing 3
MCM4 minichromosome maintenance deficient 4 (S. cerevisiae)
protein phosphatase 1, regulatory (inhibitor) subunit 15A
transmembrane 6 superfamily member 1
translocase of inner mitochondrial membrane 10 homolog (yeast)
polyribonucleotide nucleotidyltransferase 1
cAMP responsive element modulator
serpin peptidase inhibitor, clade B (ovalbumin), member 8
death-associated protein kinase 1
tryptophanyl tRNA synthetase 2 (mitochondrial)
isocitrate dehydrogenase 3 (NAD+) alpha
v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa
Jumonji, AT rich interactive domain 1B (RBP2-like)
ethanolamine kinase 1
acyl-CoA synthetase long-chain family member 1
BRCA2 and CDKN1A interacting protein
MCM6 minichromosome maintenance deficient 6 (MIS5 homolog)
HTPAP protein
lamin B2
kinesin family member 3B
heat shock 60kDa protein 1 (chaperonin)
baculoviral IAP repeat-containing 3
NGFI-A binding protein 1 (EGR1 binding protein 1)
isoleucine-tRNA synthetase
alanyl-tRNA synthetase
abhydrolase domain containing 2
NADH dehydrogenase 1 alpha subcomplex, assembly factor 1
transmembrane protein 64
proteasome (prosome, macropain) subunit, beta type, 5
cytochrome b-5
brix domain containing 1
suppressor of cytokine signaling 3
metallothionein 1X
sprouty-related, EVH1 domain containing 2
cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa
embryonic ectoderm development
ferritin, heavy polypeptide 1
pelota homolog (Drosophila)
interleukin 4 receptor
eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa
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4.73
4.72
4.72
4.69
4.69
4.68
4.62
4.60
4.52
4.51
4.47
4.46
4.45
4.43
4.43
4.42
4.41
4.39
4.36
4.35
4.31
4.28
4.22
4.21
4.17
4.04

RALA
CD40
MCM2
CHCHD4
ARF4
HUWE1
CETN3
IVNS1ABP
RQCD1
RRS1
JTV1
TICAM2
FARSLA
YIPF6
LYCAT
POLE2
TNIP2
DDX21
MT1F
TXN
GIPR
DKC1
SEC11L3
MARS
MLLT4
TIPRL

v-ral simian leukemia viral oncogene homolog A (ras related)
CD40 antigen (TNF receptor superfamily member 5)
minichromosome maintenance deficient 2, mitotin (S. cerevisiae)
coiled-coIL-helix-coiled-coIL-helix domain containing 4
ADP-ribosylation factor 4
HECT, UBA and WWE domain containing 1
centrin, EF-hand protein, 3 (CDC31 homolog, yeast)
influenza virus NS1A binding protein
RCD1 required for cell differentiation1 homolog (S. pombe)
RRS1 ribosome biogenesis regulator homolog (S. cerevisiae)
JTV1 gene
toll-like receptor adaptor molecule 2
phenylalanine-tRNA synthetase-like, alpha subunit
Yip1 domain family, member 6
lysocardiolipin acyltransferase
polymerase (DNA directed), epsilon 2 (p59 subunit)
TNFAIP3 interacting protein 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21
metallothionein 1F (functional)
thioredoxin
gastric inhibitory polypeptide receptor
dyskeratosis congenita 1, dyskerin
SEC11-like 3 (S. cerevisiae)
methionine-tRNA synthetase
mixed-lineage leukemia (trithorax homolog); translocated to, 4
TIP41, TOR signalling pathway regulator-like (S. cerevisiae)
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Genes down-regulated with 24h IL-2 + IL-12 + IL-18
Un-annotated transcripts removed.
Data filtered based on a “present” call and hybridization signal of >500 before cytokine
stimulation (T0hr).
Duplicate probe sets excluded.
•
•

609 genes down-regulated 3-fold or more
383 genes down-regulated 4-fold or more
Fold
Change
-391.76
-362.98
-282.01
-251.21
-192.18
-185.22
-168.79
-154.25
-122.01
-106.26
-104.43
-101.19
-95.36
-92.98
-87.98
-77.54
-73.98
-66.44
-65.74
-65.62
-65.34
-65.08
-63.44
-63.03
-62.21
-62.20
-61.34
-61.26
-57.20
-54.85
-49.09
-47.85
-43.91
-40.62
-40.50
-37.39
-37.04

Gene
Symbol
ZBP1
HBA1
MGAM
DUSP1
SNAI3
LDB2
EDG8
ENPP5
DPEP2
HBA2
AREG
PLXND1
SPON2
ADAM28
KRTHB6
MYOM2
TLE1
CAPN12
FZD4
TSC22D3
TKTL1
ZFP36L2
RAB37
CD52
ENC1
SCML4
FBXO32
FAIM3
AHNAK
RASGRP2
CXCR4
PER1
PRSS23
SIGLECP3
NR4A2
TSPAN32
SPTB

Gene description
Z-DNA binding protein 1
hemoglobin, alpha 1
maltase-glucoamylase (alpha-glucosidase)
dual specificity phosphatase 1
snail homolog 3 (Drosophila)
LIM domain binding 2
endothelial differentiation, sphingolipid G-protein-coupled receptor, 8
ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function)
dipeptidase 2
hemoglobin, alpha 2
amphiregulin (schwannoma-derived growth factor)
plexin D1
spondin 2, extracellular matrix protein
ADAM metallopeptidase domain 28
keratin, hair, basic, 6 (monilethrix)
myomesin (M-protein) 2, 165kDa
transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)
calpain 12
frizzled homolog 4 (Drosophila)
TSC22 domain family, member 3
transketolase-like 1
zinc finger protein 36, C3H type-like 2
RAB37, member RAS oncogene family
CD52 antigen (CAMPATH-1 antigen)
ectodermal-neural cortex (with BTB-like domain)
sex comb on midleg-like 4 (Drosophila)
F-box protein 32
Fas apoptotic inhibitory molecule 3
AHNAK nucleoprotein (desmoyokin)
RAS guanyl releasing protein 2 (calcium and DAG-regulated)
chemokine (C-X-C motif) receptor 4
period homolog 1 (Drosophila)
protease, serine, 23
sialic acid binding Ig-like lectin, pseudogene 3
nuclear receptor subfamily 4, group A, member 2
tetraspanin 32
spectrin, beta, erythrocytic (includes spherocytosis, clinical type I)
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-37.04
-36.77
-36.38
-32.32
-30.76
-27.99
-27.87
-27.00
-26.49
-26.33
-26.24
-25.97
-25.60
-24.97
-24.90
-24.74
-24.62
-24.11
-24.05
-23.98
-23.89
-23.41
-22.61
-22.58
-22.50
-22.34
-21.41
-21.00
-20.64
-20.26
-20.11
-19.86
-19.56
-19.55
-19.42
-19.31
-19.30
-18.87
-18.21
-17.94
-17.14
-17.02
-16.86
-16.80
-16.79
-16.78
-16.68
-16.58
-16.48

HHEX
TXNDC3
TMCC3
ZFP36
SORL1
SYNGR1
ABLIM1
ARHGAP12
KLF2
GAS7
CD160
MTAC2D1
NEIL1
RASA3
IL8RB
SLC1A7
MTSS1
TMEM71
RNPC1
PDCD4
TMEM2
SGSH
FAM13A1
PDZK4
GCHFR
FAM62B
SPOCK2
DLL1
YPEL1
MMP23B
C11orf32
MXI1
CENTG2
IRS2
SIGIRR
SBK1
SSX2IP
SNF1LK
SHFM3P1
ISG20
FRAT1
FOS
MXD4
KIR2DS5
MLC1
CLIC3
KIR2DL1
LRMP
CD300A

hematopoietically expressed homeobox
thioredoxin domain containing 3 (spermatozoa)
transmembrane and coiled-coil domain family 3
zinc finger protein 36, C3H type, homolog (mouse)
sortilin-related receptor, L(DLR class) A repeats-containing
synaptogyrin 1
actin binding LIM protein 1
Rho GTPase activating protein 12
Kruppel-like factor 2 (lung)
growth arrest-specific 7
CD160 antigen
membrane targeting (tandem) C2 domain containing 1
nei endonuclease VIII-like 1 (E. coli)
RAS p21 protein activator 3
interleukin 8 receptor, beta
solute carrier family 1 (glutamate transporter), member 7
metastasis suppressor 1
transmembrane protein 71
RNA-binding region (RNP1, RRM) containing 1
programmed cell death 4 (neoplastic transformation inhibitor)
transmembrane protein 2
N-sulfoglucosamine sulfohydrolase (sulfamidase)
family with sequence similarity 13, member A1
PDZ domain containing 4
GTP cyclohydrolase I feedback regulator
Family with sequence similarity 62 (C2 domain containing) member B
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2
delta-like 1 (Drosophila)
yippee-like 1 (Drosophila)
matrix metallopeptidase 23B
sortilin-related receptor, L(DLR class) A repeats-containing *
MAX interactor 1
centaurin, gamma 2
insulin receptor substrate 2
single immunoglobulin and toll-interleukin 1 receptor (TIR) domain
SH3-binding domain kinase 1
synovial sarcoma, X breakpoint 2 interacting protein
SNF1-like kinase
split hand/foot malformation (ectrodactyly) type 3 pseudogene 1
interferon stimulated exonuclease gene 20kDa
frequently rearranged in advanced T-cell lymphomas
v-fos FBJ murine osteosarcoma viral oncogene homolog
MAX dimerization protein 4
killer cell immunoglobulin-like receptor, two domains, short tail, 5
megalencephalic leukoencephalopathy with subcortical cysts 1
chloride intracellular channel 3
killer cell immunoglobulin-like receptor, two domains, long tail, 1
lymphoid-restricted membrane protein
CD300A antigen
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-16.43
-16.33
-16.08
-15.70
-15.33
-15.32
-15.20
-15.16
-14.96
-14.90
-14.52
-14.49
-14.35
-14.32
-14.22
-14.02
-13.92
-13.88
-13.86
-13.75
-13.62
-13.57
-13.52
-13.51
-13.44
-13.43
-13.33
-13.21
-13.08
-13.07
-13.05
-12.80
-12.77
-12.63
-12.41
-12.40
-12.39
-12.08
-11.98
-11.97
-11.80
-11.71
-11.71
-11.70
-11.65
-11.65
-11.62
-11.49
-11.46

GARNL4
SELPLG
GPR56
AIM1
KIR3DL3
RNF166
AK5
SYNE1
ZBTB16
MIR
RAB27B
CECR1
PTGDS
KLHL24
GZMM
SLA2
TMC8
SPN
KIR3DL1
CXXC5
APBA2
RGS2
RNF125
CHST12
KIR2DS4
C3AR1
STMN3
WHDC1L1
AGPAT4
YPEL2
BIN1
SFXN3
NR1D2
PDGFD
CNNM3
SOX4
ADCY7
SIGLEC7
GSTM1
TSEN54
PLEKHG3
BNC2
SEPT6
AMY2B
FOSL2
PSCD1
ATP8A1
CDKN2D
PTGDR

GTPase activating Rap/RanGAP domain-like 4
selectin P ligand
G protein-coupled receptor 56
absent in melanoma 1
killer cell immunoglobulin-like receptor, three domains, long tail, 3
ring finger protein 166
adenylate kinase 5
spectrin repeat containing, nuclear envelope 1
zinc finger and BTB domain containing 16
myosin regulatory light chain interacting protein
RAB27B, member RAS oncogene family
cat eye syndrome chromosome region, candidate 1
prostaglandin D2 synthase 21kDa (brain)
kelch-like 24 (Drosophila)
granzyme M (lymphocyte met-ase 1)
Src-like-adaptor 2
transmembrane channel-like 8
sialophorin (gpL115, leukosialin, CD43)
killer cell immunoglobulin-like receptor, three domains, long tail, 1
CXXC finger 5
amyloid beta (A4) precursor protein-binding, family A, member 2
regulator of G-protein signalling 2, 24kDa
ring finger protein 125
carbohydrate (chondroitin 4) sulfotransferase 12
killer cell immunoglobulin-like receptor, two domains, short tail, 4
complement component 3a receptor 1
stathmin-like 3
WAS protein homology region 2 domain containing 1-like 1
1-acylglycerol-3-phosphate O-acyltransferase 4
yippee-like 2 (Drosophila)
bridging integrator 1
sideroflexin 3
nuclear receptor subfamily 1, group D, member 2
platelet derived growth factor D
cyclin M3
SRY (sex determining region Y)-box 4
adenylate cyclase 7
sialic acid binding Ig-like lectin 7
glutathione S-transferase M1
tRNA splicing endonuclease 54 homolog (SEN54, S. cerevisiae)
pleckstrin homology domain containing, family G member 3
basonuclin 2
septin 6
amylase, alpha 2B; pancreatic
FOS-like antigen 2
pleckstrin homology, Sec7 and coiled-coil domains 1(cytohesin 1)
ATPase, aminophospholipid transporter (APLT), type 8A, member 1
cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
prostaglandin D2 receptor (DP)
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-11.37
-11.36
-11.34
-11.32
-11.31
-11.31
-11.26
-11.20
-11.19
-11.16
-11.11
-11.10
-11.08
-11.00
-11.00
-10.88
-10.80
-10.80
-10.75
-10.74
-10.65
-10.47
-10.40
-10.20
-10.07
-9.93
-9.89
-9.87
-9.80
-9.75
-9.75
-9.73
-9.73
-9.66
-9.63
-9.59
-9.58
-9.55
-9.50
-9.46
-9.44
-9.43
-9.41
-9.34
-9.11
-9.08
-9.08
-9.07
-9.04

TBC1D10C
ZNF331
PECAM1
SH2D1B
CD7
ATM
NR4A3
CYBA
PBXIP1
ZAP70
MGAT4A
DHRS1
DAB2
ATXN7L1
BNIP3L
UBE1L
TSC22D1
AVPI1
MYO1F
LY9
KIR3DL2
GSN
BCL11B
RNF103
EVER2
ERBB2
SFRS5
TSPAN2
COL6A2
ABCB1
AUTS2
PTPN22
MPPE1
DUSP2
MYLIP
KLHL3
SNTB2
KIR2DL3
CIDEB
BTBD15
LDLRAP1
FAM8A1
LLGL2
PELI2
OSBPL5
IL11RA
PITPNM2
MLLT3
FBXL3A

TBC1 domain family, member 10C
zinc finger protein 331
platelet/endothelial cell adhesion molecule (CD31 antigen)
SH2 domain containing 1B
CD7 antigen (p41)
ataxia telangiectasia mutated
nuclear receptor subfamily 4, group A, member 3
cytochrome b-245, alpha polypeptide
pre-B-cell leukemia transcription factor interacting protein 1
zeta-chain (TCR) associated protein kinase 70kDa
mannosyl (alpha-1,3-) beta-1,4-N-acetylglucosaminyltransferase A
dehydrogenase/reductase (SDR family) member 1
disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)
ataxin 7-like 1
BCL2/adenovirus E1B 19kDa interacting protein 3-like
ubiquitin-activating enzyme E1-like
TSC22 domain family, member 1
arginine vasopressin-induced 1
myosin IF
lymphocyte antigen 9
killer cell immunoglobulin-like receptor, three domains, long tail, 2
gelsolin (amyloidosis, Finnish type)
B-cell CLL/lymphoma 11B (zinc finger protein)
ring finger protein 103
epidermodysplasia verruciformis 2
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, (avian)
splicing factor, arginine/serine-rich 5
tetraspanin 2
collagen, type VI, alpha 2
ATP-binding cassette, sub-family B (MDR/TAP), member 1 *
autism susceptibility candidate 2
protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
metallo phosphoesterase
dual specificity phosphatase 2
myosin regulatory light chain interacting protein
kelch-like 3 (Drosophila)
syntrophin, beta 2 (dystrophin-associated protein A1, basic component 2)
killer cell immunoglobulin-like receptor, two domains, long tail, 3
cell death-inducing DFFA-like effector b
BTB (POZ) domain containing 15
low density lipoprotein receptor adaptor protein 1
family with sequence similarity 8, member A1
lethal giant larvae homolog 2 (Drosophila)
pellino homolog 2 (Drosophila)
oxysterol binding protein-like 5
interleukin 11 receptor, alpha
phosphatidylinositol transfer protein, membrane-associated 2
mixed-lineage leukemia (trithorax homolog); translocated to, 3
F-box and leucine-rich repeat protein 3A
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-9.02
-9.01
-8.94
-8.91
-8.86
-8.82
-8.79
-8.72
-8.69
-8.68
-8.58
-8.42
-8.40
-8.39
-8.34
-8.34
-8.31
-8.28
-8.26
-8.24
-8.14
-8.11
-8.05
-8.05
-8.04
-8.00
-7.97
-7.89
-7.89
-7.87
-7.85
-7.77
-7.74
-7.72
-7.68
-7.65
-7.63
-7.62
-7.61
-7.61
-7.58
-7.56
-7.56
-7.55
-7.52
-7.49
-7.49
-7.48
-7.42

RAB11FIP4
CASP8
FOXO1A
KIR2DL4
KLF12
F2R
AKAP2
AHSA2
KIR2DS1
TMEM59
IFITM1
RNASET2
KIR2DL5B
NMT2
ADHFE1
GALNT12
ZNF238
IFITM2
SLCO3A1
NUAK2
CTSF
ZNF198
SAMD3
PAPD5
VPS26B
RCSD1
SEPT9
BZRAP1
PTPRN2
PLEKHA1
TRIB2
ABTB1
SCAND1
ARHGAP8
P2RY8
PSCD4
YPEL3
WASPIP
FGL2
ITGAM
ITGA4
SIPA1
SERTAD3
KLRG1
KLRF1
MIB2
CEP78
CACNA2D2
ANXA1

RAB11 family interacting protein 4 (class II)
caspase 8, apoptosis-related cysteine peptidase
forkhead box O1A (rhabdomyosarcoma)
killer cell ig-like receptor, two domains, long cytoplasmic tail, 4
Kruppel-like factor 12
coagulation factor II (thrombin) receptor
A kinase (PRKA) anchor protein 2
AHA1, activator of heat shock 90kDa protein ATPase homolog 2
killer cell ig-like receptor, two domains, short cytoplasmic tail, 1
transmembrane protein 59 *
interferon induced transmembrane protein 1 (9-27)
ribonuclease T2
killer cell ig-like receptor, two domains, long cytoplasmic tail, 5B
N-myristoyltransferase 2
alcohol dehydrogenase, iron containing, 1
UDP- GalNAc-:polypeptide N-acetylgalactosaminyltransferase 12
zinc finger protein 238
interferon induced transmembrane protein 2 (1-8D)
solute carrier organic anion transporter family, member 3A1
NUAK family, SNF1-like kinase, 2
cathepsin F
zinc finger protein 198
sterile alpha motif domain containing 3
PAP associated domain containing 5
vacuolar protein sorting 26 homolog B (yeast)
RCSD domain containing 1
septin 9
benzodiazapine receptor (peripheral) associated protein 1
protein tyrosine phosphatase, receptor type, N polypeptide 2
pleckstrin homology domain containing, family A member 1
tribbles homolog 2 (Drosophila)
ankyrin repeat and BTB (POZ) domain containing 1
SCAN domain containing 1
Rho GTPase activating protein 8
purinergic receptor P2Y, G-protein coupled, 8
pleckstrin homology, Sec7 and coiled-coil domains 4
yippee-like 3 (Drosophila)
Wiskott-Aldrich syndrome protein interacting protein
fibrinogen-like 2
integrin, alpha M (complement component receptor 3, alpha, CD11b)
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
signal-induced proliferation-associated gene 1
SERTA domain containing 3
killer cell lectin-like receptor subfamily G, member 1
killer cell lectin-like receptor subfamily F, member 1
mindbomb homolog 2 (Drosophila)
centrosomal protein 78kDa
calcium channel, voltage-dependent, alpha 2/delta subunit 2
annexin A1
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-7.41
-7.33
-7.31
-7.29
-7.29
-7.15
-7.10
-7.08
-7.06
-7.02
-7.01
-6.92
-6.89
-6.89
-6.87
-6.85
-6.83
-6.80
-6.77
-6.76
-6.71
-6.64
-6.63
-6.63
-6.62
-6.60
-6.60
-6.59
-6.58
-6.50
-6.46
-6.42
-6.42
-6.42
-6.38
-6.37
-6.33
-6.30
-6.30
-6.30
-6.28
-6.28
-6.27
-6.26
-6.26
-6.23
-6.23
-6.23
-6.23

TRAF3IP3
HSPC072
OTUD1
ASCL2
ATHL1
IGF1R
SEMA4C
RASGEF1A
ZFP276
CDK5R1
BCR
TP53INP1
TGFB1
FLJ10244
NOD3
TYROBP
IL24
ARHGAP9
MLL5
PLEKHF1
ELF2
HLA-DPB1
AXIN1
FYB
TAF9L
GALT
WDFY1
AMT
DLG5
NRBP2
SDCCAG33
CENTB1
CYBRD1
PTPLAD2
HBP1
TRIM74
SAMHD1
AK1
LGR6
IFITM3
CALM1
ADAMTS10
FLOT2
PLCL2
EFHC1
CCL28
FCGR2B
OSBPL7
SMAD3

TRAF3 interacting protein 3
HSPC072 protein
OTU domain containing 1
achaete-scute complex-like 2 (Drosophila)
ATH1, acid trehalase-like 1 (yeast)
insulin-like growth factor 1 receptor
semaphorin 4C
RasGEF domain family, member 1A
zinc finger protein 276 homolog (mouse)
cyclin-dependent kinase 5, regulatory subunit 1 (p35)
breakpoint cluster region
tumor protein p53 inducible nuclear protein 1
transforming growth factor, beta 1 (Camurati-Engelmann disease)
Ral-A exchange factor RalGPS2
NOD3 protein
TYRO protein tyrosine kinase binding protein
interleukin 24
Rho GTPase activating protein 9
myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog)
pleckstrin homology domain containing, family F, member 1
E74-like factor 2 (ets domain transcription factor)
major histocompatibility complex, class II, DP beta 1
axin 1
FYN binding protein (FYB-120/130)
TAF9-like RNA polymerase II, TBP-associated factor, 31kDa
galactose-1-phosphate uridylyltransferase
WD repeat and FYVE domain containing 1
aminomethyltransferase (glycine cleavage system protein T)
discs, large homolog 5 (Drosophila)
nuclear receptor binding protein 2
serologically defined colon cancer antigen 33
centaurin, beta 1
cytochrome b reductase 1
protein tyrosine phosphatase-like A domain containing 2
HMG-box transcription factor 1
tripartite motif-containing 50B or of tripartite motif-containing 74 *
SAM domain and HD domain 1
adenylate kinase 1
leucine-rich repeat-containing G protein-coupled receptor 6
interferon induced transmembrane protein 3 (1-8U)
calmodulin 1 (phosphorylase kinase, delta)
ADAM metallopeptidase with thrombospondin type 1 motif, 10
flotillin 2
phospholipase C-like 2
EF-hand domain (C-terminal) containing 1
chemokine (C-C motif) ligand 28
Fc fragment of IgG, low affinity IIb, receptor (CD32)
oxysterol binding protein-like 7
SMAD, mothers against DPP homolog 3 (Drosophila)
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-6.19
-6.15
-6.15
-6.14
-6.12
-6.12
-6.11
-6.10
-6.10
-6.06
-6.04
-6.01
-5.95
-5.94
-5.94
-5.87
-5.87
-5.82
-5.82
-5.78
-5.78
-5.76
-5.76
-5.74
-5.73
-5.65
-5.64
-5.62
-5.56
-5.55
-5.55
-5.55
-5.54
-5.52
-5.52
-5.50
-5.47
-5.45
-5.45
-5.45
-5.45
-5.44
-5.44
-5.43
-5.41
-5.35
-5.35
-5.34
-5.31

SPTBN1
ACSS1
PTPRE
TIMP1
EVL
BTN3A1
IFNGR1
PLAC8
VAV3
IFIT2
BTG1
PPP2R5C
HIST1H1C
ADD3
LAT
HSH2D
PLCB2
SEC31L2
UNC84B
DTX3
SLC4A4
S100A4
TOB1
DGKQ
PLCD1
PCL1
FAM46A
TTLL3
DIP2
RKHD2
PARP8
AGTPBP1
CPT1A
LCK
SERTAD2
IREB2
LOC153222
NAP1L5
CDC25B
ZNF395
LTB4R
LGALS9
CCNG2
LY6E
MLKL
BCL10
UBE2B
MNAB
MAST3

spectrin, beta, non-erythrocytic 1
acyl-CoA synthetase short-chain family member 1
protein tyrosine phosphatase, receptor type, E
TIMP metallopeptidase inhibitor 1
Enah/Vasp-like
butyrophilin, subfamily 3, member A1
interferon gamma receptor 1
placenta-specific 8
vav 3 oncogene
interferon-induced protein with tetratricopeptide repeats 2
B-cell translocation gene 1, anti-proliferative
protein phosphatase 2, regulatory subunit B (B56), gamma isoform
histone 1, H1c
adducin 3 (gamma)
linker for activation of T cells
hematopoietic SH2 domain containing
phospholipase C, beta 2
SEC31-like 2 (S. cerevisiae)
unc-84 homolog B (C. elegans)
deltex 3 homolog (Drosophila)
solute carrier family 4, sodium bicarbonate cotransporter, member 4
S100 calcium binding protein A4
transducer of ERBB2, 1
diacylglycerol kinase, theta 110kDa
phospholipase C, delta 1
prenylcysteine lyase
family with sequence similarity 46, member A
tubulin tyrosine ligase-like family, member 3
disco-interacting protein 2 (Drosophila) homolog
ring finger and KH domain containing 2
poly (ADP-ribose) polymerase family, member 8
ATP/GTP binding protein 1
carnitine palmitoyltransferase 1A (liver)
lymphocyte-specific protein tyrosine kinase
SERTA domain containing 2
iron-responsive element binding protein 2
adult retina protein
nucleosome assembly protein 1-like 5
cell division cycle 25B
zinc finger protein 395
leukotriene B4 receptor
lectin, galactoside-binding, soluble, 9 (galectin 9)
cyclin G2
lymphocyte antigen 6 complex, locus E
mixed lineage kinase domain-like
B-cell CLL/lymphoma 10
ubiquitin-conjugating enzyme E2B (RAD6 homolog) *
membrane-associated nucleic acid binding protein
microtubule associated serine/threonine kinase 3
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-5.30
-5.26
-5.25
-5.23
-5.22
-5.20
-5.19
-5.17
-5.17
-5.16
-5.15
-5.15
-5.14
-5.10
-5.10
-5.07
-5.03
-5.01
-5.00
-4.99
-4.96
-4.95
-4.94
-4.92
-4.91
-4.90
-4.89
-4.88
-4.82
-4.81
-4.79
-4.74
-4.66
-4.63
-4.61
-4.55
-4.53
-4.46
-4.44
-4.40
-4.39
-4.38
-4.33
-4.30
-4.29
-4.27
-4.27
-4.26
-4.26

GNS
RNF44
COL13A1
ANKRD9
PYHIN1
CD47
ICAM3
ALAD
CARD11
SELL
CAMK2G
KLF3
DOK2
CD8A
ADRB2
HPCAL1
PYCARD
HDAC4
NUDT11
KCNAB2
SYTL1
PRKACB
ITGB7
FRAT2
GFOD1
FAM13A1OS
INPP4A
CD6
RBL2
LAPTM5
UNRIP
NALP1
SPSB3
PRKCBP1
PLA2G6
BOK
BRWD1
MIDN
CABC1
TFDP2
HSCARG
GKAP1
DDIT4
HSPBAP1
EPC1
ARRB1
SSH2
ARL4C
MAPRE2

glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID)
ring finger protein 44
collagen, type XIII, alpha 1
ankyrin repeat domain 9
pyrin and HIN domain family, member 1
CD47 antigen (Rh-related antigen, integrin-associated signal transducer)
intercellular adhesion molecule 3
aminolevulinate, delta-, dehydratase
caspase recruitment domain family, member 11
selectin L (lymphocyte adhesion molecule 1)
calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
Kruppel-like factor 3 (basic)
docking protein 2, 56kDa
CD8 antigen, alpha polypeptide (p32)
adrenergic, beta-2-, receptor, surface
hippocalcin-like 1
PYD and CARD domain containing
histone deacetylase 4
nudix (nucleoside diphosphate linked moiety X)-type motif 11
potassium voltage-gated channel, shaker-related subfamily, beta member 2
synaptotagmin-like 1
protein kinase, cAMP-dependent, catalytic, beta
integrin, beta 7
frequently rearranged in advanced T-cell lymphomas 2
glucose-fructose oxidoreductase domain containing 1
family with sequence similarity 13, member A1 opposite strand
inositol polyphosphate-4-phosphatase, type I, 107kDa
CD6 antigen
retinoblastoma-like 2 (p130)
lysosomal associated multispanning membrane protein 5
unr-interacting protein
NACHT, leucine rich repeat and PYD (pyrin domain) containing 1
splA/ryanodine receptor domain and SOCS box containing 3
protein kinase C binding protein 1
phospholipase A2, group VI (cytosolic, calcium-independent)
BCL2-related ovarian killer
bromodomain and WD repeat domain containing 1
midnolin
chaperone, ABC1 activity of bc1 complex like (S. pombe)
transcription factor Dp-2 (E2F dimerization partner 2)
HSCARG protein
G kinase anchoring protein 1
DNA-damage-inducible transcript 4
HSPB (heat shock 27kDa) associated protein 1
enhancer of polycomb homolog 1, (Drosophila)
arrestin, beta 1
slingshot homolog 2 (Drosophila)
ADP-ribosylation factor-like 4C
microtubule-associated protein, RP/EB family, member 2
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-4.20
-4.20
-4.13

ZBTB1
NDRG3
TNRC6B

zinc finger and BTB domain containing 1
NDRG family member 3
trinucleotide repeat containing 6B
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Appendix II: Expression changes of ChIP-chip target genes
Genes on ChIP-chip list which increase with IL-2+IL-12+IL-18 stimulation (24h)
Must be called “present” after stimulation by Affymetrix algorithm
Fold change greater than 1.3 in both donors
Duplicate probe sets not removed
206975_at
206432_at
223383_at
231094_s_at
230372_at
225520_at
223382_s_at
225959_s_at
225960_at
225962_at
221331_x_at
226056_at
212561_at
200759_x_at
214179_s_at
210538_s_at
226057_at
222981_s_at
236341_at
216985_s_at
202748_at
221981_s_at
200758_s_at
208079_s_at
202557_at
36564_at
213038_at
230499_at
1553096_s_at
208536_s_at
216602_s_at
204822_at
202159_at
1558143_a_at
242907_at
206536_s_at
208985_s_at
209927_s_at
52285_f_at
234362_s_at
225831_at
222343_at
1558173_a_at
222509_s_at

Gene ID
LTA
HAS2
ZNRF1
MTHFD1L
HAS2
MTHFD1L
ZNRF1
ZNRF1
ZNRF1
ZNRF1
CTLA4
CDGAP
RAB6IP1
NFE2L1
NFE2L1
BIRC3
CDGAP
RAB10
CTLA4
STX3A
GBP2
WDR59
NFE2L1
STK6 (AURKA)
STCH
IBRDC3
IBRDC3
BIRC3
BCL2L11
BCL2L11
FARSLA
TTK
FARSLA
BCL2L11
GBP2
BIRC4
EIF3S1
C1orf77
CEP76
CTLA4
LUZP1
BCL2L11
LUZP1
ZNF672

Donor 1
4213.9
815.2
39.2
38.7
33.5
30.2
28.6
23.2
14.0
13.0
12.9
10.4
9.5
8.2
7.4
6.0
6.0
6.0
5.7
5.3
5.1
4.9
4.9
4.9
4.8
4.7
4.5
4.3
4.3
4.1
4.1
4.1
4.0
3.9
3.9
3.9
3.7
3.7
3.6
3.6
3.6
3.6
3.5
3.4

Donor 2
1686.3
63.2
367.5
26.7
24.5
44.7
33.5
41.2
19.5
80.8
3.3
7.1
11.1
12.2
11.2
4.0
4.6
8.2
5.4
3.9
3.2
2.6
6.3
6.3
3.9
6.3
6.1
2.6
1.7
1.3
4.8
4.8
4.3
1.7
2.3
3.2
4.3
3.6
3.0
2.3
3.2
1.7
1.9
3.1
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217364_x_at
222980_at
202558_s_at
200050_at
218810_at
225267_at
218979_at
212286_at
200935_at
224775_at
218195_at
223212_at
212397_at
224714_at
203372_s_at
231794_at
220153_at
201921_at
200039_s_at
202941_at
200974_at
228363_at
221832_s_at
209653_at
225859_at
212250_at
1553224_at
223397_s_at
224713_at
225682_s_at
219311_at
204484_at
203373_at
1555486_a_at
202468_s_at
209238_at
208264_s_at
205042_at
202506_at
223076_s_at
226743_at
212289_at
205114_s_at
209055_s_at
202078_at
213117_at
212398_at
219383_at
1554433_a_at
221831_at
202559_x_at
209056_s_at
238505_at
201735_s_at

EIF3S1
RAB10
STCH
ZNF146
ZC3H12A
KPNA4
RMI1
ANKRD12
CALR
IWS1
C6orf211
ZDHHC16
RDX
MKI67IP
SOCS2
CTLA4
ENTPD7
GNG10
PSMB2
NDUFV2
ACTA2
BIRC4
KIAA0601
KPNA4
BIRC4
MTDH
LUZP1
NIP7
MKI67IP
POLR3H
CEP76
PIK3C2B
SOCS2
FLJ14213
CTNNAL1
STX3A
EIF3S1
GNE
SSFA2
NSUN2
SLFN11
ANKRD12
CCL3L1
CDC5L
COPS3
KLHL9
RDX
FLJ14213
ZNF146
KIAA0601
C1orf77
CDC5L
ADPRH
CLCN3

3.3
3.2
3.1
3.1
3.1
3.0
3.0
2.9
2.9
2.9
2.8
2.8
2.8
2.8
2.7
2.7
2.7
2.6
2.6
2.5
2.5
2.5
2.5
2.5
2.4
2.4
2.4
2.4
2.4
2.3
2.3
2.3
2.3
2.3
2.2
2.2
2.2
2.2
2.2
2.1
2.1
2.1
2.1
2.1
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0

2.7
4.0
2.8
2.7
4.7
1.7
3.5
2.9
4.1
2.0
2.5
4.0
3.1
3.0
2.5
1.4
3.0
3.4
4.0
3.3
3.1
1.9
2.0
2.1
1.9
3.0
2.3
2.5
2.5
4.0
3.1
1.3
2.3
4.6
4.6
2.6
2.5
2.2
1.6
1.8
4.2
2.6
2.3
2.1
2.3
1.8
2.0
2.2
1.8
1.8
2.0
1.9
1.8
1.9
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236207_at
220329_s_at
202591_s_at
203429_s_at
205585_at
225268_at
201771_at
244519_at
223288_at
204841_s_at
225858_s_at
212251_at
213233_s_at
202001_s_at
219575_s_at
224768_at
224692_at
1552792_at
218505_at
205150_s_at
218099_at
205273_s_at
218068_s_at
214697_s_at
209432_s_at
235056_at
228162_at
200945_s_at
212245_at
200902_at
201039_s_at
214838_at
225748_at
212953_x_at
201046_s_at
223005_s_at
219079_at

SSFA2
C6orf96
SSBP1
C1orf9
ETV6
KPNA4
SCAMP3
ASXL1
USP38
EEA1
BIRC4
MTDH
KLHL9
NDUFA6
COG8
IWS1
PPP1R15B
SOCS4
WDR59
KIAA0644
TEX2
PITRM1
ZNF672
ROD1
CREB3
ETV6
ESD
SEC31L1
MCFD2
SEP15
RAD23A
SFT2D2
C6orf93
CALR
RAD23A
C9orf5
CYB5R4

1.9
1.9
1.9
1.9
1.9
1.8
1.8
1.8
1.8
1.7
1.7
1.7
1.7
1.7
1.7
1.7
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.5
1.5
1.5
1.5
1.4
1.4
1.4
1.4
1.4
1.4
1.3
1.3

1.7
1.9
2.9
1.7
1.9
1.5
2.8
1.8
1.6
2.3
1.7
1.8
2.3
1.7
1.5
1.8
1.7
2.0
1.6
5.5
1.7
1.8
2.0
1.3
1.9
1.3
2.1
1.6
1.3
1.7
1.9
1.5
1.8
2.3
1.8
1.6
1.8
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Genes on ChIP-chip list which decrease with IL-2+IL-12+IL-18 stimulation (24h)
Must be called “present” before stimulation by Affymetrix algorithm
Fold change greater than 1.3 in both donors
Duplicate probe sets not removed
Probeset
240718_at
204867_at
204674_at
35974_at
214032_at
1557261_at
1555613_a_at
213908_at
208442_s_at
216979_at
210858_x_at
212672_at
202587_s_at
211021_s_at
1564093_at
202308_at
1557257_at
207292_s_at
243165_at
1554786_at
235430_at
221088_s_at
38290_at
1562442_a_at
203825_at
212257_s_at
227515_at
234968_at
1570352_at
1553387_at
225980_at
215605_at
236662_at
204280_at
203118_at
214060_at
209112_at
206543_at
210365_at
206544_x_at
222868_s_at

Gene ID
LRMP
GCHFR
LRMP
LRMP
ZAP70
WHDC1L1
ZAP70
WHDC1L1
ATM
NR4A3
ATM
ATM
AK1
RGS14
NEK1
SREBF1
BCL10
MAPK7
BTF3
C20orf32
C14orf43
PPP1R9A
RGS14
SSBP1
BRD3
SMARCA2
STAMBP
C9orf55
ATM
ATM
C14orf43
NCOA2
CRAMP1L
RGS14
PCSK7
SSBP1
CDKN1B
SMARCA2
RUNX1
SMARCA2
IL18BP

Donor 1
-42.8
-20.7
-12.8
-11.8
-11.4
-9.4
-9.3
-8.0
-7.7
-7.4
-6.8
-6.8
-6.8
-5.9
-5.2
-4.2
-4.2
-4.1
-3.7
-3.6
-3.6
-3.5
-3.5
-3.3
-3.2
-3.2
-3.2
-3.2
-3.1
-3.1
-3.1
-3.0
-3.0
-3.0
-2.9
-2.9
-2.9
-2.8
-2.7
-2.7
-2.7

Donor 2
-77.0
-24.3
-20.4
-25.5
-10.9
-17.0
-8.9
-14.6
-14.9
-15.1
-11.4
-14.8
-5.8
-41.1
-6.9
-2.5
-6.6
-2.3
-2.6
-14.9
-3.3
-2.4
-3.8
-4.4
-2.4
-2.6
-2.4
-11.1
-10.3
-2.5
-4.0
-5.7
-5.6
-3.3
-1.7
-3.3
-3.7
-3.9
-4.2
-2.3
-3.1
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242349_at
38241_at
232521_at
204821_at
1558050_at
212875_s_at
1554631_at
207564_x_at
200931_s_at
203312_x_at
232931_at
204168_at
204675_at
207563_s_at
1554571_at
217707_x_at
209984_at
235539_at
212756_s_at
211284_s_at
241027_at
212307_s_at
219994_at
1559309_at
219957_at
201332_s_at
210959_s_at
200678_x_at
200747_s_at
212032_s_at
229787_s_at
208129_x_at
206542_s_at
227648_at
35617_at
204820_s_at
204494_s_at
209285_s_at
1557258_a_at
221729_at
219114_at
214251_s_at
212760_at
205052_at
235745_at
212206_s_at
1553346_a_at
52159_at
209240_at
216041_x_at
218378_s_at
219543_at
222108_at
224391_s_at

HECTD1
BTN3A3
PCSK7
BTN3A3
EIF2B5
C21orf25
ATM
OGT
VCL
ARF6
ASCC3L1
MGST2
SRD5A1
OGT
APBB1IP
SMARCA2
JMJD2C
NUMA1
UBR2
GRN
OPA1
OGT
APBB1IP
MCFD2
RUFY2
STAT6
SRD5A1
GRN
NUMA1
PTOV1
OGT
RUNX1
SMARCA2
C3
MAPK7
BTN3A3
C15orf39
C3orf63 (RAP140)
BCL10
COL5A2
C3orf18
NUMA1
UBR2
AUH
ERN1
H2AFV
TNRC6A
HEMK1
OGT
GRN
PRKRIP1
MAWBP
AMIGO2
SIAE

-2.7
-2.6
-2.6
-2.6
-2.6
-2.5
-2.5
-2.5
-2.5
-2.4
-2.4
-2.4
-2.3
-2.3
-2.2
-2.2
-2.2
-2.2
-2.1
-2.1
-2.1
-2.1
-2.1
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0
-1.9
-1.9
-1.9
-1.9
-1.9
-1.9
-1.9
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8
-1.8
-1.7
-1.7
-1.7
-1.7
-1.7
-1.7
-1.7
-1.7
-1.7

-4.4
-3.6
-2.8
-2.8
-2.2
-2.4
-1.7
-2.4
-2.3
-1.7
-2.0
-2.9
-2.8
-1.8
-2.6
-2.9
-2.5
-1.7
-1.9
-2.4
-5.0
-2.1
-2.3
-1.8
-3.6
-2.0
-2.0
-1.7
-1.5
-1.8
-2.7
-1.4
-2.3
-1.8
-2.0
-1.6
-2.0
-2.0
-2.0
-2.3
-2.3
-2.1
-1.9
-1.9
-1.8
-1.8
-2.2
-1.5
-1.4
-1.4
-2.0
-3.0
-1.9
-4.3
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239378_at
231406_at
241683_at
224481_s_at
201331_s_at
215087_at
203285_s_at
209068_at
218126_at
224705_s_at
239212_at
208990_s_at
226867_at
213328_at
218620_s_at
1553993_s_at
1558111_at
1555594_a_at
218621_at
214861_at
223393_s_at
212205_at
212454_x_at
210110_x_at
225794_s_at
218811_at
205732_s_at
225172_at
223392_s_at
221118_at
202932_at
225795_at
233015_at
201924_at
1556931_at
230185_at
205684_s_at
1554678_s_at

PITRM1
TMEM142B
HECTD1
HECTD1
STAT6
C15orf39
HS2ST1
HNRPDL
FAM82C
TNRC6A
C6orf93
HNRPH3
C9orf55
NEK1
HEMK1
MED25
MBNL1
MBNL1
HEMK1
JMJD2C
ZNF537
H2AFV
HNRPDL
HNRPH3
C3
TMEM142B
NCOA2
CRAMP1L
ZNF537
PKD2L2
YES1
C3
MBNL1
AFF1
CALR
THAP9
C9orf55
HNRPDL

-1.7
-1.7
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6
-1.6
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.5
-1.4
-1.4
-1.4
-1.4
-1.4
-1.4
-1.3
-1.3
-1.3
-1.3
-1.3
-1.3
-1.3

-3.5
-1.5
-1.8
-1.7
-1.6
-2.6
-1.4
-1.5
-1.3
-1.8
-1.9
-1.6
-2.4
-1.7
-1.5
-1.8
-1.6
-1.6
-1.6
-2.4
-1.5
-1.5
-1.4
-1.9
-1.7
-1.4
-2.2
-1.9
-1.4
-1.5
-2.9
-1.4
-1.5
-1.8
-5.4
-2.2
-2.3
-1.3
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Appendix III: Genes changed 1.3-fold in NK cells with PRDM1 knockdown
Genes Increased with PRDM1 knockdown in Primary NK cells (48h)
Must be called “present” after k by Affymetrix algorithm
Fold change greater than 1.3 in both donors
Duplicate probe sets not removed

2+12 Up
FLJ25791
HBA1
CXCL10
IL1R1
DLL1
FAM26F
PTK2
CD160
IPO11
VNN2
DDX17
SLC16A7
DMRTA2
HBA2
TNFRSF10B
CBX3
CLK4
BCAR3
VEGF
JAK2
GART
ZAK
PHOSPHO2
ZNF238
FBXO8
FLJ37034
SOCS1
TRFP
IDH1
TFAM
ELF2
PARP15
NUAK2
SEPT6
TRIB2
SIP1
POLR3G
C3orf23
PGBD4
EHBP1
AIM1

2+12+18 Up
Donor 1
4.72
3.29
2.69
2.52
2.19
2.07
2.03
1.99
1.93
1.87
1.75
1.73
1.71
1.66
1.64
1.64
1.57
1.53
1.51
1.50
1.50
1.49
1.46
1.46
1.45
1.45
1.44
1.43
1.43
1.43
1.43
1.42
1.41
1.40
1.40
1.40
1.39
1.39
1.39
1.39
1.38

Donor 2
1.78
1.31
1.61
2.10
1.35
1.54
2.12
2.78
1.65
1.53
3.22
1.50
1.42
1.41
1.88
1.67
1.35
1.54
1.49
1.31
1.38
1.76
1.47
1.54
1.37
1.53
1.32
1.33
1.45
1.32
1.37
1.45
1.54
1.47
1.31
1.54
1.36
1.67
1.93
2.08
1.69

C10orf97
HIPK3
RAB8B
LRAP
PSMA3
WHDC1L1
RINZF
CXCL11
SCOC
SP1
SGPP1
MAF
MLSTD2
ZNF230
NR4A3
PDCD4
FLI1
MBNL1
MST4
ITGA4
NEDD1
CAPRIN1
B4GALT6
JAK1
MGC33214
PSAT1
EIF4A2
NCK1
IGJ
MCL1
SPFH1
CD58
LIG4
STAT6
STAT1
PLCL2
PRKAB1
NCBP1
LYZ
SYPL1
ARPP-19
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Donor 1
8.64
5.82
5.31
4.96
4.70
4.61
4.05
4.02
3.92
3.91
3.88
3.88
3.85
3.77
3.70
3.47
3.43
3.42
3.33
3.09
3.08
3.06
3.05
3.03
2.98
2.94
2.92
2.89
2.86
2.79
2.74
2.73
2.70
2.68
2.67
2.64
2.62
2.58
2.57
2.54
2.53

Donor 2
1.31
1.91
1.70
2.04
1.45
2.29
1.44
2.30
1.84
1.42
1.81
1.37
1.92
1.49
1.32
1.71
1.57
2.00
1.33
1.89
1.43
1.33
1.70
1.41
1.59
1.55
1.35
1.57
1.84
1.44
1.73
1.35
1.61
1.76
1.35
1.53
1.52
2.16
1.79
1.42
1.36

FXR1
ALS2CR2
DIAPH1
TCF4
ELK4
CCDC109B
PLXNA4A
GAS5
HADHA
C16orf35
LRMP
NEXN
MYC
SYPL1
WHDC1L1

1.38
1.37
1.37
1.36
1.36
1.35
1.35
1.35
1.34
1.34
1.32
1.32
1.32
1.32
1.31

2.48
1.34
1.49
1.48
1.51
1.68
2.22
1.32
1.33
1.52
1.35
1.34
1.40
1.38
1.75

LACTB2
GFM2
HEG1
CAMK2D
EFHC2
STAM2
SKIL
SH2B3
CDKN2D
LOC51136
TCF7L2
CRSP3
TCF7
PPM1D
GK5
GPATC2
ZNRF3
MLLT10
WTAP
DDEF1
RKHD2
SH2D1A
LOC387763
NMD3
PCTK2
XCL1
BCL2L11
LPIN1
CYP1B1
B3GNT2
JAK2
MGC14595
ATF1
MAML2
SEPT6
CYBRD1
KIAA0828
RBM7
KLRK1
FH
ANXA1
ASXL2
CCDC126
SERINC1
PLEKHF2
SELL
CRIM1
NUMA1
MAP2K7
KLRD1
ADORA2B
SOCS1
PGM2
ZNF238
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2.50
2.50
2.45
2.41
2.39
2.37
2.35
2.34
2.34
2.34
2.28
2.27
2.26
2.25
2.20
2.19
2.19
2.18
2.17
2.14
2.13
2.13
2.12
2.12
2.12
2.11
2.10
2.08
2.08
2.07
2.05
2.05
2.04
2.02
2.02
1.97
1.97
1.97
1.96
1.95
1.95
1.94
1.94
1.93
1.91
1.91
1.89
1.89
1.87
1.87
1.84
1.84
1.83
1.83

1.32
2.52
1.93
1.54
1.94
1.41
1.46
1.59
2.18
1.30
1.49
1.37
1.46
1.56
1.53
1.38
2.17
1.38
1.78
1.32
1.70
1.37
2.10
1.30
1.57
1.31
1.82
1.75
1.35
1.55
1.57
1.31
1.30
1.55
1.57
1.85
1.42
1.66
1.52
2.21
1.46
1.52
1.65
1.37
1.36
1.63
1.33
1.56
2.16
1.44
1.49
1.40
1.31
1.44

IL23R
KIAA2026
PTK2
PTPN4
FLJ23053
AIM1
PGGT1B
SETD2
HIVEP1
ETV6
TRA@
ZDHHC2
PTPN1
LRMP
PSMD10
RAB6IP1
FLCN
DKFZp761P0423
KLHL6
KPNA1
KIAA1432
MBP
ARHGAP26
SURB7
IRF2BP2
MYADM
KLF2
C1orf174
SAV1
HCRP1
TAP1
DHX40
MOBKL2B
UST
EBI2
PEX12
CSF1
SPRY2
DLEU2
BCAR3
TMEM64
LOC352333
ZNF644
NIN
KIAA0974
ENPP3
HBA2
EPS8
FGFBP2
SCN10A
C13orf15
LPGAT1
GSK3B
GUSBP1
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1.82
1.81
1.80
1.78
1.77
1.76
1.75
1.75
1.74
1.73
1.72
1.71
1.70
1.70
1.70
1.70
1.68
1.68
1.68
1.68
1.67
1.67
1.65
1.64
1.63
1.63
1.60
1.60
1.59
1.59
1.58
1.58
1.58
1.58
1.57
1.57
1.56
1.56
1.55
1.55
1.55
1.54
1.53
1.52
1.50
1.49
1.48
1.47
1.47
1.46
1.45
1.44
1.44
1.44

2.62
1.35
1.46
1.31
1.52
1.69
1.51
1.58
1.31
1.40
1.44
1.40
1.45
1.71
1.51
1.54
1.35
1.40
1.37
1.31
1.48
1.34
1.37
1.62
1.32
1.40
2.29
1.39
1.45
1.55
1.40
1.34
2.12
1.88
1.62
1.38
1.47
1.30
1.32
1.43
1.32
1.39
1.87
1.50
1.66
1.85
1.64
1.47
1.73
1.32
1.62
1.45
1.31
3.78

ZNF217
VTI1B
C12orf5
FBXO9
HTATIP2
DOCK9
GPR84
RSNL2
EIF5A2
PTEN
EXOSC6
CD160
NEXN
PHACTR2
SLC23A2
ARHGAP25
PELI2
APP
ARIH2
LOC391020
LOC150819
VNN2
SCML1
TLE1
KLRF1
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1.44
1.43
1.43
1.43
1.43
1.43
1.42
1.41
1.40
1.40
1.40
1.40
1.40
1.39
1.37
1.36
1.35
1.35
1.35
1.34
1.33
1.33
1.32
1.31
1.31

1.35
1.31
1.50
1.41
1.60
1.37
1.37
1.32
1.54
1.80
1.35
1.57
1.59
1.37
1.44
1.56
1.51
1.81
1.36
1.43
1.56
1.32
1.85
1.64
1.68

Genes Decreased with PRDM1 knockdown in Primary NK cells (48h)
Must be called “present” before knockdown by Affymetrix algorithm
Fold change greater than 1.3 in both donors
Duplicate probe sets removed
2+12 Down
DPF3
KBTBD4
MYCBP
SNTB2
GPR97
SKIL
VANGL1
CLU
SDCBP
RTKN
PTGDS
NEIL1
TMEM32
INADL
MYO1D
ABCG1
NDFIP2
ACTN1
OACT2
THRAP5
MED8
RAB23
C21orf91
FAM46C
FLJ10525
ARHGEF12
PTGER3
ARPC1A
GORASP1
PRDM1
GABARAPL1
KIR2DL3
KIR2DL1
MLLT1
FLJ11184
KIF21A
KIR2DS5
DTYMK
PAG1
KIR2DL5B
DLEU2
LNX2
ZNF537
TMEM33
PPP1R13B

2+12+18 Down
Donor 1
-7.79
-3.89
-3.74
-3.72
-2.34
-2.27
-2.21
-2.10
-1.88
-1.84
-1.83
-1.74
-1.71
-1.70
-1.69
-1.69
-1.66
-1.64
-1.63
-1.62
-1.61
-1.61
-1.60
-1.59
-1.55
-1.55
-1.54
-1.53
-1.51
-1.49
-1.47
-1.44
-1.44
-1.42
-1.42
-1.41
-1.41
-1.41
-1.40
-1.40
-1.39
-1.39
-1.39
-1.38
-1.38

Donor 2
-1.86
-1.57
-1.95
-1.64
-1.47
-1.43
-1.85
-2.13
-1.39
-1.45
-1.40
-1.63
-1.64
-1.91
-1.49
-1.37
-1.37
-1.37
-1.50
-1.54
-1.45
-1.31
-1.39
-1.93
-1.43
-1.53
-1.39
-1.54
-1.32
-1.81
-1.54
-1.53
-1.86
-1.34
-1.93
-1.31
-1.49
-1.32
-1.59
-1.73
-1.31
-1.68
-1.59
-1.40
-1.34

LOC348667
IL6R
C8orf15
TncRNA
KLF12
ACACB
ADM
ZMIZ2
ITPR1
NAG8
KIF21A
RBM25
GPR107
SCFD1
CLCC1
FBXO31
LOC286208
KIAA1618
FCHO1
MGC23284
MCM10
CDC25A
GMPPA
GALNT6
C15orf42
HDLBP
PDIA4
CD7
BIRC5
FLJ22795
SMARCC1
MKI67
EWSR1
FOXM1
CCND2
EBP
UNC84B
HELLS
NFKBIB
FLJ36090
E2F2
SDC4
ANXA11
CHPF
SIMP
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Donor 1
-3.33
-3.16
-3.14
-2.93
-2.69
-2.56
-2.46
-2.38
-2.37
-2.30
-2.29
-2.12
-2.10
-2.10
-2.05
-2.03
-2.01
-1.96
-1.95
-1.94
-1.91
-1.88
-1.84
-1.84
-1.83
-1.80
-1.80
-1.78
-1.77
-1.75
-1.72
-1.71
-1.71
-1.68
-1.67
-1.66
-1.65
-1.64
-1.64
-1.62
-1.62
-1.61
-1.60
-1.59
-1.59

Donor 2
-1.96
-1.37
-1.49
-1.45
-1.38
-1.56
-1.58
-1.41
-1.40
-1.54
-1.67
-1.44
-1.96
-1.83
-1.47
-1.33
-1.55
-2.26
-1.35
-1.92
-1.56
-1.35
-1.31
-1.31
-1.79
-1.36
-1.36
-1.32
-1.31
-1.35
-1.37
-1.41
-1.42
-1.49
-1.53
-1.30
-1.37
-1.47
-1.35
-1.39
-1.51
-1.39
-1.30
-1.32
-1.46

SAC3D1
TIMP1
MTMR4
ANXA5
MAD1L1
KIR3DL2
KIR3DL1
ATP6V0E2L
EHD4
GALNACT-2
C6orf89
TWSG1

-1.38
-1.36
-1.36
-1.36
-1.35
-1.35
-1.35
-1.34
-1.33
-1.31
-1.31
-1.31

-1.39
-1.60
-1.70
-1.40
-1.30
-1.61
-1.43
-1.37
-1.44
-1.47
-1.31
-1.34

ZBTB32
CDT1
MLLT1
ALCAM
SCARB1
PDE4DIP
RRBP1
ENO2
S100A4
PCYT2
FLJ20254
AYTL2
MGC3020
SDF2L1
AURKB
CDRT4
SF3B1
TMCC2
MAPK13
NALP2
DTYMK
NCAPG
PML
NCAPD2
PDXK
MFSD2
NT5DC2
SLC43A3
PTP4A3
NSDHL
PCSK5
FLJ14627
PARP2
FAM57A
HRBL
KIAA1641
HYMAI
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-1.59
-1.58
-1.57
-1.55
-1.54
-1.54
-1.53
-1.52
-1.51
-1.50
-1.50
-1.49
-1.49
-1.49
-1.48
-1.48
-1.47
-1.47
-1.47
-1.47
-1.47
-1.45
-1.42
-1.41
-1.39
-1.38
-1.38
-1.37
-1.36
-1.36
-1.36
-1.35
-1.33
-1.32
-1.32
-1.31
-1.31

-1.36
-1.52
-1.45
-1.34
-1.73
-1.35
-1.30
-1.47
-1.38
-1.54
-1.35
-1.33
-1.32
-1.39
-1.71
-1.32
-1.44
-1.77
-1.37
-1.31
-1.61
-1.30
-1.32
-1.30
-1.33
-1.33
-1.33
-1.37
-1.36
-1.34
-1.37
-1.36
-1.32
-1.49
-1.39
-1.69
-1.64
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